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 Abstract 
L’impiego di molecole reattive nei processi di drug discovey è spesso 
scoraggiato a causa della loro potenziale tossicità od instabilità 
metabolica. Infatti, se non adeguatamente indirizzata verso il bersaglio 
desiderato, la loro reattività nei confronti di bersagli biologici alternativi o 
rispetto a nucleofili biologici come il glutatione (GSH) potrebbe tradursi in 
effetti tossici indesiderati. D'altra parte, composti reattivi in grado di 
legare selettivamente i loro recettori con interazioni covalenti 
potrebbero essere utili per il trattamento di molte malattie clinicamente 
rilevanti, nonché per lo sviluppo di nuovi strumenti per l’indagine 
biologica o farmacologica. All’interno di questa classe di sostanze, i 
composti in grado di legare covalentemente i gruppi tiolici cisteinici 
rappresentano una delle classi più promettenti per lo sviluppo di 
composti farmacologicamente sfruttabili. La reattività specifica di questi 
composti nei confronti dei gruppi sulfidrilici fornisce loro la capacità di 
legare selettivamente i residui cisteinici esposti dal bersaglio designato 
limitando, nel contempo, la loro interazione con altri nucleofili presenti 
nell'ambiente biologico. Considerando che la cisteina è scarsamente 
espressa nella struttura primaria di molte proteine rispetto ad altri 
aminoacidi strutturali, solo un limitato sottoinsieme di bersagli biologici 
dovrebbe presentare residui cisteinici esposti al solvente disponibili ad 
essere legati da questa classe di composti. Inoltre, dal momento che è 
raro rilevare proteine non correlate che condividano uno stesso pattern 
di esposizione di residui cisteinici dopo il processo di folding, il 
microambiente esistente intorno ai residui cisteinici esposti può essere 
sfruttato per sviluppare composti covalenti ad alta specificità, in grado 
di discriminare target biologici differenti fra le proteine esprimenti residui 
cisteinici accessibili. In questo modo, i composti sviluppati potrebbero 
essere utilizzati come “tagging agents” ad alta specificità nel contesto 
della sperimentazione biologica ma anche, successivamente ad un 
 incremento della loro stabilità metabolica e/o della loro specificità di 
azione ottenuto attraverso opportune ottimizzazioni strutturali, come 
farmaci. Farmaci cisteino-reattivi già in commercio quali la Fosfomicina 
(Monouril ®), l’Omeprazolo (Antra ®) ed il Disulfiran (Antabuse ®), così 
come molti altri composti in fase di sperimentazione, rappresentano 
ottimi esempi di come composti in grado di legare covalentemente 
residui cisteina possano essere sfruttati a livello farmacologico. Durante 
lo svolgimento di questo progetto di Dottorato di Ricerca sono stati 
progettati e sintetizzati nuovi inibitori covalenti ad attività cysteine-trap 
per il dominio Tyrosin Kinasico dell’Epidermal Growth Factor Receptor 
(EGFR-TK) e per l’enzima MonoAcylGlyceorol Lypase (MAGL). Entrambi 
questi enzimi presentano residui di cisteina esposti al solvente adatti ad 
essere legati da composti ad attività cystene-trap opportunamente 
progettati. L’interazione covalente di questi composti con i loro relativi 
bersagli porta alla formazione di complessi farmaco-enzima 
sufficientemente stabili da produrre un binding irreversibile, o per lo 
meno di lunga durata, dei residui cisteinici bersaglio e quindi in grado di 
assicurare un’elevata occupazione recettoriale. Il binding covalente di 
EGFR-TK risulta essere utile per il trattamento di forme di cancro in cui 
l'espressione di una forma mutata di EGFR (T790M) è in grado di conferire 
farmaco-resistenza nei confronti dei convenzionali inibitori non covalenti 
di EGFR. In questi casi, il legame covalente con il residuo cisteinico 
Cys773 presente all’interno del sito attivo di EGFR-TK comporta 
un’incrementata affinità di legame per il target, garantisce un’elevato 
livello di occupazione recettoriale e consente di superare il fenomeno 
della farmaco-resistenza. L’aumento di affinità indotto dall’instaurarsi 
dell’interazione covalente fra questi composti ed un dato bersaglio 
biologico può anche essere considerata come un buon punto di 
partenza per la messa a punto di studi SAR finalizzati all’ottimizzazione 
strutturale dei composti considerati. In questo senso, infatti, la 
 manipolazione strutturale di composti ad attività covalente può essere 
effettuata con un diminuito rischio di perdere affinità per il bersaglio 
designato. Questo concetto è stato applicato alla progettazione di 
nuovi inibitori cysteine-trap per MAGL. In questo caso, i composti 
sintetizzati sono stati progettati per presentare livelli elevati di diversità 
strutturale al fine di ottimizzare il loro fitting recettoriale.  
Tutti i composti sintetizzati nell’ambito di questio progetto di Dottorato 
presentano una porzione cisteino-reattiva (warhead) di struttura 
variabile legata a diversi motivi strutturali non reattivi (driver groups) 
progettati per modulare il receptor fitting. 
L’inibizione di EGFR-TK mediante composti ad attività cysteine-trap è 
stata portata a termine utilizzando composti caratterizzati da un driver 
group di tipo 6-amino-4-(3-bromoanilino)chinazolinico collegato ad una 
piccola collezione di warheads, selezionate in modo da possedere un 
ampio spettro di meccanismi di interazione covalente. Per i composti 
sintetizzati è stata valutata la capacità di inibire il processo 
autofosforillativo di attivazione di EGFR come anche di inibire la 
proliferazione di popolazioni cellulari tumorali overesprimenti EGFR. 
Inoltre, al fine di valutare il loro potenziale terapeutico nei riguardi di 
tumori resistenti ai convenzionali inibitori non covalenti di EGFR, è stata 
indagata la loro efficacia nell’inibire la proliferazione cellulare in cellule 
tumorali esprimenti EGFR T790M. 
L’inibizione di MAGL mediante composti ad attività cysteine-trap cisteina 
è stata ottenuta variando sia le warheads sia i driver groups 
caratterizzanti i composti utilizzati. Dal momento che per tale scopo si 
sono utilizzate solamente tre tipologie di warhead eterocicliche, la 
variabilità dei gruppi cisteino-reattivi in questo studio SAR può essere 
considerata modesta. Al contrario, al fine di esplorare l’intorno 
farmacoforico dei residui cisteinici bersaglio, la porzione driver è stata 
oggetto di una più ampia manipolazione strutturale.  
 L’elevata potenza inibitoria fornita dai composti sintetizzati relativamente 
a EGFR-TK e MAGL è incoraggiante e dimostra come composti ad 
attività cysteine-trap possano essere efficacemente utilizzati nell’ambito 
dei processi di drug discovery. Inoltre, i bassi profili di citotossicità rilevati 
unitamente all'efficacia dimostrata di alcuni inibitori di EGFR-TK 
nell’inibire la proliferazione cellulare su linee tumorali resistenti mostra 
come tipi di warhead differenti possano essere impiegate per lo sviluppo 
di nuovi inibitori irreversibili di EGFR capaci di superare la farmaco-
resistenza indotta dell’espressione di EGFR T790M con un migliorato 
rapporto di efficacia/tossicità. 
 Abstract 
The use of reactive molecules in drug discovery is often discouraged 
because of their potential toxicity or metabolic instability. Indeed, if not 
properly driven to the desired target, their reactivity toward biological 
nucleophiles like glutathione (GSH) or unwanted biological target could 
result in unfavourable toxicological outcomes. On the other hand, 
reactive agents able to selectively bind their receptors with covalent 
interactions could be beneficial for the treatment of many clinically 
relevant diseases as well as for the development of new tools for 
biological or pharmacological investigation. 
Among covalent reactive compounds, cysteine trapping compounds 
are one of the most pharmacologically exploitable classes of substances 
able to bind their target by establishing a covalent interaction. Their 
specific reactivity toward thiols provides them the ability to selectively 
bind cysteine exposing target without covalently interacting with other 
nucleophiles presents in the biological environment. Considering that 
cysteine has a low expression level in proteins with respect of other 
structural aminoacids, only a limited subset of biological targets should 
present solvent exposed cysteine suitable to be bound by cysteine 
trapping agents. Moreover, since it is uncommon to find unrelated 
folded proteins with a similar cysteine exposure pattern, the 
microenvironment around cysteine residues can be exploited to develop 
specific cysteine trapping agents able to discriminate different targets 
among cysteine exposing proteins. 
In this way, cysteine trapping agents could be used as specific labelling 
agents in biological investigations or, once their metabolic stability and 
target specificity are increased by proper structural optimizations, as 
drugs.  
Commercial cysteine reactive drugs like fosfomycin (Monouril ®), 
omeprazole (Antra ®) or disulfiram (Antabuse ®), as well as many other 
 drug candidates, are good examples of the pharmacological 
exploitability of this kind of covalent modifier.  
New specific cysteine reactive covalent inhibitors for Epidermal Growth 
Factor Receptor Tyrosine Kinase domain (EGFR-TK) and for 
MonoAcylGlyceorol Lypase enzyme (MAGL) were designed and 
synthesized during this accomplishment of this PhD project. Both of these 
enzymes present solvent exposed cysteine residues suitable for binding 
with properly designed thiol reactive compounds. The resulting 
covalently strengthened drug-enzyme complexes are often stable 
enough to provide long-lasting or irreversible binding of the targeted 
cysteine and to assure high receptor occupancy. The irreversible binding 
of EGFR-TK is beneficial for the treatment of cancer in which the 
expression of a mutated form of EGFR (T790M) induces drug resistance 
toward conventional non-covalent drugs. In this case, the covalent 
binding of Cys773 on EGFR-TK provides an increased binding affinity for 
the target, assures high level of EGFR-TK occupancy and overcomes the 
drug resistance. The increased target affinity provided by the covalent 
binding mode can also represents a good starting point to set-up SAR 
studies focused on the structural optimization of selected ligands. 
Indeed, the structural manipulation of a covalent binder can be carried 
out with a decreased risk of binding affinity loss. This concept was 
applied to the design of new cysteine trapper MAGL inhibitors. In this 
case, the synthesized compounds were designed to present high 
structural diversity levels in order to optimize their receptor fitting. 
All synthesized compounds within this PhD project present a variable 
cysteine reactive portion (warhead) linked to different non-reactive 
structural motives (driver group) designed to modulate the receptor 
fitting. EGFR-TK cysteine targeting was achieved using a well-known 6-
amino-4-(3-bromoanilino)quinazoline driver group linked to a small panel 
of warheads based on a wide spectrum of cysteine trapping 
 mechanisms.  In this case, the ability of the synthesized compounds to 
inhibit the auto-phosphorylative EGFR activation process as well as to 
inhibit the proliferation of EGFR overexpressing cells was evaluated. 
Moreover, their effectiveness to hamper the proliferation of cells 
expressing EGFR T790M was evaluated too, in order to evaluate their 
therapeutic potential on drug resistant tumour cells. 
MAGL cysteine targeting was achieved varying both warheads as well 
as driver portions. Because only three kinds of heterocyclic cysteine 
reactive portions were used as warhead portions, the warhead diversity 
was maintained low in this SAR study. On the other hand, a wider 
structural manipulation of the driver portion was carried out to explore 
the pharmacophoric space around the targeted cysteine. 
The high inhibition potency achieved by synthesized compounds on 
EGFR-TK and MAGL is encouraging and shows how much cysteine 
trapping agents could be useful in drug discovery processes. Moreover, 
the low cytotoxicity profiles and the effectiveness of some synthesized 
EGFR-TK inhibitors to hamper the proliferation of cell harbouring T790M 
EGFR shows that different kinds of cysteine reactive warheads could be 
used to develop new EGFR irreversible inhibitors able to overcome the 
drug resistance in tumours with enhanced efficacy/toxicity ratio. 
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1.1 Introduction 
Pharmaceutical industry usually disregards or filters out screening hits 
containing potentially reactive functionalities, in favour of compounds 
that modulate protein functions through non-covalent interactions. 
Indeed, the potentially non-discriminant covalent interactions of these 
reactive substances with biological nucleophiles like glutathione (GSH) or 
with unwanted biological target (off-target proteins, DNA, etc.) could 
result in early or delayed unfavourable toxicological outcomes. 1  In 
addition, even when screened covalent drug candidates display 
attractive toxicological profiles in preclinical models, their reactivity 
could represent a possible triggering element for idiosyncratic reactions. 
Because of the eventual occurrence of these detrimental effects, 
development of drugs containing reactive functionalities is often 
discouraged in pharmaceutical companies, even when the reactivity of 
the designed compounds is modest and/or limited to the desired 
biochemical target. 
On the opposite, there are instances where controlled covalent 
modification of target has proven to be exploitable for the development 
of drugs, pharmacological tools or biomarkers for biological assays. 
Many commercially available drugs were recognized as covalent 
modifiers in hindsight, exerting their pharmacological functions on 
enzymes, receptors or structural proteins by covalent modification of 
their target.2 All of these compounds present a molecular structure in 
which a chemically reactive fragment “warhead” is able to establish 
covalent interactions, reversible or not, with one or more nucleophilic 
residues exposed on the surface or into an inner cavity of the target. 
Their target selectivity depends on their structure as well as on their 
warheads reactivity. While the former is important for drug-target 
recognition and for proper warhead positioning, the latter is 
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fundamental to ensure an effective covalent binding to the target 
without reacting with off-target nucleophiles. The covalent binding of 
one of these drugs to the desired biological target usually, but not 
exclusively, provides a prolonged non-competitive and irreversible target 
inactivation at low micromolar or nanomolar concentration range. 
Among covalent modifiers, compounds able to selectively bind the 
thiol portion of cysteine residues on proteins without reacting with other 
nucleophiles are attracting the interest of scientific community. Indeed, if 
compared to other nucleophile-reactive compounds (such as serine or 
tyrosine-reactive molecules), the cysteine-oriented reactivity of this kind 
of compounds could furnish an additional source of selectivity that is 
beyond the fitting optimization provided by proper structural modulation. 
This is because cysteine residues in a primary protein structure are usually 
less abundant than the number of other structural amino acids.3 In this 
way, the positions of cysteines on folded protein structure can be used 
as a specific binding point for cysteine-trapping covalent modifiers and 
the microenvironment around cysteine residues could be exploited to 
develop specific cysteine trapping agents able to discriminate different 
targets among cysteine exposing proteins. This concept has been 
applied to the development of drugs such as cysteine-protease inhibitors 
(e.g. cathepsin and caspase inhibitors), tyrosine kinase inhibitors (e.g. 
EGFR inhibitors) and lipase inhibitors (MAGL cysteine trap inhibitors) but 
also to the development of pharmacological tools to localize, study and 
validate cysteine exposing targets. 
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1.1.1 Covalent drug-target interaction: an orthogonal 
approach to design pharmacological tools or drugs 
Covalent modifier can orthosterically 4  as well as allosterically, 5 
modulate the biological activity of their targets through a typical kinetic 
sequence. In the early stages of drug-target complex formation, a given 
covalent modifier competes with endogenous ligands or substrates to 
reach its binding site. Once reached the target, a covalent bound is 
formed within the drug-target complex, which is thus stabilized. This 
stabilization hampers the binding of other ligands or substrates to the 
target and switches the kinetic of interaction from competitive to non-
competitive. This switching process takes some time to be completed 
and this can explain why the inhibition of enzyme and receptor by 
covalent modifier is usually time-dependent. Considering this double-
staged binding behavior, non-covalent interactions provided by 
structural features of a given covalent modifier play a fundamental role 
during the target-ligand competitive recognition. The covalent reactivity 
of these compounds becomes determinant only once the warhead is 
properly positioned in the targeted binding site. In this way, covalent and 
non-covalent interactions concur to define both binding affinity and 
reversibility of covalent modifiers. Notably, the contribution of warhead 
reactivity to the observed target occupancy increases as the non-
covalent structural contribution decreases. Thus, a low reactive covalent 
binder requires a highly optimized structure to deliver its covalent 
reactivity on the desired target. 
Often, the additional binding energy provided by the formation of 
covalent bounds between a covalent modifier and its biological target is 
enough to decrease the number of non-covalent interactions usually 
needed to achieve the desired pharmacological potency. Thus, very 
often the operational binding affinity, as much as the observed 
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biological activity, of a covalent modifier for a biological target results 
higher than those shown by their non-covalent counterparts. While this 
could be useful to assure high binding affinity also to structurally 
unoptimized ligands, the same covalent reactivity could be responsible 
for target selectivity lacking and/or metabolic instability of these 
compounds. Thus, the potential indiscriminate reactivity of warheads 
carried by these molecules could result in early or delayed unfavourable 
toxicological outcomes.1 These would be due to immunological 
responses, genetic or epigenetic changes of expressed proteins or long-
term inhibition of key biological targets involved in housekeeping 
functions (e.g. enzymes involved in protein synthesis). Despite these 
problems, the use of covalent modifiers for QSAR set-up could be 
beneficial, at least in preliminary stages of drug design studies. Indeed, 
the high basal biological effectiveness possessed by these compounds 
could represent a good starting point for further structural optimization. In 
this way, an improved biological potency as well as target selectivity 
could be easily achieved, minimizing the occurrence of off-target 
toxicity. Furthermore, once the nature of targeted residues is defined, a 
proper warhead reactivity modulation can further improve the selectivity 
of designed compounds, driving the covalent reactivity only toward 
target that expose the same kind of residues (see Chapter 1.2). 
Most of covalent modifiers react with their targets inhibiting them. 
Nevertheless, it is reported that some covalent binder are able to 
covalently activate their targets. For instance, isothiocyanate AM841 (40, 
scheme 1) was reported to be able to covalently activate GPCR 
cannabinoid receptor type 1 (CB1) stabilizing the active form of this 
receptor by Cys355 targeting.6 
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Scheme 1.1. Covalent binding of AM841 to CB1 receptor. Isothiocyanate warhead 
colored in red. 
 
Since the largest part of the binding energy of a covalent modifier is 
generated by the covalent bond formation event, the extent of the 
obtained pharmacological effect can range from reversible to 
irreversible, depending on the stability of covalent strengthened drug-
target complex.  
In case of a covalent irreversible interaction, the provided long-
lasting target inhibition or activation can be directly exploited to 
develop highly effective pharmacological or biological tools. On the 
other hand, an irreversible target inhibition could be clinically useful too, 
because it possesses some advantages with respect to the reversible 
one. For instance, an irreversible modifier doesn’t need prolonged 
circulating blood levels to achieve a desired biological effect. Once the 
target is deactivated by covalent bond formation, the biological effect 
should persist even after the drug leaves the bloodstream.7 Moreover, 
irreversible covalent modulation should be considered the first choice 
strategy to achieve an effective treatment of diseases such as cancer or 
aggressive infections, which require high target occupancy to be 
treated.2 
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1.1.2 From reactants to drugs 
As previously described, the warhead reactivity could be 
responsible for poor toxicological or pharmacokinetic profiles because of 
off-target toxicity or extensive metabolic degradation respectively. 
Moreover, it is reported that some warheads, normally focused to react 
only with a tight spectrum of nucleophile species, can be metabolically 
over-activated, increasing their reactivity and becoming able to 
indiscriminately react with an enlarged collection of nucleophiles. An 
example of this behavior can be provided by the comparison of 
reactivity of halogenated and non-halogenated derivatives of isothiazol-
3(2H)-one. Non-halogenated isothiazol-3(2H)-one based warheads have 
been recognized as very specific cysteine-trapping moieties because of 
their ability to selectively react with strong nucleophile like thiols without 
undergoing any relevant addition of weaker nucleophiles carrying 
hydroxyl- or amino- functionalities. 8  Non-halogenated 2-
methylisothiazoliN-3(2H)-one (42, Scheme 1.2) reacts with aqueous 
solution of N-acetylcysteine, a model nucleophile designed to mime 
biological thiols like glutathione, preferentially undergoing a ring opening 
reaction triggered by the attach of the nucleophile species on 
sulfenamidic sulfur atom. 
 
 
Scheme 1.2. Reactivity of non halogenated isothiazol-3(2H)-one toward thiols. Warhead 
portion colored in red. 
 
On the other hand, halogenated derivatives like 5-chloro-2-
methylisothiazolin-3(2H)-one 44 are more reactive in the same reaction 
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conditions. They react with N-acetylcysteine producing open chain 
product like 46, 48 and 49 (Scheme 1.3).  
 
 
Scheme 1.3. Reaction pathway N-Methyl 5-chloroisothiazol-3(2H)-one 1 once exposed 
to nucleophiles (Nu) like N-acetyllysine, H2O and N-acetylcysteine. 46, 48 and 49 
represent the general main products observed in this study. 
 
These product are formed by a two-step mechanism in which 5-
chloroisothiazol-3(2H)-one 44 can initially undergo a simple addition of 
thiol to the sulfur atom forming a mixed disulfide. Subsequently, this 
disulfide undergoes a second nuclephilic attack resulting in the 
cleavage of the disulfidic bond and forming a very reactive thioacyl 
chloride intermediate 45.8,9 The latter is too reactive to exert any kind of 
specific reactivity and so can freely react with N-acetylcysteine or H2O 
to produce the observed open chain products 46 and 48 or  49 
respectively. The different reactivity of 5-chloroisothiazol-3(2H)-one 44 
toward N-acetyllysine in absence or in presence of N-acetylcysteine also 
support the proposed double stage mechanism. Indeed, while in 
absence of N-acetylcysteine 5-chloroisothiazol-3(2H)-one 44 doesn’t 
react with N-acetyllysine, in presence of N-acetilcysteine only N-
acetyllisyl derivative 47 and 50 were detected. These finding confirm the 
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role of thiols to enhance the reactivity of chlorinated isothiazol-3(2H)-one 
inducing the formation of unselective thioacyl chloride intermediate 45.8 
Since both non-halogenated isothiazol-3(2H)-one and 
benzo[d]isothiazol-3(2H)-ones derivatives can quickly react with 
biological thiols like glutathione, it was proposed that intracellular 
glutathione could neutralize the biocide effect of these sulfenamides in 
living cells whereas, on the contrary, it could over-activate 5-
chloroisothiazol-3(2H)-one 44 enhancing its toxicity. 10,11 
The “double facet” chemical and biological behaviour described 
for isothiazol-3(2H)-one related warheads represents a good example of 
how small modifications of warhead structure could result in big 
reactivity changes. This wide range of reactivity modulation gives a 
great opportunity to calibrate the chemical reactivity of covalent 
modifiers for the desired biological target, in order to achieve selectivity 
and good metabolic stability. In theory, the best toxicological and 
pharmacokinetic profile achievable by a covalent modifier is matched 
by compounds carrying low reactive warheads which show poor 
reactivity toward solution of nucleophiles under physiological conditions 
but, after appropriate positioning on target binding site, becomes able 
to selectively react with the desired nucleophile residue. Thus, even if 
there are examples of blockbuster drugs containing very active 
warheads like activated esters (aspirin 50, figure 1.1) and epoxides 
(fosfomycin 51, figure 1.1), the majority of successful drugs contains 
functionalities in which the reactivity is attenuated to achieve targeted 
modulation. 
 
Figure 1.1. Highly reactive blockbuster drugs. Warhead portions colored in red. 
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Despite the warhead reactivity modulation could represent a good 
way to develop covalent binder able to deliver the desired therapeutic 
effect with good safety profiles, very often a proper structural 
optimization is also required to reach these goals. Indeed, as discussed in 
the previous chapter, an improved receptor fitting is useful to enhance 
the ligand-target recognition, limiting off-target risks and, especially in 
presence of low reactive warhead, to increase the receptor occupancy. 
The structural optimization can involve the whole molecular structure of a 
covalent modifier but, usually, it is focused on a specific non-reactive 
“driver portion” linked to the “warhead” by a neutral “linker portion”. The 
modular structural scheme here described is very common among 
pharmaceutically-oriented covalent binders and it is thought to allow a 
free manipulation of structural determinants without accidentally 
modifying the warhead reactivity. Also length or shape changes of the 
“linker portion” can assist in the structural improvement process. It should 
be designed to bring the reactive portion of the covalent binder close 
and with a proper orientation to the targeted nucleophile residue, 
favouring the establishment of covalent bonds. Finally, driver groups as 
well as linker portions can be decorated with different substituents not 
only to enhance the pharmacodynamic profile but also to improve 
ADME parameters. For instance, introduction of hydrophilic substituents 
on these compounds represents a common strategy to increase their 
solubility and to modulate their distribution and/or elimination. 
An example of well-balanced reactivity and recognition is 
represented by β-lactam antibiotics like penicillins and cephalosporins. 
They possess a highly optimized structure able to mime the acyl-D-alanyl-
D-alanine terminal portion of the endogenous substrate of bacterial DD-
transpeptidase enzyme.12 “Driver group” and the “warhead” portions 
are largely overlapping in these compounds so that structural 
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manipulation of the former can impact on the reactivity of the latter 
(Figure 1.2) 
 
 
Figure 1.2. The structure of a D-alanyl-D-alanine dipeptide model is compared with N-
acetylaminopenicillanic and N-acetylaminocephalosporanic acids scaffolds, used as 
penicilline and cephalosporine backbone models respectively. The role of acetyl group 
on D-ala-D-ala model is to mime the peptidic bond that join the D-ala-D-ala dipeptide 
to the remaining structure of growing peptidoglycan within cell wall. Warhead portions 
(circled in red) are recognizable within the driver group structural motif. 
 
Once competitively bounded to the DD-transpeptidase active site, the 
carbonyl portion of β-lactam warhead present in these antibiotics starts 
to undergo nucleophilic attack of the catalytic serine of the enzyme. This 
attack, followed by subsequent β-lactam ring opening and amide 
nitrogen displacement, results in the formation of a catalytically inactive 
and hydrolytically stable form of acyl-DD-transpeptidase (scheme 1.4) 
Acetyl-D-Ala-D-
 
N- N-Acetyl-D-Ala-D-Ala-OH N-acetylaminopenicillanic 
 
N-acetylaminocephaloporanic 
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Scheme 1.4. Acylation mechanisms of penicillin and cephalosporin derivatives. It has 
been proposed that cephalosporines and penicillins can share or not the same serine 
acylation mechanism dependently to the presence of a good or a bad leaving group 
(LG or BLG respectively) in vinilogous position to the β-lactam nitrogen atom.13 
 
The irreversible inhibition of DD-transpeptidase activity leads to the 
blockade of bacterial cell wall biosynthesis and provide to these 
antibiotic agents with a very effective bactericidal action. Notably, the 
D-alanyl-D-alanine fragment mimicry provided by these compounds 
limits the intrinsic reactivity of the β-lactam warhead only to the desired 
target and drastically decreasing their off-target toxicity. 
An alternative strategy to focus the warhead reactivity of a given 
covalent modifier on the desired target without using highly optimized 
driver portion is to limit its action within a specific biological 
compartment only. The easiest way to achieve this goal is to perform a 
pharmacokinetic parameter modulation. For instance, the reactivity of 
some covalent modifiers could be limited only to a specific biological 
district by simply changing their solubility or their trans-mucosal uptake. A 
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good application of the described strategy has been reported for β-
lactone THL (Tetrahydrolipstatin, Orlistat ®, 55, Figure 1.4), a human 
Pancreatic Lipase (hPL) covalent irreversible inhibitor.  
 
Figure 1.4. Structure of Orlistat 55, a hPL irreversible inhibitor drug. 
 
In this case, the poor intestinal uptake of THL helps to keep the 
acylating potential of THL within the intestinal lumen so excluding the 
occurrence of any systemic toxicity. In this way, the reactivity of THL β-
lactone warhead has been pharmacokinetically driven toward the 
catalytically active serine of hPL without requesting any structural 
optimization. 
Otherwise, a more complex approach to compartmentalize the 
action of covalent binders is to design them to act as pro-drugs or as 
mechanism-based inhibitors. In this way, their masked warhead will be 
unveiled only near or inside the desired target respectively and so 
dramatically decreasing their unspecific toxicity. A good example of 
covalent reactive pro-drugs is represented by H+/K+ ATPase inhibitors like 
Omeprazole (Antra ®, 18, Scheme 1.6). The latter possesses a good trans-
membrane uptake and no recognizable warheads can be found within 
its structure. After administration, it can freely reach the bloodstream 
without delivering its reactivity until it reaches gastric oxyntic cells. At this 
stage, omeprazole is exposed to pH value below 4 and its structure starts 
to undergo a complex rearrangement that leads to the formation of 
highly reactive compounds 58 and 59 (Scheme 1.6). 
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Scheme 1.6. Omeprazole acidic assisted rearrangement. The formation of two kind of 
cysteine trapping intermediates (warheads colored in red), a sulfenic acid 58 or a 
cyclic sulfenamide 59 respectively, has been proposed.36 
 
Immediately after, these unstable intermediates quickly react with 
one or more cysteine residue on H+/K+ ATPase, inhibiting its catalytic 
activity. Since, omeprazole efficiently undergoes this kind of 
rearrangement only at pH<4, the covalent inhibitory effect of this drug is 
highly compartmentalized within oxyntic cells. This target-localized 
formation of reactive intermediates reduces the systemic exposure to this 
drug and decreases the occurrence of potential off-target toxicity.  
Finally, vigabatrin (Sabril ®, 60, scheme 1.7) represents a good 
example of mechanism-based covalent modifier. vigabatrin can be 
orally administered providing a specific covalent and irreversible 
inhibition of human GABA aminotransferase, a key enzyme involved in 
GABA catabolism. In animal models, vigabatrin has been recognized to 
protect against convulsion seizures inducing raised brain GABA levels in 
CNS. The anticonvulsant potential of this drug has been quickly 
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pharmacologically exploited for the short-term treatment of epilepsy in 
human. It has been proposed that vigabatrin 60, once reversibly and 
non-covalently bound into the enzyme active site, inhibits GABA 
aminotransferase by irreversible alkylation of Lys258 residue, normally 
involved to the binding of cofactor pyridoxal phosphate (PLP). 14  As 
previously described, the warhead responsible of the covalent GABA 
aminotransferase inhibition is not directly embedded into vigabatrin 
structure but is formed thanks to the normal transaminase activity of its 
target enzyme. Indeed, it is postulated that vigabatrin can form an 
imminium adduct 61 with PLP cofactor. The tautomerization of imminium 
compound 61 lead to an activated enamine species 62 able to 
covalently and irreversibly bind Lys258 by a Mannich addition-based 
mechanism (scheme 1.7).  
 
Scheme 1.7. Mechanism-based activation of vigabatrin 60 and subsequent GABA 
aminotransferase covalent inhibition. The alkylation of Lys258 by activated enamine 
warhead (colored in  red, compound 62) irreversibly inhibit the target. 
 
In this way, this mechanism-based activation provides to vigabatrin 
60 a very high specificity for the desired target and greatly limits the 
occurrence of off-target toxicity. 
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1.2 Cysteine reactive compounds 
As reported in the previous chapter, a proper warhead reactivity 
modulation can enhance the specificity of designed covalent drug 
candidates for a given target. The same concept can be expanded 
designing warheads able to selectively bind a subset of nucleophiles in 
chemical reaction models as well as in biological environments. Indeed, 
following the HSAB (Hard and Soft Lewis Acids and Bases) theory, 
electrophile warhead centres could be tailored to have “hard” or “soft” 
properties in order to direct their reactivity mainly toward “hard” or “soft” 
nucleophiles, respectively. Hard nucleophiles usually have high charge-
density so that are well represented by small charged or highly polarized 
species. Their charge-directed interactions with electrophiles species 
don’t strictly require a well overlapping of nucleophile orbitals with the 
electrophile's accepting ones because charge attraction are enough to 
drive their nucleophilic attack.  
On the opposite, soft nucleophiles reactivity is based on orbitals 
overlapping rather than on charge-directed interactions. Usually, they 
aren’t particularly polarized and present large available orbitals for the 
nucleophilic interaction with the electrophilic partner. 15 , 16  From a 
biological point of view, it is reported that thiol residues of cysteines or 
glutathione and the oxygen of DNA bases are recognizable as the 
softest and the hardest biological nucleophiles respectively. Amino 
groups of lysine or histidine as well as hydroxyl group of serine or 
threonine are considered hard enough to occupy an intermediate 
position between thiols and oxygen atoms of DNA nucleotides.17 On the 
base of these assumptions, a proper tuning of hard/soft reactivity could 
drive the warhead of a given covalent modifier to selectively react with 
soft nucleophiles like thiols, limiting side reactions with harder 
nucleophiles like amine- or hydroxyl- based species. 
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In this way, the achieved nucleophyle-based selectivity could provide 
additional selectivity to the designed covalent modifiers, help them to 
discriminate the desired thiol exposing target from undesired ones.  
Considering that cysteines are coded only with a frequency of 2.26% on 
mammalian proteome,3 is very improbable that different proteins would 
share the same cysteines distribution pattern. This finding represents a 
formidable source of diversity that can be exploited by researcher to 
design very specific covalent modifiers able, after proper structural 
optimization and warhead reactivity tuning, to discriminate similar 
cysteine exposing protein that only differs for their cysteine exposition 
pattern. This opportunity makes cysteine trapping the most promising 
pharmaceutically exploitable class of covalent binders because of their 
theoretical ability to reach the highest target selectivity among them. 
Moreover, cysteine-trapping compounds should present a more 
favorable toxicological profile than other unspecific covalent modifiers. 
For instance, they should not able to directly produce stable covalent 
DNA modifications. On the other hand, their thiol-oriented reactivity 
could be responsible of their increased sensitivity toward glutathione 
mediated bioinactivation. Apart the impact that this detoxication 
mechanism could have on their pharmacokinetic profiles, the resulting 
reduced levels of glutathione induced by these compounds could be 
responsible of intracellular oxidoreductive equilibrium impairment and 
histological toxicity. Despite this, cysteine-trapping compounds are the 
most represented class among covalent reactive compounds currently 
evaluated as drug candidates or that have already reached the 
market.2 Beyond their pharmaceutical exploitability, cysteine trapping 
compounds are also widely used as biological tool to study and/or 
validate clinically important biological targets. For instance, highly 
potent and specific cysteine-trapper are employed as Activity-Based 
Probes (ABP)18 , 19  or AFfinity-Based Probes (AFBP) to label a subset of 
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related cysteine exposing proteins across proteome. While the labeling 
potential of ABP is directed toward catalytically active cysteine residues, 
AFBP are designed to react less specifically with all kind of solvent 
exposed thiol residues. Cysteine reactive ABP and AFBP are usually 
designed to contain easily recognizable tag portions (e.g. fluorescent, 
radioactive or biotinylated functionalities) in order to improve the 
purification and the identification of labeled proteins.19 
Development of cysteine-protease inhibitors has shown that many 
warheads with different chemical reactivity are able to selectively react 
with specific catalytic or non-catalytic cysteine residues in cysteine-
protease active sites. Despite this, a specific cysteine trapping activity 
has been verified only for few of considered warhead classes. For 
instance, β-lactone based warheads has been claimed to irreversibly 
inhibit Hepatitis Virus A 3C cysteine protease (HVA 3C) by Cys172 
covalent targeting4 but, in the same time, this warhead has been 
reported to be responsible of the irreversible acylation of the catalytic 
serine of hPL.20 In this way, only a limited kind of chemical entities can be 
considered to possess a true cysteine-specific reactivity.2, 21  These 
cysteine-specific warheads can be classified on the base of their 
reaction mechanisms. So they can be grouped as (1) nucleophile 
substitution reaction based, (2) addition reaction based and (3) 
addition-elimination reaction based warheads. 
 
1.2.1 Nucleophile substitution reaction-based cysteine 
reactive compounds: activated α-methylketones 
α-methyketones having an appropriate leaving group attached to 
their α-methylene portion are able to alkylate cysteine targeted residue 
by nucleophylic substitution (Figure 1.5).  
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Figure 1.5. Structure and reaction mechanism of activated α-methylketone. Warhead 
portions are colored in red. 
 
All activated α-methylketones here reported are widely used as 
labeling agents in biological investigation and many of them can be 
readily bought because of their commercial availability. α-fluoro-,22 α-
diazo-, 23  and α-acyloxy- methylketones4 (65, 66 and 67 respectively, 
Figure 1.5) have been proved to be stable in model reactions carried out 
exposing them to thiols like glutathione and 1,4-dithio-DL-threitol (DTT). 
This chemical behavior suggests that they should possess low 
warhead reactivity able to prevent the alkylation of unwanted targets or 
to hamper their glutathione-dependent biological deactivation. All 
reported α-methyketones have been joined to different kind of peptidic 
or peptidomimetic driver groups in order to develop potent and 
irreversible cysteine protease inhibitors. Dependently on their driver 
group tailoring,  α-fluoromethylketone based compounds 65 have been 
reported to inhibit a wide range of pharmacologically relevant cysteine 
proteases4, 24 , 25  like cathepsin B, calcipain and cruzain. Good 
pharmacokinetic profiles have been reported for many α-
fluoromethylketones. They were proved to be orally available and to 
have high target specificity and to not induce mutagenicity. Despite 
their therapeutic potential against disease like rheumatoid arthritis, 
Malaria and Chagas’ diseases, α-fluoromethylketones presents some 
toxicity problems related to their metabolic reprocessing. Indeed, their 
metabolic degradation releases the extremely toxic fluoroacetate anion 
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that, miming acetate units in cellular Krebb cycle, acts as metabolic 
poison in mammalians.4  
α-aryloxy- and α-acyloxy- methylketones (66 and 67 respectively) were 
reported to irreversibly react with target cysteines forming stable 
thioether derivatives. Despite this, different kinds of α-aryloxy- and α-
acyloxy- methylketones were reported to inhibit the cysteine protease 
caspase-1 irreversibly or reversibly as well. α-acyloxymethylketones are 
been found quite effective to inhibit liver cathepsin B activity after in vivo 
administration in rat. α-aryloxy- and α-acyloxy- methylketone warheads 
can be also recognized within the structure of new EGFR irreversible 
inhibitors designed and synthesized during the accomplishment of this 
PhD project. 
 
1.2.2 Nucleophile substitution reaction-based cysteine 
reactive compounds: disulfides and sulfenamides 
Disulfide bond forming warheads like disulfides (A and B, Figure 1.6) 
and sulfenamides (C and D, Figure 1.6) represent good examples of 
“soft” electrophiles able to selectively react with “soft” nucleophiles like 
thiols. Disulfides and sulfenamides are one of the most frequently 
pharmacologically exploited kind of cysteine trapping warheads 
reported in literature. In term of reactivity, disulfides26 and sulfenamides27 
are mainly characterized by the ability of sulfur atom to be attached by 
soft nucleophile species with subsequent neighboring heteroatom 
displacement as reported in figure 1.6. 
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Disulfides derivatives A and B were reported to inhibit alcohol 
dehydrogenase (ALDH), 28 , 29  Human Immunodeficiency Virus 
nucleocapsid zinc finger protein (HIV-1 NCp7), 30  Epidermal Growth 
Factor Receptor (EGFR)31 and MonoAcylGlycerol apse (MAGL).32,33  
 HIV-1 NCp7 play a pivotal role for HIV life cycle and its mutation or 
modification is not tolerated. NCp7 select the viral RNA from cellular RNA 
for its dimerization and packaging, stimulate reverse transcription and 
protect the viral RNA from nucleases. It was reported that disulfides 
inhibits NCp7 by a covalent binding of one of three cysteine residues 
present within zinc-finger motives of the enzyme. The covalent 
modification destabilizes the Zn2+ ion coordination and triggers the 
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ejection of metal ion from the targeted zinc finger motif. The resulting 
unfolding of zinc fingers impairs the viral RNA recognition process and 
slow down viral replication. Despite this interesting finding about HIV-1 
NCp7 inhibition, disulfides are more known as ALDH irreversible inhibitors. 
The commercially available drug disulfiram (Antabuse ®, 68, Scheme 1.8) 
irreversibly inhibits human alcohol dehydrogenase (ALDH) in vitro28 and in 
vivo29 binding its catalytic residue Cys305. 
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Scheme 1.8. Inhibitory mechanism of disulfiram 37 on human alcohol dehydrogenase. 
 
While in vitro studies have suggested that the ALDH inhibition was 
accomplished by the formation of mixed disulfide 68, a metabolic 
dependent activation of disulfiram has been observed in vivo. In this 
way, it is thought that Cys305 was irreversibly bound by the 
thiocarbamoylthioesther intermediate 71 rather than mixed disulfides 
adduct 69.29 
Despite no commercially available drugs are based on isothiazol-
3(2H)-one (Figure 1.6, C) or 1,2,4-thiadiazole (Figure 1.6, D) warheads, 
these sulfonamide warheads have been reported to be present in a 
large amount of biologically active compounds. Even sharing a similar 
warhead structure, these compounds have shown an impressive 
versatility in term of biological target diversity range.  
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Dependence of observed biological activity to their reactivity 
toward thiols has been demonstrated only for few sulfenamide 
compounds like isothiazol-3(2H)-ones and 1,2,4-thiadiazoles  (figure 1.7). 
Indeed, the formation of disulfide bridges between these warheads and 
their designed targets has been directly observed only for isothiazol-
3(2H)-ones34 and 1,2,4-thiadiazoles35 derivatives by LC-MS analysis and X-
ray diffraction respectively. 
For instance, the inhibition P56lck kinase by isothiazol-3(2H)-ones34 
has been confirmed by comparison of mass spectra of native P56lck 
kinase with the isothiazol-3(2H)-one-labeled one. These spectra shows 
three different covalent modified cysteine residues and their positions 
have been elucidated by further LC-MS analysis on tryptic fragments of 
isothiazol-3(2H)-one-labeled P56lck kinase. 
 
 
Figure 1.7. Sulfenamidic compound for which biological activity is proved to be 
dependent to their cysteine trapping reactivity. 
 
On the hand, only indirect experimental evidences have been 
reported to support a possible correlation between the cysteine trapping 
activity of many others sulfenamide derivatives and their biological 
effects (Figure 1.8).35,36, 37, 38,39, 40, 41 
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Figure 1.8. Sulfenamidic compounds for which biological activity is suspected to be 
dependent to their cysteine trapping reactivity. The experimental way used to verify the 
disulfidic nature of covalent target modification is specified by apex characters: a DTT 
addition, recovery of target biological activity; b L-cysteine addition, loss on biocide 
activity of tested compounds; c disulfide bond formation evaluation by zinc extrusion 
measurements, d DTT addition: loss of radioactivity from [H3]-omeprazole-target adduct. 
 
For instance, the formation of disulfide bridges between tested 
sulfenamide warhead and targeted cysteine residue has been often 
established observing the effects of disulfide reducing agents on the 
covalent modified target. Indeed, restoration of free cysteine residues 
usually leads to the target biological activity recovery37a, 35, 38, 41 or to 
other measurable effects such as radioactivity loss when radio-labeled 
sulfenamides are used for target modification.36 Unfortunately, these 
findings did not prove the occurrence of cysteine covalent modification 
but they only have provided indications about this occurrence. Finally, 
the thiol-trapping activity of some isothiazol-3(2H)one derivatives has 
been only postulated and not yet experimentally verified (Figure 
1.9).42,43,44 
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Figure 1.9. Sulfenamidic compounds for which biological activity is suspected to be 
dependent to their cysteine trapping reactivity. 
 
Non-halogenated 2-methylisothiazol-3(2H)-one presents a very 
specific reactivity toward thiols and it has been found unreactive toward 
other nucleophiles like amines and alcohols in aqueous solution. Despite 
the presence of a potential Michael acceptor system, no Michael 
addition to the conjugated carbon-carbon double bond of isothiazol-
3(2H)–one derivatives has been observed until now.8 Since isothiazol-
3(2H)-ones and benzo[d]isothiazol-3(2H)-ones derivatives have been 
reported as highly reactive toward thiols9 and responsible to induce skin 
sensitization in exposed subjects,8,45 one can be tempted to consider 
these warhead too reactive to be druggable. Otherwise, low in vivo 
toxicity and good bioavailability have been reported for some isothiazol-
3(2H)-one derivatives.40b, 42b N-unsubstituted benzo[d]isothiazol-3(2H)-
ones carrying different substituents on benzo fused ring have been in 
vivo orally administered in mice or rats to evaluate their antimicrobials 
potential.  LD50 values for each of them have been collected (Table 1.1). 
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Compound R1 Form of preparation Animal LD50 
71 5-Cl N/A mouse 390 mg/Kg 
72 6-CH3 N/A mouse 510 mg/Kg 
73 6-Cl Suspension 
(free base) 
mouse ≈ 4600 mg/Kg 
73 6-Cl Suspension 
(free base) 
rat >4300 mg/Kg 
73’ 6-Cl Sodium salt mouse 1400 mg/Kg 
 
Table 1.1. In vivo toxicity of benzo[d]isothiazol-3(2H)-one derivatives carrying different 
substituents on the aromatic portion. 
 
Among tested compounds, 6-Chloro derivative 73 shows the lower 
LD50 value and its toxicity seems related to its solubility (the sodium salt 
derivative 73’ is more soluble and more toxic than suspended free base 
counterpart 73). When orally administered in mice, 6-
chlorobenzo[d]isothiazol-3(2H)-one 73 has been found able to inhibit the 
growth of a wide-spectra of microorganisms within the intestinal 
environment with no selection of any particular kind of them. Despite 
this, the bacteriostatic activity of 6-chlorobenzo[d]isothiazol-3(2H)-one 
73, probably due to its poor solubility, has been found restricted to the 
gastrointestinal lumen because it was unable to prevents systemic 
infections in mice induced by E.coli or Str. Pyogenes (with drug oral doses 
of 40 mg/Kg and 100 mg/Kg). 
Despite 6-chlorobenzo[d]isothiazol-3(2H)-one 73 has shown a low 
acute toxicity, chronic administration of increased amounts of 6-
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chlorobenzo[d]isothiazol-3(2H)-one 73 in rat has produced a significant 
but reversible increase in relative liver-weight. Notably, no histologically 
detectable changes have been found (table 1.2). 
  
Oral dose Relative liver-weight increased Histological changes 
60 mg/Kg NO NO 
180 mg/Kg YES NO 
540 mg/Kg YES NO 
 
Table 1.2. In vivo chronic toxicity of 6-chlorobenzo[d]isothiazol-3(2H)-one at different 
oral doses. 
 
In addition to these low toxicity levels, a very good pharmacokinetic 
profile has been reported for another N-alkyl benzo[d]isothiazol-3(2H)-
ones like (2R,3S)-3-methyl-2-(3-oxobenzo[d]isothiazol-2(3H)-yl)pentanoic 
acid 74 (Table 1.3). This derivative has been in vitro found effective to 
inhibit the HIV proliferation in HIV infected Chick Embryonic Metastasis 
cells (EC50 from 1.9 to 6.7 µM dependently to the kind of considered HIV 
strain) with a good therapeutic indices (TC50/EC50 > 12). The 
pharmacokinetic of 74 has been explored by in vivo (mice) sub-
cutaneous and oral administrations (Table 3). 
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Adm. route 
Dose 
(mg/Kg) 
Cmaxa 
(µg/ml) 
AUCa 
(µg*h/ml) 
T1/2 
(h) 
F 
% 
SC 
125 83 380 2.7 N/A 
200 108 645 4.6 N/A 
PO 
125 49 327 2.1 82 
200 83 661 4.6 100 
Table 1.3. Pharmacokinetic data of in vivo (mice) administration of compound 45. 
a Plasmatic concentrations have been determined as free thiol equivalents by 
reduction of all samples with DTT. 
 
The maximal reached concentration in plasma (Cmax) and AUC 
were increased proportionally in tested dosing range. Compound 74 was 
reported well tolerated at the tested doses with a calculated half-life of 
3.5 h and an oral bioavailability of 91%. Taken together, these findings 
provide a solid rational to consider isothiazol-3(2H)-one and 
benzo[d]isothiazol-3(2H)-ones as suitable warhead portions for the 
development of new highly selective and druggable cysteine trapping 
compounds. 
Finally, 1,2,4-thiadiazoles have been reported to react with thiols 
with the same reaction mechanism suggested for isothiazol-3(2H)-one 
and benzo[d]isothiazol-3(2H)-ones warheads (Figure 1.6, D). Like 
previously reported sulfonamide warheads, 1,2,4-thiadiazoles have been 
reported to selectively react with soft nucleophiles like cysteine, without 
undergoing nucleophilic attack by other harder nucleophiles like amines 
or alcohols. Some 1,2,4-thiadiazole derivatives were reported be stable 
when exposed to reducing agents like DTT for hours and to inhibit 
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cysteine protease such as papain and cathepsin by covalent targeting 
of their catalytic cysteine residues 35  
The highly focused reactivity toward thiols shared by all reported 
sulfenamide warheads as well as the good pharmacokinetic and 
toxicological profiles characterizing some benzo[d]isothiazol-3(2H)-one 
based compounds could suggest a good druggability for these kind of 
warheads. In this way, they could be suitable for pharmacologic 
exploitation. 
 
1.2.3 Addition reaction-based cysteine reactive compounds: 
simple addition reaction based warheads 
This class includes strained three membered rings reactive moieties (A, B, 
C) as well as α-cyanomethyl derivatives (D) able to undergo addition 
reactions (Figure 1.10). 
Figure 1.10. General structures and reaction mechanisms of most representative three 
membered ring and cyanomethylamide warheads. Warhead portions are colored in 
red. 
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Epoxysuccinates (A) and α-aminoalkylepoxydes (C) have been 
reported to be stable in presence of nucleophiles as thiols.4 Moreover, 
aziridine derivatives (B) have been reported as stable in presence free 
thiols like cysteine and also in presence of species carrying free hydroxyl- 
or amino group like threonine or glutamate.46 Among this collection of 
three membered ring warheads, epoxysuccinate warheads are the most 
studied and widely reported in literature. The first discovered 
epoxysuccinyl derivative with inhibitory activity toward cysteine protease 
was E-64 (75, Figure 1.11), a natural compound initially isolated from 
Aspergillus japonicus. 
 
Figure 1.11. Structure of E-64 from Aspergillus japonicus. Warhead portion is colored in 
red. 
 
E-64 was reported as highly potent irreversible covalent inhibitor of 
many cysteine proteases. It is reported that E-64 does not react with 
other kind of protease but was unable to selectively drive its reactivity 
toward a specific cysteine protease. In this way, E-64 inhibits a large 
number of cysteine proteases like papain, ficin, bromelain, chatepsin 
(subtypes B, H, F, K, L, O, S, V and X), calpain, cruzain and other 
proteases. For these reasons, since discovered, E-64 was used as 
unspecific ABP (Activity-Based Probe, see chapter 1.2) for biological 
investigation purposes. Many other derivativatives of E-64, all of them 
possessing a trans-configured epoxyde functionality, have been 
synthesized by modification of decorating groups neighboring the 
epoxyde warhead portion. They were used as AFBP (see also Chapter 
1.2) to study the histochemical distribution and the biological functions of 
cysteine proteases. 
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Epoxysuccinates were found very effective in vivo as cysteine 
protease inhibitors because of their high potency, stability and 
permeability into cells and tissues. In vivo administration of 
epoxysuccinates has been found effective to decrease osteoblasts-
dependent bone resorption and to induce cytoprotection in heart and 
brain ischemic animal models.4 
Cyanomethylamides (D) were reported as cysteine protease 
inhibitors too. Since cyanomethylamide moiety can be easily recognized 
as warhead portion on both serine47 and cysteine trapping compounds, 
cyanomethylamide warheads cannot be considered cysteine selective 
themselves. On the other hand, the high specificity and the excellent 
pharmacokinetic profile of cyanomethylamide armed compound like 
odanacatib (76, Scheme 1.9) make this warhead class worthwhile in 
term of druggability. Odanacatib has reported to covalently interact 
with an unspecified cysteine group on cathepsin K, inhibiting this enzyme 
by formation of a reversible thioimidate complex (Pinner reaction). 
 
 
Scheme 1.9. Covalent binding mechanism of odanacatib toward cathepsin K by Pinner 
reaction. The equilibrium between thioimidate complex and the reaction mechanism 
intermediate 76’’ make the covalent binding completely reversible. The odanacatib 
warhead portion is colored in red. 
 
The inhibition of cathepsin K provided by odanactib could be useful 
to decrease the bone resorption rate in pathological conditions. 48 
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Actually, odanactib represents one of the most clinically advanced drug 
candidate (phase III) for the treatment of post-menopausal osteoporosis. 
 
1.2.4 Addition reaction-based cysteine reactive compounds: 
Michael addition reaction based warheads 
As reported for disulfides and sulfenamides, α,β-unsaturated 
systems could represent good examples of “soft” electrophylic warheads 
able to selectively add “soft” nucleophiles (like thiols) to their conjugated 
carbon-carbon double bonds, undergoing Michael addition reaction. 
Both α,β-unsaturated carbonyls and α,β-unsaturated sulfones (A’, A’’ and 
B respectively, Figure 1.12) provide irreversible alkylation of targeted 
cysteines.  
 
Figure 1.12. General structures of α,β-insaturated Michael acceptor warheads with 
specific reactivity toward cysteine residues. 
 
Despite Michael acceptor systems are claimed to be highly 
selective for cysteine addition, not all of them are druggable enough to 
be embedded in molecules designed for therapeutic purposes. Among 
them, vinylsulphones (B) should represent the most druggable class 
because they were reported to be very stable toward glutathione 
exposure.4 On the opposite, the highly activated Michael system present 
in maleimides (A’) quickly reacts with thiols suggesting an unfavorable 
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metabolic profiles for molecules carrying this warhead. On the other 
hand, the highly focused cysteine-trapping reactivity of maleimides 
allows their use as warhead portions in compounds designed to act as 
pharmacological or biological tools rather than as drugs.49 The use of 
α,β-unsaturated carbonyl derivatives (A, figure 1.12) as cysteine protease 
inhibitors is very limited. Rhinovirus 3C protease (3CP) has been targeted 
by α,β-unsaturated carbonyl derivatives. This cysteine protease is 
essential for the rhinovirus life cycle because it is responsible of the 
cleavage of the virus polyproteins into structural and enzymatic proteins, 
crucial for virus replication. The most clinically advanced α,β-unsaturated 
carbonyl derivative for 3CP protease inhibition is rupintrivir 77 (phase II), a 
promising drug candidate for the treatment of “common cold” (Figure 
1.13).  
 
Figure 1.13. Structure of rupintrivir, the most clinically advanced irreversible 
peptidomimetic inhibitor of Rhinovirus 3CP. Warhead portion is colored in red. 
 
Rupintrivir was reported to irreversibly inhibit Rhinovirus 3C protease 
by covalent binding of the catalytic cysteine residue in the active site of 
the enzyme, decreasing the severity of “common cold” in humans.4 
Unfortunately, the development of rupintrivir 77 is actually stopped 
because of lack of clinical efficacy in naturally occurred rhinovirus 
infections.50 
α,β-unsaturated sulfones B were used as ABP or AFBP (see Chapter 
1.2) for biological investigations as well as very successful cysteine 
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protease inhibitors. They are stable and unreactive toward nucleophiles 
outside the cysteine protease catalytic machinery. α,β-unsaturated 
sulfone warhead can be recognized within the molecular structure of 
promising bone resorption inhibitors as well as anti-trypanosome, anti-
malarial and anti-protozoal agents. Outside of cysteine protease 
framework, both α,β-unsaturated carbonyl and α,β-unsaturated sulfones 
derivatives were reported to covalently bind and irreversibly inhibit 
pharmacologically important targets like EGFR (see Chapter 2). 
 
1.2.5 Addition-elimination reaction based cysteine reactive 
compounds 
Within this warhead class, only the alkylhydrazinecarboxylate 
warhead has been reported to selectively react with thiols rather than 
other kind of nucleophiles (Figure 1.14) 
 
Figure 1.14. Overview of the two stage carbamoylating mechanism of 
alkylhydrazinecarboxylate warheads 54. 
 
Like other carbamates, these warheads were reported able to 
carbamoylate the target producing a carbamoylcysteine residue which, 
in some biological environments, can result stable to hydrolysis. This was 
Cysteine modifiers in drug discovery.                                              Chapter 1 
35 
accomplished through a two stage reaction mechanism in which the 
nuclephilic attach of thiol leads to the formation of an unstable 
tetrahedral intermediate. After this, the tetrahedral structure of 
intermediate collapse and the alkyloxy leaving group is displaced away 
to produce the stable carbamoylated enzyme (Figure 1.4). The specific 
reactivity of this kind of warheads toward thiols was related to the low 
nucleofugicity of the alkyloxy leaving group. Indeed, among biological 
nucleophiles, only thiols are strong enough to efficiently displace this bad 
leaving group. This means that only thiol exposing biological targets 
could be efficiently carbamoylated by these warheads. The 
dependence of their carbamoylating potential to the nucleofugicity of 
oxygenated leaving group can be easily verified considering the serine-
trapping activity of carbamate carrying more nucleofuge leaving 
group.4 Despite the specific cysteine reactivity showed by 
alkylhydrazinecarboxilate warheads, no therapeutic applications were 
reported for such compounds. Nevertheless, the good solution stability of 
alkylhydrazinecarboxilate moieties allows their use as active site titrants 
for cysteine protease quantification or, once linked to a proper driver 
group, as tools for in vivo investigations.4 
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1.3 Cysteine-reactive compounds as drugs or 
pharmacological tools: some steps forward 
As described in Chapters 1.2, cysteine-trapping compounds can be 
efficiently used as biological or pharmacological tools and as drugs as 
well. Next chapters will show how structure tailoring and/or warhead 
reactivity modulation strategies can be applied to cysteine trapping 
compounds in order to develop new covalent inhibitors for 
pharmacologically relevant cysteine-exposing targets like Epidermal 
Growth Factor Receptor (EGFR) (Chapter 2) or MonoAcylGlycerolLipase 
(MAGL) (Chapter 3). The development of a new covalent EGFR pro-
drug, able to unmask its Michael acceptor warhead within the EGFR ATP 
binding side, will be reported too (Chapter 2). 
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2.1 Introduction 
Receptor protein kinases (RPTKs) play a central role in signal 
transduction pathways, regulating cell division and differentiation. 
Among them, the epidermal growth factor receptor (HER-1/ErbB1/EGFR), 
one of the most important member of ErbB protein family, is involved in 
the regulation of several key processes such as cell proliferation, survival, 
adhesion, migration, and differentiation. 51  Overexpression of EGFR 
tyrosine kinase was reported in a variety of human tumors and was 
associated with poor prognosis.52,53 Therefore, inhibition of EGFR kinase 
activity has emerged as a promising new approach to cancer therapy 
and several small molecule tyrosine kinase inhibitors are currently in 
clinical use or development. Out of the numerous inhibitors of EGFR 
reported in the last few years, compounds competing with ATP for 
binding at the catalytic tyrosine kinase domain of EGFR are of special 
interest. Unfortunately, despite the clinical efficacy of some of these 
compounds as anticancer drugs, accumulated clinical experience 
indicates that specific populations of patients can develop resistance 
against these drugs due to expression of a mutated form of EGFR.54 In 
order to overcome this occurrence some covalent irreversible EGFR 
inhibitors are synthesized by researchers. These derivatives act as non-
competitive inhibitors binding the ATP-binding site of EGFR-TK domain by 
a covalent irreversible interaction with a solvent exposed cysteine 
residue. Despite these drugs are proven to be effective to overcome the 
drug resistance induced by EGFR mutation,55  it is reported that their 
effective clinical efficacy is limited by occurrence of dose–limiting 
toxicity problems.97 Since few kinds of warhead portions have been 
embedded to irreversible EGFR inhibitors tested until now,31, 89-86 an 
expanded exploration of different cysteine-reactive warhead could help 
to achieve better toxicological profiles. In this way, a systematic 
EGFR targeting                                                                                    Chapter 2 
39 
structure-reactivity relationship study could be carried out on these 
compounds to enhance their toxicity/efficacy ratio. 
2.1.1 The HER receptor family: structure, expression and 
physiological functions 
The human epidermal growth factor receptor (HER) family (also 
known as ErbB receptor family) is composed of EGFR/HER-1/ErbB1, HER-
2/ErbB2, HER-3/ErbB3, and HER-4/ErbB4. These receptors share common 
structural features like an amino-terminal extracellular ligand-binding 
domain (except HER-2/ErbB2), a single transmembrane anchoring 
domain and a carboxy-terminal intracellular domain endowed with 
tyrosine kinase activity (except HER-3/ErbB3) and involved in regulatory 
functions (Figure 2.1).53 Among HER receptor family, only HER-1, HER-3, 
and HER-4 bind canonical growth factor ligands while no ligands were 
identified for HER-2. Except HER-3, all other HER family members are 
active as tyrosine kinases.53,56 
 
 
Figure 2.1. The HER family members. Known ligands are reported in the upper position 
for each depicted receptor.57 
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Each HER receptor is fundamentally an inactive monomer that 
dimerizes in response to ligand binding. The dimerization process 
activates the tyrosine kinase activity of the receptor and triggers a 
complex downstream signalling network involved to regulation of 
specific aspects of cell function 58  such as gene expression, cellular 
proliferation, angiogenesis, and inhibition of apoptosis (Figure 2.2)  
 
 
Figure 2.2. The EGFR signalling network.53 
 
HER-1/ErbB1/EGFR could be considered the most studied and 
clinically important member of HER receptor family. A large spectrum of 
ligands can bind this receptor inducing its homo- or heterodimerization 
with remaining HER members (especially with HER-2) on the cellular 
surface. Once dimerized, the autophosphorylation of the 
intracytoplasmic EGFR portion take place. Phosphorylated tyrosine 
residues on EGFR intracellular domain serve as binding sites for the 
recruitment of signal transducers and activators of intracellular substrates 
which then stimulate an intracellular transduction cascade that transmit 
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signals to the cellular nucleus (Figure 2.2).59,60 Finally, the EGFR signalling is 
mainly inactivated through endocytosis of the dimeric receptor-ligand 
complexes. The contents of the resulting endosomes are then either 
degraded or recycled to the cell surface58,61 
 
2.1.2 The role of EGFR activation in human development and 
diseases 
The HER family lies at the head of a complex signal transduction 
cascade that modulates cell proliferation, survival, adhesion, migration 
and differentiation. While growth-factor-induced EGFR signalling is 
essential for many normal morphogenic processes and involved in 
numerous additional cellular responses, the aberrant activity of members 
of this receptor family has been shown to play a key role in the 
development and growth of tumor cells. It is also reported that 
stimulation of EGFR pathways could also contribute to the development 
of malignancy of tumors,51,62 promoting tumor cell motility, adhesion and 
metastasis. 63  In addition, a link between EGFR activation and 
angiogenesis, which is crucial to sustain tumor growth and invasion, has 
been described. 64,65   
2.1.3 Pharmacological potentials of EGFR inhibition 
Over the recent years, much evidence has been collected to 
implicate the EGFR and its family members in the development and 
progression of numerous human tumors. The EGFR can results in tumor 
development by different mechanisms acting either separately or in 
combination. This includes receptor overexpression, gene amplification, 
activating mutations, and autocrine factor loops. Most epithelial tumors, 
such as head-and-neck, colorectal carcinoma, lung carcinoma, 
esophageal carcinoma, gastric carcinoma, and breast carcinoma, 
EGFR targeting                                                                                    Chapter 2 
42 
overexpress the EGFR. The discovery of constitutive active mutations of 
the EGFR has been described, providing another mechanism for EGFR-
induced tumorigenesis. The mutated EGFR variant EGFR (v) III, the best 
characterized and the most frequently found in human tumors, presents 
a constitutive-active, ligand independent tyrosine kinase activity that 
stimulates cell proliferation in the absence of activating ligands.66,67 For 
the pivotal role of EGFR in tumor development and progression, this 
receptor has become a target for anticancer drug development, and 
several inhibitors of the EGFR are currently in clinical use or development. 
In addition, EGFR inhibition has been very recently proved to be 
pharmacologically exploitable as a new strategy to enhance the nerve 
regeneration in injured nervous tissues. Indeed, EGFR inhibition seems to 
slow down the formation of glial scars inhibiting the astrocytes 
proliferation and to promote nerve regeneration in vitro and in vivo.68 
2.1.4 EGFR inhibition strategies 
The evidence of significant involvement of EGFR in the growth of 
solid tumors provides a strong rationale for developing agents that target 
the EGFR signalling system. Various approaches have been described 
regarding EGFR-targeted therapies (figure 1.3). These include: (i) 
monoclonal antibodies (mAb) that compete with activating ligands at 
the extracellular domain, (ii) small molecule inhibitors that target the 
intracellular tyrosine kinase domain, (iii) immunotoxins conjugates, (iv) 
EGFR-targeted antisense oligonucleotides, and (v) downstream inhibitors 
of the EGFR signalling pathway. 
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Figure 2.3. Therapeutic strategies for blocking the EGFR signalling network53 
 
Among these approach, small-molecule compounds that interfere with 
intracellular EGFR tyrosine kinase activity are, together with monoclonal 
antibodies, the most extensively studied approach to block the EGFR 
signal. Small-molecule inhibitors target the intracellular tyrosine kinase 
domain of the receptor and inhibit the activation of downstream 
signalling pathways. These agents has shown many advantages over 
the other larger molecules directed to EGFR: they can be made more 
easily, they may show increased penetration into solid tumors, and they 
may have the advantage over targeting the extracellular region 
especially in cases where truncation of the extracellular domain of 
EGFR has led to ligand independent tyrosine kinase activity. 
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2.2 EGFR-TK domain inhibitors 
Dependently to their binding mode with EGFR-TK domain, EGFR 
tyrosine kinase inhibitors can be classified in two different classes: 1) ATP-
competitive inhibitors (reversible) and 2) ATP non-competitive inhibitors 
(irreversible or partially reversible). 
The first class is populated by many structurally different compounds 
able to inhibit EGFR-TK activity by competing with ATP for binding at the 
catalytic domain of the enzyme. As a class, they interact with TK-domain 
in a reversible and non-covalent manner. Despite the clinical efficacy of 
some of these compounds as anticancer drugs in specific populations of 
patients with tumors harboring oncogenic forms of tyrosine kinases EGFR 
variant (v) III,69 accumulated clinical experience on non-small-cell lung 
cancers (NSCLCs) indicates that most patients develop resistance due to 
expression of mutated EGFR.54 The replacement of the gatekeeper 
threonine 790 by a bulkier methionine residue in this mutated EGFR (EGFR 
T790M) seems to increase the EGFR-TK affinity for ATP so to decrease the 
binding effectiveness of competitive reversible drugs for the same 
receptor binding site. Despite the potency decreasing induced by this 
mutation is not so dramatic, the intracellular ATP concentration become 
higher enough to push-out the drug from EGFR ATP-binding site so to 
restore the EGFR-TK functionality.70  
In order to assure to these molecules an effective binding also in 
presence of T790M mutation, the second class of EGFR-TK inhibitors was 
developed by scientists. Compounds belonging to this class have 
structures still designed to mime ATP within the active site of EGFR-TK but 
they are equipped also with a warhead portion that allow them to 
covalently interact with a cysteine residue located within the ATP-
binding site of EGFR-TK. Their covalent binding mode provides a non-
competitive inhibition of EGFR-TK, overcoming in this way the drug 
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resistance induced by T790M. Moreover, the additional binding affinity 
provided by formation of covalent adducts often give to these 
compounds the ability to bind and to inhibit one or more receptors 
among the remaining catalytically active HER members. This expanded 
binding spectra could be used to turning off more completely the HER 
receptors signalling, especially when there are evidences that other HER 
receptors than EGFR are involved into tumor growing process. For 
instance, they could be useful in the treatment of breast cancer in which 
the overexpression of HER-2 was detected in about 30% of cases.71 
2.2.1 EGFR-TK domain structure 
As determined by crystallography,82 the EGFR kinase domain (EGFR-
TK domain) consists of two major lobes separated by a narrow cleft 
(hinge region) that defines the ATP-binding pocket and the site where 
ATP-mimetic inhibitors interact with the enzyme. The N-terminal lobe 
consists of mostly β-strands and one conserved α helix. The C-terminal 
lobe is largely helical and contains a segment, the activation loop, 
which includes the tyrosine residues that are phosphorylated for activity. 
The hinge region connects the two lobes (Figure 2.4 a). 
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    a      b 
Figure 2.4. (a) The structure of the catalytic domain of EGFR in complex with tarceva; 
(b) Structure of the ATP-binding site of EGFR. 
 
The ATP-binding site of EGFR can be divided into five regions: the 
adenine region, the sugar pocket, two hydrophobic regions, and the 
phosphate binding region (Figure 2.4 b). In the adenine region, the 
adenine ring of ATP can engage hydrogen bond interactions with amino 
acid residues of the hinge region. The sugar pocket is of hydrophilic 
character, it contains the Cys773 residue, unique to the EGFR family of 
kinase, that could provide to covalent inhibitors both potency and 
selectivity (see below). The hydrophobic pockets are not normally 
occupied by ATP but may be used for the design of new inhibitors. 
Finally, the phosphate binding region has high solvent exposure and 
does not play a key role with respect to the binding affinity.  
2.2.1 Reversible EGFR-TK inhibitors 
Probably the erliest widely used EGFR inhibitor was the isoflavone 
genistein (Figure 2.5). 72  Genistein belong to the first class of EGFR-TK 
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inhibitors because inhibits EGFR in the submicromolar range by 
competing at the ATP-binding site of the enzyme. 
Among these class members, the most advanced in clinical 
development are 4-anilino-quinazolines,73,74 with two derivatives, gefitinib 
(Iressa™, AstraZeneca) and erlotinib (Tarceva™, Genentech/Roche), 
recently approved for clinical use in the treatment of non-small-cell lung 
cancer (NSCLC) (Figure 2.5).  
 
Figure 2.5. Chemical structures of some known reversible EGFR TK inhibitors. 
 
4-Anilino-quinazolines represents a highly selective and potent class 
of ATP-competitive EGFR TK inhibitors with reported IC50 values in the 
nanomolar and subnanomolar range. Eventually, a number of 
alternative chemical classes were also shown to be equally efficient 
structural templates including other bicyclic pharmacophores such as 
pyridopyrimidines, 75  quinoline-3-carbonitriles, 76  pyrimidopyrimidines, 77 
pyrrolopyrimidines, 78  and pyrazolopyrimidines, 79  as well as tricyclic 
molecules such as imidazoloquinazolines, pyrroloquinazolines, and 
pyrazoloquinazolines.80,81 
Although many different chemical templates have been explored 
over the years, the more successful compounds possess certain common 
structural elements that are responsible for the tight-binding affinity to 
their targets. The disclosed structure of EGFR co-crystallized with the 
inhibitor erlotinib (Tarceva™),82 as well as some of the earlier predictions 
for inhibitor-enzyme interactions using homology models of EGFR,76,81,83 
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have been used to explain how these inhibitors can achieve their 
remarkable affinity and selectivity. 
The crystal structure of the kinase domain from the EGFR with the 
EGFR TK specific inhibitor erlotinib (Tarceva™),82 provided direct 
structural evidences about how 4-anilinoquinazoline ATP-competitive 
inhibitors bind, at a molecular level, the catalytic domain of EGFR (Figure 
2.6).  
 
Figure 2.6. EGFR TK domain co-crystallized with erlotinib (Tarceva™). 
 
The N1-C8 edge of the quinazoline nucleus is directed into the 
adenine pocket with the substituents at the C6 and C7 positions directed 
out toward the solvent and the aniline pointed into a hydrophobic 
pocket (Figures 2.6 and 2.7). 
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Figure 2.7. Interactions established by 4-anilino-quinazoline scaffold within the ATP-
binding site of EGFR. 
 
 The N1 of the quinazoline points toward the amide NH of Met769, 
forming a stable hydrogen bond. The other ring nitrogen, N3, is involved 
in a second hydrogen bond with the side-chain hydroxyl group of Thr766 
through a water molecule which bridges the two groups. Other protein 
interactions with the quinazoline template have been proposed for the 
C2 and C8 positions (figure 1.7). The 4-aniline group, including the 3’ and 
4’ substituents, clearly plays an important role in the affinity and 
selectivity for 4-anilinoquinazoline inhibitors. The phenyl ring is tilted out of 
the plane of the quinazoline, allowing the substituent at the 3’ position, 
which is an acetylene moiety in the case of erlotinib, to fit more precisely 
into a hydrophobic pocket. This well-defined hydrophobic pocket 
appears to be occupied by 4-anilinoquinazoline inhibitors but not by ATP, 
which might explain in part the much greater affinity for these inhibitors 
than the enzyme’s natural substrate. 
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2.2.2 Covalent irreversible EGFR-TK inhibitors 
These compounds belong to the previously defined second class of 
EGFR-TK inhibitors and are been designed mainly to overcome the drug 
resistance toward gefitinib or erlotinib treatment induced by the 
expression of EFGR T790M in tumor cells. Most potent and clinically 
advanced members of this class share a common 4-anilino-quinazoline 
or 4-anilino-3-cyanoquinoline core structure with reversible ATP 
competitive inhibitors and this confers to them the ability to bind the ATP 
binding site of EGFR-TK domain with high potency and specificity (Figure 
2.8). 
 
 
Figure 2.8. Collection of most representative irreversible covalent EGFR inhibitors with 
embedded warhead portions colored in red. Among them, brackets names indicate 
the most clinically advanced members. 
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 On the other hand, the presence in these compounds of a reactive 
warhead portion (such as (1,2-dithiolan-3yl)alkylamide,31 
chloroacetamide, 84  acrylamide, 85  propargylamide 86  or 
vinylsulphonamide85) linked to the 6 position of the heterocyclic driver 
group give them the ability to covalently bind EGFR-TK, inhibiting it in a 
non-competitive manner (Figure 2.9.).  
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Figure 2.9. Warhead diversity among 4-anilnoquinazoline based irreversible ERGF-TK 
inhibitors.  
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Despite most of these covalent modifiers have been reported to 
irreversibly inhibit EGFR-TK activity, is important to underline that the 
ability of them to covalently bind the desired target cannot be 
considered a strictly requirement to achieve an irreversible action. 
Indeed, it has been reported that non-covalent inhibitors of EGFR-TK like 
lapatinib (Tykerb ®),87 are able to irreversibly inhibit EGFR. 
Since the enzyme activity depends on the presence of free and fully 
functional enzyme in the testing medium, there are two conditions that 
can lead to an irreversible target inhibition (Scheme 2.1): 
1. The used inhibitor presents very a high Kinhib values (tight binding). In 
this case, most of free enzyme “E” is bound by the inhibitor “I” and 
converted to the inactive non-covalent complex I. This condition 
does not lead to a fully irreversible inhibition of the target because 
the enzyme activity can be recovered by addition of high amount 
of a proper ligand able to compete with the inhibitor “I” for the 
binding site. Despite this, compounds like these could act as 
irreversible inhibitors at least from a clinical point of view. 
2. The used inhibitor is able to decrease the concentration of non-
covalent drug-enzyme complex I available to regenerate the free 
active enzyme “E”. This could occur when the complex I 
undergoes conversion to more stable complexes like covalent 
bound complex II or non-covalent stabilized complex III (the 
increased stability of the latter is often generated by 
conformational changes of bound enzyme). The formation of 
covalent stabilized complexes II (for which Kcov defines their 
formation ratio) can be usually induced by a covalent inhibitor 
whereas the formation of non-covalent stabilized complexes III (for 
which Knon-cov defines their formation ratio) is more frequently 
hypothesized when non-covalent binders are used. However, also 
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inhibitors designed to covalently react with a given target could 
generate non-covalent stabilized complexes like complexes III 
rather than covalent bound complex like II. 
 
E E I
E I
E I *
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k-1
Non covalent
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Kinhib = k1/k-1
k2
k3
k-2
k-3
Covalent binding
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Non-covalent binding
Knon-cov = k3/k-3
+ I
I
II
III
Scheme 2.1. Enzyme inhibition kinetics for covalent modifiers and non-covalent binder 
on a given enzyme “E”. 
 
The irreversible inhibition of EGFR-TK provided by lapatinib is due to the 
formation of a very stable non-covalent complex between the drug and 
the unactive conformation of EGFR-TK (complex type III, scheme 2.1). 
The high stability of this complex (it has been reported an estimated 
complex half-life of 300 min)87 decrease the amount of free available 
enzyme “E” and provide a long lasting inhibition of EGFR-TK. On the 
contrary, covalent EGFR-TK inhibitors reported in literature decrease the 
amount of free available enzyme “E” forming with it covalent stabilized 
complexes (complex type II, scheme 2.1). Despite the equilibrium 
constant of covalent bound complexes (Kcov) is often so high to make 
this process irreversible, a good chemical stability for obtained 
complexes is a fundamental requirement to achieve an irreversible 
effect. Indeed, covalent complexes II could undergo chemical 
degradation (hydrolytic processes, etc.) that finally lead to the release of 
a modified inhibitor I’ and to the catalytically active free enzyme “E” 
(Scheme 2.2). 
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Scheme 2.2. Kinetic of covalent complex II chemical degradation. 
 
Considering these assumptions, not all covalent EGFR-TK inhibitor can be 
automatically considered irreversible. From a kinetic point of view, 
irreversible EGFR-TK inhibitors can be achieved only using covalent 
modifier characterized by high Kcov values (Scheme 2.1) and low Kdegr 
values (Scheme 2.2).  
As described in Chapter 1.1.2, also for EGFR covalent modifiers 
described in literature a general functional structure defined by a driver 
portion, a linker and a warhead portion can be recognized. In addition, 
a “tuning portion” involved into pharmacokinetic profile tuning of such 
compounds can be identified too (Figure 2.10). 
 
 
Figure 2.10. General structure of 4-anilinoquinazoline (X=N, R3=not present) and 4-
anilino-3-cyanoquinoline (X=C, R3=CN) based covalent inhibitors: warhead portion in 
red, linker portion in black, driver portion in green and tuning portion in blue. 
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The 4-anilino-quinazoline or 4-anilino-3-cyanoquinoline core 
structure act as a “driving portion” for these compounds, driving the 
warhead reactivity to form covalent interactions mainly within the ATP 
binding site of EGFR-TK. Indeed, it provide, as previously described for the 
first EGFR-TK inhibitors class, an optimized non-covalent drug-target 
interaction that bring, together with the contribution of linker portion, the 
electrophilic-carbon atom of the warhead into close proximity with the 
nucleophilic thiol atom of target cysteine (Cys773 for EGFR-TK). This 
facilitates the rapid formation of the covalent drug-enzyme complex 88 
reducing, in the same time, the occurrence of off-target risks. The stability 
of the established covalent interaction influences reversibility and 
duration of EGFR-TK inhibition. In this way, only warheads able to provide 
strong and stable covalent bonds with targeted cysteines would induce 
an irreversible inhibition of EGFR-TK, with duration that only depend from 
receptor turnover rate on cell surface. Among covalent inhibitors listed in 
Figure 2.9, alkylating derivatives are the best to leading an irreversible 
inhibition of EGFR-TK.31 In particular, Michael addition-based mechanism 
inhibitors like PD168393 2 are proved to inhibit EGFR-TK activity with high 
potency and a long-lasting effect by a stable alkylation of cysteine 
residue 773 inside the ATP binding site of EGFR-TK domain (figure 2.11).89  
Alkylation of Cys773
(irreversible inhibitors)N
N NH
Br
NH
O
 
Figure 2.11. EGFR-TK domain co-crystallized with PD168393.89 
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This inhibition results insensitive to the intracellular ATP levels and 
represents the rational to explain why these compounds were found 
able to assure an effective inhibition of EGFR T790M tyrosine kinase 
activity. Moreover, the additional binding energy provided by formation 
of covalent drug-cysteine adducts decrease the number of non-
covalent interactions usually needed to achieve the desired 
pharmacological potency.2 In this way, these kind of compounds can 
bind their targets without needing a fine structural modulation of driver 
portion. For this reason, despite the high affinity of 4-anilinoquinazoline 
and 4-anilino-3-cyanoquinoline based driver groups for the ATP binding 
site of EGFR-TK, many of these covalent modifiers often inhibit multiple 
cysteine exposing targets inside and outside HER receptor family. 90 
Despite this enlarged target spectrum could appear detrimental for the 
target selectivity of these compounds, it provide, on the contrary, 
additional selectivity to these inhibitors because force them to exert their 
biological activity only toward a short list of cysteine exposing targets 
(Table 1.1) without interfere with the activity of other kind of kinases. This 
is possible because, despite the primary sequence of ATP binding site is 
highly conserved among kinases, only few of them have a cysteine 
residue within the ATP binding site located in the same position of Cys773 
in EGFR and so suitable to be bound by these inhibitors (Table 2.1). 
EGFR targeting                                                                                    Chapter 2 
57 
 
Table 2.1. Alignment of primary sequences of ATP binding site portions of kinases. 
Among kinases only eleven kinases have a cysteine residue located in the same 
position of Cys773 in EGFR (boxed residues).90 
 
Moreover, the inhibition of additional HER receptors beyond EGFR 
could be useful for treatment of cancers forms in which other HER 
receptor members play an important role in tumor growth and 
immortalization. For instance, HER-2 was suspected to be an important 
player in the development of tumors because was found overexpressed 
in many kind of cancers,91,71 and this occurrence is generally correlates 
with poor prognosis and decreased survival. 
HER-2 is the most preferred partner for EGFR heterodimerizations and 
promotes tumors growth inducing enhanced proliferation, migration and 
resistance to apoptosis in cancer cells. Moreover, HER-2 containing 
dimers have features (like slow ligand dissociation, high stability, relaxed 
ligand specificity, slow endocytosis, rapid recycling and prolonged firing) 
that prolong and enhance the EGFR downstream signaling.57 
Recently, a synergic pharmacological response induced by 
inhibition of both EGFR and HER-2 has been reported.92 This multi target 
approach have provides better outcomes than traditional therapies only 
focused on selective EGFR or HER-2 inhibition93 and it could represent the 
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rational for development of new multi target covalent modifiers for 
cancer treatment. 
In vitro tests show that the most of clinically advanced irreversible 
EGFR-TK covalent inhibitors are able to inhibit multiple targets among HER 
members (Table 2.2). 
 
 
Table 2.2. Target selectivity within HER receptor family of most clinically advanced 4-
anilinoquinazolinic and 4-anilino-3-cyanoquinolinic irreversible EGFR-TK inhibitors. Except 
for EKB-569 (pelitinib) that binds EGFR selectively, IC50 values shown that almost of them 
can inhibits multiple targets.94 
 
Among listed compounds, CI-1033 (canertinib) shows the most 
expanded target spectrum since it can irreversibly inhibits EGFR, HER-2 
and HER-4 by irreversible alkylation of Cys773, Cys805 and Cys778 
respectively. Inhibiting all catalytically active members of HER receptor 
family, this compound can theoretically completely shut down the HER 
receptors downstream signaling. Notably, canertinib was reported to 
induce poly-ubiquitinilation and degradation of HER-2 so to interfere with 
EGFR and HER-2 heterodimerization process. Therefore, together with the 
irreversible inhibition of EGFR, the high activity shown by this compound 
in preclinical models could be explained also considering this additional 
mechanism of action.95 
In comparison to CI-1033 (canertinib), BIBW-2992 (afatinib, Tovok ®) 
and HKI-272 (neratinib) present increased target specificity, since they 
are reported as dual inhibitors of EGFR and HER-2 only. Between them, 
the higher HER-2 specificity showed by HKI-272 (neratinib) has been 
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addressed to the presence of the 2-pyridin-2-ylmethoxy decoration of 
the 4-anilino-3-cyanoquinoline driver portion.96  
Finally, EKB-569 (pelitinib) represents an exception among these 
covalent modifiers because it has proved to be very selective for EGFR 
at nM concentrations. 
Despite all of just described compounds are able to bind EGFR 
T790M mutants with high potency both in vitro and in vivo models, it is 
reported that their effective clinical efficacy, especially in patients with 
gefitinib and erlotinib-resistant NSCLC, is limited by occurrence of dose–
limiting toxicity problems.97 Indeed, since the ATP affinity for EGFR T790M 
and for wild type EGFR (wtEGFR), the concentration of irreversible 
inhibitors required to inhibit EGFR T790M will also effectively inhibits 
wtEGFR. The concurrent inhibition of wtEGFR results in side effects like skin 
rash and diarrhea that hamper the reaching of plasma concentrations 
sufficient to inhibit EGFR T790M. 
In order to solve these problems, a second generation of EGFR 
irreversible inhibitors was very recently synthesized. It is composed only by 
three compounds at the moment: WZ4002, WZ3146, and WZ8040 (Figure 
2.12a).97 As described for other EGFR irreversible inhibitors, all of them 
present a warhead portion responsible of the covalent binding of Cys773 
within the ATP binding site of EGFR. On the other hand, these 
compounds are characterized by a completely redesigned driver 
portion that increases their selectivity against EGFR T790M mutant rather 
than against wtEGFR (Figure 2.12b).  
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Figure 2.12. a) General structure of second EGFR covalent irreversible inhibitors 
generation: warhead portion in red, linker portion in black, driver portion in green. 
Despite authors haven’t defined any tuning portion for these molecules, the piperidine 
moiety could be recognized as a possible tuning portion (in blue), useful to enhance 
the solubility of these inhibitors. b) Toxicity-Efficacy gap between EGFR covalent 
irreversible inhibitors belonging to the first and to the second generation respectively. 
 
X-ray diffraction analysis of EGFR T790M co-crystallized with WZ4002 
showed why these compound are so selective for EGFR T790M (Figure 
2.13).  
 
 
Figure 2.13. EGFR T790M co-crystallized with WZ4002. Dashed lines indicate main 
interactions with the “hinge” region of EGFR-TK domain. Observing the conformation of 
WZ4002, is easy to understand the importance of the phenyl linker portion to bring the 
acrylamide warhead close to Cys797 (Cys773 in an alternative numbering scheme).97 
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While the anilinopyrimidine driver portion of WZ4002 provide an 
effective interaction with the “hinge” region of ATP binding site of EGFR 
T790M by a bi-dentate hydrogen bonding interaction with Met793 
residue, the chlorine substituent on the pyrimidine ring contacts the 
mutant gatekeeper residue Met790 through an hydrophobic interaction. 
This hydrophobic interaction could be responsible of the observed 
selectivity of WZ4002 for EGFR T790M rather than for wtEGFR. Indeed it 
can take place with the properly positioned Met 790 residue in EGFR 
T790M but it is disfavored when Thr790 is present in this position in wtEGFR. 
Beyond the driving portion, the linker portion is fundamental to allow to 
covalent inhibition of EGFT T790M. Indeed, the ‘linker’ phenyl ring lies 
roughly perpendicular to the pyrimidine core juxtaposing the acrylamide 
warhead with the thiol group of Cys797 (Cys773 in an alternative 
numbering scheme) and facilitating the covalent bond formation.97 
These compounds were found effective toward in vitro and in vivo 
cancer models harboring EGFR T790M mutation. WZ4002 has been tested 
in mouse lung cancer models harboring EGFR T790M and it has provided 
a significant tumor regression without exert any significant inhibition of 
EGFR WT. The enhanced selectivity for EGFR T790M of these compounds 
could be useful for the clinical treatment of gefitinib-resistant cancers in 
human patient avoiding the occurrence of dose-limiting side effects 
related to wtEGFR inhibition. Furthermore, they could be administered 
before that the EGFR T790M occurs, in order to prevent it. 
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2.3 Synthesized EGFR inhibitors 
2.3.1 Aim of the work 
Considering the acrylamide moiety of 6-acrylamide-4-(3-
bromoanilino)quinazoline 98  (2, PD168393, Figure 2.8 and 2.9) as a 
reference warhead fragment, the role of different cysteine reactive 
groups inserted on the 6-amino-4-(3-bromoanilino)quinazoline driver 
portion (3, Table 2.6) was explored in terms of covalent EGFR WT and 
EGFR T790M inhibition.99. Combining knowledge from existing covalent 
modifier drugs and late-stage clinical candidates, as well as from known 
EGFR tyrosine kinase inhibitors, new irreversible EGFR inhibitors 1-14 
carrying different cysteine-reactive groups at position 6 (Scheme 2.4 and 
Table 2.6) were designed and synthesized. In particular, embedded 
warhead portions were designed to possess different reaction 
mechanisms toward nucleophiles: (i) nucleophilic addition (epoxides 4, 
5, and 6); (ii) nucleophilic substitution with in situ release of a leaving 
group (phenoxymethylamides 7, 8, and 9); (iii) carbamoylation 
(carbamate 10); (iv) Pinner reaction with formation of a thioimidate 
adduct (nitrile 11); (v) disulfide bond formation (isothiazolinone 12, 
benzisothiazolinone 13, and thiadiazole 14). 
 
 
 
Compd R Proposed inhibition mechanism 
2 
O  
Michael addition 
(reference compound for EGFR irreversible inhibition) 
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3 H  
No covalent interactions 
(reference compound for EGFR reversible inhibition) 
4 
O
(R)(R)
H
H
O
O
EtO
 
Nucleophilic Addition 5 
O
(S) (S)
H
H
O
OEtO  
6 
O
(S) (R)
H
H
O
N
 
7 
 
Nucleophilic substitution 
8 
 
9 
 
10 
 
Carbamoylation 
11 
 
Pinner reaction 
12 
 
 
Disulfide bond formation 
13 
 
14 
O
S
N
N
 
 
Table 2.3. Overview of designed warheads. Proposed reaction mechanisms are 
reported too. 
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In some cases, warhead reactivity was also tentatively modulated 
by introduction of electron-withdrawing groups (9 vs 8 and 7).  
In order to increase the target selectivity and, in the same time, to 
decrease the potential off-target toxicity of compounds 2, the pro-drug 
15 was synthesized too.  
 
Compound R Proposed inhibition mechanism 
15 
 
Michael addition 
(Pro-drug) 
Table 2.4. Designed warheads overview. Proposed reaction mechanisms are reported 
too. 
 
Compound 15 presents the N,N-dimethylethylamide side chain in place 
of acrylamide warhead of compound 2. Despite the unsaturated β-
aminoamide moiety of compound 15 lacks of reactive electrophilic 
centres to directly interact with nucleophiles species, it is known that, 
especially when exposed to basic conditions, β-aminocarbonyl 
compounds like 15 can undergo retro-Michael reaction so restore the 
acrylamide warhead of compound 2 (Scheme 2.3).100,101 
 
 
Scheme 2.3. Basic catalytic activation of compound 15. Warhead portion of resulting 
acrylamide 2 is colored in red.  
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Indeed, in presence of a general base, the β-amino group becomes free 
to deprotonate the neighbouring α-carbon. The resulting tautomerization 
of compound 15 produces the enolate 91 and starts the β-elimination 
reaction to from the acrylamide final product 2. In this way, 
deprotonation of the α-carbon can be recognized as the key step of this 
reactions sequence. 
The enolization step can be induced using basic catalysis in solution but it 
could also take place within specific areas of a biological target in 
which a proper positioned basic residue could deprotonate the α-
carbon and triggers the enolization process. In this way, only once the 
compounds 15 have bound the EGFR-TK active site, β-aminoamide 
portion could start to eliminate Et2NH to unmasking the highly reactive 
acrylamide warhead of compound 2. Then, the acrylamide moiety of 
compound 2 could react with Cys773 so to irreversibly alkylate and 
inactivate EGFR.  
Despite some findings seems to confirm the involvement of this kind of 
enzyme-suicide reminiscent mechanism for the irreversible inhibition of 
Thyroid Hormone Receptor provided by a β-aminocarbonyl derivative,102 
no experimental data have been reported to support the hypothesis that 
β-aminoamide 15 could undergo a retro-Michael reaction within the 
hydrophilic sugar pocket of EGFR ATP binding site. If this hypothesis will be 
verified, the pro-drug behaviour of β-aminoamide 15 could drastically 
limit potential off-target toxicity normally associated to the use of 
acrylamides like compound 2. 
In order to test the nonspecific toxicity of warhead portions and the 
contribute of 4-(3-bromoanilino)quinazoline driver group to the observed 
inhibition potency, derivatives 16 and 17 (Scheme 2.5 and Table 2.5) 
were synthesized too. In these compounds, two of the cysteine-trap 
portions within the series were linked to a naphthalene based driver 
group that, because lacking the structural elements required for EGFR 
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ATP-binding interaction, should not be able to recognize the molecular 
target. 
 
Compound Structure 
Proposed inhibition 
mechanism 
16 O
O
H
N
 
Nucleophilic substitution 
17 
H
N
O
(R)
(R)
H
H
O
O
EtO
 
Nucleophilic substitution 
Table 2.5. Designed warheads overview. Proposed reaction mechanisms are reported 
too. 
 
Evaluation of EGFR tyrosine kinase inhibition potential of new 
synthesized compounds was carried out by enzyme-based and cell-
based assays. While, enzyme-based assays were performed to evaluate 
the ability of synthesized compound to inhibit human EGFR as purified 
protein, cell-based assays were designed to obtain more information 
about their kinase inhibitor effectiveness on intact living cells. 
The anti-proliferative and pro-apoptotic activities as well as their 
effects on downstream EGFR-dependent signaling pathways of 
synthesized compounds were also investigated in the gefitinib-resistant 
H1975 NSCLC cell line which expresses EGFR T790M. In order to identify 
new irreversible EGFR inhibitors active on a mutated gefitinib-resistant cell 
line, structure-activity relationships within the series of synthesized 
compounds were evaluated. 
 
2.3.2 Chemistry. 
The amides 4-14 and 16-17 of Table 2.6 were synthesized by 
coupling their precursor amines (3 or 106) with the appropriate 
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carboxylic acid (92, 93, 95-101), carboxylate (94), or carboxylic ester 
(102), as described in Schemes 2.4 and 2.5. 6-Amino-4-(3-
bromoanilino)quinazoline 3 was prepared in three steps from 4-
nitroanthranilonitrile 103 as previously described (Scheme 2.4).99,103 
O2N C
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Scheme 2.4. Synthesis of compounds 3-14. (i) H2SO4, formic acid, reflux; (ii) SOCl2, 
dioxane, reflux; (iii) 3-bromoaniline, i-PrOH, 60 °C; (iv) Fe, AcOH, EtOH/H2O, reflux; (v) 
Method A: dichloromethylene dimethyliminium chloride, NaHCO3, 92 (for 4) or 93 (for 5), 
CH2Cl2, 0 °C; Method B: HBTU, DMF, 94, rt. (for 6). Method C; PCl5, 95 (for 7) or 96 (for 8) 
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or 97 (for 9) or 99 (for 11), CH2Cl2, reflux. Method D; DCC, 98 (for 10) or 100 (for 12) or 101 
(for 13), DMF, 0 °C to rt. Method E; t-ButOK, 102 (for 14), DMF, MW, 100 °C. 
 
Briefly, 103 was refluxed in formic acid and sulfuric acid to give 6-
nitro-4-oxoquinazoline 104, which was chlorinated with thionyl chloride in 
dioxane and subsequently treated with 3-bromoaniline to yield 6-nitro-4-
(3-bromoanilino) quinazoline 105. Reduction of the 6-nitro group with iron 
and acetic acid in aqueous ethanol gave the 6-amino-4-(3-
bromoanilino)quinazoline 3. 
The epoxy derivatives 4 and 5 were synthesized by coupling 3 with 
carboxylic acids 92 and 93, respectively, using dichloromethylene 
dimethyliminiumchloride as the coupling reagent (method A, Scheme 
2.4), while 6 was obtained from 94 with O-(benzotriazol-1-yl)-N,N,N’,N’-
tetramethyluronium hexafluorophosphate (HBTU) (method B, Scheme 
2.4). Compounds 7-9 and 11 were prepared as described in method C 
(Scheme 2.4) from the amine 3 and the acyl chlorides obtained from 95 
(for 7), 96 (for 8), 97(for 9), or 99 (for 11). Derivatives 10, 12, and 13 were 
synthesized employing N,N-dicyclohexylcarbodiimide (DCC) as the 
coupling reagent and 98, 100, and 101, respectively, as carboxylic acids 
(method D). Amide 14 was obtained by adding potassium tert-butoxide 
to a premixed mixture of ester 102 and amine 3 and exposing the 
reaction mixture to microwave irradiation (method E, Scheme 2.4).  
Amides 16 and 17 were synthesized by reacting 2-naphthylamine 
106 with carboxylic acids 92 (method A) and 95 (method C), respectively 
(Scheme 2.5).  
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Scheme 2.5. Synthesis of compounds 16 and 17. (i) Method A: dichloromethylene 
dimethyliminium chloride, NaHCO3, CH2Cl2, 0 °C; (ii) Method C: PCl5, CH2Cl2, reflux. 
 
Finally, the amide 15 was prepared coupling the precursor amine 3 
with 3-chloropropionic acid and displacing the chlorine atom in β-
position of compound 118 with dimethylamine (Scheme 2.6) 
 
 
Scheme 2.6. Synthesis of compound 15. (i) 3-chloropropionyl chloride reflux; (ii) Et2-NH 
33% v/v, NaI, EtOH abs, reflux. 
 
Carboxylic acids 95-99 were commercially available, while 92-94, 
100, 101, and the ester 102 were prepared as shown in Schemes 2.7 and 
2.8. 
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Scheme 2.7. Synthesis of warheads 17-19. (i) KOH, abs. EtOH, 0 °C; (ii) 5% KHSO4, rt; (iii) 
NaBH4, EtOH, 0 °C; (iv) MsCl, Et3N, CH2Cl2, 0 °C to rt; (v) anhydrous piperidine, KI, DMF, 0 
°C to rt. 
 
The (2R,3R)-epoxy diester 107 104  was partially hydrolyzed to the 
desired (2R,3R)-monoethyl ester 92105 or selectively monoreduced to the 
hydroxyl ester 108.106 Mesylation of the alcohol 108 and substitution with 
piperidine gave the epoxy ester 109, which was hydrolyzed to afford the 
desired carboxylate 94. The (2S,3S)-monoethyl ester 93 was synthesized 
by partial hydrolysis of the proper (2S,3S)-epoxy diethyl ester 110.107 The 
isothiazolinone derivative 100 was synthesized as shown in Scheme 2.8. 
 
 
Scheme 2.8. Synthesis of Warheads 100-102. (i) SO2Cl2, ClCH2CH2Cl, rt; (ii) 1 M TFA, reflux; 
(iii) BrCH2COOEt, Et3N, THF, rt; (iv) HCl reflux; (v) CH2Cl2, reflux; (vi) NCCOOEt, p-xylene, 
reflux.  
 
3,3’-Dithiodipropionamide 111108 was cyclised with sulfuryl chloride 
to isothiazolinone 112,109 which was hydrolyzed to the desired carboxylic 
acid 100 by refluxing in 1 M trifluoroacetic acid. The benzisothiazolinone 
carboxylic acid 101 and the ethyl 3-isopropyl-1,2,4-thiadiazole-5-
carboxylate 102 were prepared as described in Scheme 2.8, according 
to literature methods.110, 111 
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2.3.3 Results and discussion 
As described in chapter 4.1.3 (Experimental section), the effects of 
synthesized compound on the tyrosine kinase activity of human EGFR 
were investigated. These assays were carried out on membrane 
associated EGF receptor on living human cell line (cell-based assays) as 
well as on purified protein (enzyme-based assays). Cell-based assays 
were used to estimate the reversibility of EGFR tyrosine kinase activity 
inhibition and the antiproliferative effect provided by tested compounds. 
On the other hand, their inhibitory potencies (IC50) were calculated from 
data obtained from cell-based as well as enzyme-based assays. 
Despite compound 15 was tested too, the collected biological 
data are still under evaluation. For this reason, no experimental data 
about compound 15 will be reported in this PhD thesis.  
A preliminary direct evaluation of the inhibitory potency of 
synthesized compounds on human EGFR was carried out by an enzyme-
based assay. In this test, the EGFR-dependent phosphorylation of a 
suitable peptide substrate was quantified by time-resolved fluorimetric 
measurements in presence or in absence of inhibitors. The determined 
IC50 values are reported in Table 2.6. 
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Compd R kinase assaya  autophosphorylation assayb 
  IC50 (nM)  % inhibition (1 µM) IC50 (µM) 
    1 h 8 h 1 h 8 h 
2 
 
1.69 ± 0.16  98.6 ± 1.4 93.6 ± 6.3 0.012 ± 0.004 0.152 ± 0.037 
3 H n.d.  98.5 ± 1.5 0.0 ± 0.1 0.030 ± 0.010 >10.00 
4 
 
0.50 ± 0.12  100.0 ± 0.0 96.6 ± 1.1 0.011 ± 0.007 0.145 ± 0.030 
5 
 
0.49 ± 0.04  96.7 ± 3.3 95.7 ± 1.3 0.034 ± 0.009 0.068 ± 0.009 
6 
 
1.24 ± 0.13  99.4 ± 0.6 96.3 ± 1.5 0.007 ± 0.001 0.044 ± 0.010 
7 
 
9.25 ± 0.71  93.5 ± 7.5 71.4 ± 7.2 0.076 ± 0.054 0.292 ± 0.068 
8 
 
8.43 ± 0.16  97.4 ± 1.8 77.6 ± 10.1 0.031 ± 0.008 0.291 ± 0.011 
9 
 
23.6 ± 1.75  91.5 ± 4.3 91.4 ± 7.6 0.084 ± 0.037 0.078 ± 0.032 
 73 
10 
 
0.37 ± 0.05  95.2 ± 0.2 79.9 ± 16.4 n.d. n.d. 
11 
 
0.17 ± 0.02  95.0 ± 3.2 23.6 ± 9.6 n.d. n.d. 
12 
 
0.36 ± 0.08  79.6 ± 8.1 24.7 ± 14.7 n.d. n.d. 
13 
 
0.85 ± 0.05  69.0 ± 16.3 30.7 ± 14.3 n.d. n.d. 
14 
 
129 ± 17.3  82.3 ± 9.1 66.9 ± 13.8 n.d. n.d. 
15 
 
Not reported.  Not reported Not reported Not reported Not reported 
16  n.d.  0.0 ± 0.1 0.0 ± 0.1 n.d. n.d. 
17  n.d.  0.0 ± 0.1 0.0 ± 0.1 n.d. n.d. 
 
Table 2.6. EGFR tyrosine kinase and autophosphorylation inhibition in A431 cells. a Concentration to inhibit by 50% EGFR tyrosine kinase 
activity. IC50 values were measured by the phosphorylation of a peptide substrate using time-resolved fluorimetry (see Experimental 
Section). Mean values of three independent experiments ± SEM are reported. b Inhibition of EGFR autophosphorylation was measured in 
A431 intact cells by Western blot analysis. Percent inhibition at 1 µM concentration and IC50 values were measured immediately after and 8 
h after removal of the compound from the medium (1 h incubation). Mean values of at least two independent experiments ± SEM are 
reported.  
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Reported kinase assay data show that substitution of the acrylamide 
warhead of reference compound 2, with an epoxy- (4-6), a carbonylic- 
(carbamate 10 and nitrile 11), or a (benzo)isothiazolinonic- (12 and 13) 
one do not impact so much on the observed inhibition potency on 
purified enzyme, leading to equally potent or more potent inhibitors. 
Despite showing slightly decreased inhibition potency, also compounds 
carrying phenoxyacetamidic warheads (compounds 7-9) potently inhibit 
EGFR with IC50 values in the low nanomolar range. On the contrary, in the 
tested conditions, kinase inhibition potency is notably reduced by the 
introduction of a 1,2,4-thiadiazole warhead (14). 
All these findings are in agreement with previously published SAR 
profiles of the 4-anilinoquinazoline ring85,112,113,114 in which the ATP-binding 
site of EGFR seems tolerant to the introduction of differently sized and 
shaped substituents at position 6 of this heterocyclic driver group.  
In order to obtain more information about the biological activity of 
synthesized compounds on living cell, enzyme-based assays were 
replaced by cell-based assays. In this way, the reversibility of EGFR 
inhibition provided by these compounds was investigated on A431 
human epidermoid cancer cell line by Western blotting (Figure 2.14 and 
Figure 2.15). This cell-based assay was carried out incubating A431 cells, 
which overexpress wild type EGFR, with each synthesized inhibitor for 1 h 
and washing them free of drug. The degree of EGFR 
autophosphorylation was measured either immediately after or 8 h after 
removal of the inhibitor from the medium.88 
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Figure 2.14. Autophosphoriyation test in A431 cells. The inhibition of EGFR 
autophosphorylation is determined using a specific anti-phosphotyrosine anti-body by 
Western blot analysis and compared with some reference results as (1) the basal EGFR 
autophosphorylation activity ( - EGF / - EGFR inhibitor; green colored boxed area), (2) 
the maximum EGFR autophosphorylation response ( + EGF / - EGFR inhibitor; violet 
colored boxed area), (3) the EGFR autophosphorylation inhibition provided by a fixed 
amount of reference compound 2 (+ EGF / + reference irreversible EGFR inhibitor; red 
colored boxed area). An example of an autophosphorylation inhibition result is offered 
too. The upper line of this Western blot image shows the TK inhibition immediately after 
incubation whereas the lower one shows the TK-inhibition 8h after. 
 
Among tested compounds, irreversible and reversible EGFR inhibitors 
can be recognized comparing their results with those observed for 
irreversible and reversible reference compounds 2 and 3 respectively. 
Indeed, as previously reported,98 compounds showing 80% or greater 
EGFR inhibition 8 h after their removal from the medium are recognizable 
as irreversible inhibitors whereas compounds showing 20-80% of residual 
inhibition can only be considered as partially irreversible ones. Only for 
compounds that showed the highest inhibitory potencies toward EGFR at 
1 µM concentration on A431cell line, dose-dependency was 
investigated (Figure 2.15) and IC50 determined (Table 2.6). 
EGFR targeting                                                                                    Chapter 2 
76 
 
Figure 2.15. Irreversible inhibitory actions of compounds 4-9 on EGFR 
autophosphorylation. A431 cells were incubated with the investigated compound for 1 
h and stimulated with EGF either immediately after or 8 h after removal of the 
compound from the medium. Western blot analysis was done using monoclonal 
antibodies directed to p-Tyr1068. 2 and 3 were used as irreversible and reversible 
reference compounds, respectively. Representative blots of three independent 
experiments are shown. Total EGFR is shown as loading control. 
 
While the reference compound 3 does not exert any irreversible 
inhibition, reference irreversible compound 2 as well as many of the 
newly synthesized derivatives like epoxides 4-6 and phenoxyacetamide 
9, irreversibly inhibit EGFR activity, with inhibition values higher than 90% 
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after 8 h washout. On the other hand, only a partially irreversible 
inhibition was provided by compounds 7-8 and 10-14 under the testing 
conditions, with percent inhibition of EGFR autophosphorylation between 
24 and 80%. (Table 2.6) 
The irreversible inhibition provided by compounds 4-6 could be 
addressed to the ability of their epoxide rings to undergo nucleophilic 
attack by Cys773 so to generate a stable enzyme-bound addition 
product.85,98 Compounds 4-6 showed dose-dependent inhibition of EGFR 
autophosphorylation in A431 cells with IC50 values comparable to that of 
2. Despite compounds 4 and its (2S,3S) enantiomer 5 showed similar 
affinity for purified human EGFR, they inhibit EGFR tyrosine kinase activity 
differently 1 h after and 8 h after the removal of the compound from the 
reaction medium. If compared with compound 4, compound 5 was 
slightly less potent to inhibit EGFR after 1 h treatment but showed slightly 
higher potency 8 h after its removal. Despite these limited differences 
may not allow the establishment of accurate structure-activity 
relationships, different contribution in term of reversible and irreversible 
binding could explain these IC50 value changes. Indeed, the IC50 value 
at 1 h could be addressed to both reversible binding to the EGFR 
catalytic site, by weak interactions at the enzyme surface, and to 
irreversible binding, due to the formation of a covalent bond with an 
exposed cysteine. On the other hand, the IC50 value measured 8 h after 
ligand removal only would depend to the extent of irreversible covalent 
binding. 
In agreement with reported data about acrylamide and 
propargylamide derivatives,115,116 the introduction of a basic group in the 
warhead portion improved inhibitor potency of compound 6. Despite, 
the presence of the piperidine group did not improve the affinity toward 
purified EGFR enzyme with respect to the epoxysuccinate 4, the 
introduction of this basic group increased the inhibitory activity of 
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compound 6 (Figure 2.15 entry E and Table 2.6). The amino group could 
act as (i) an intramolecular catalyst for nucleophilic additions to the 
cysteine-reactive center, (ii) a water-solubilizing group, (iii) an additional 
site for hydrogen bond recognition with acidic residues within the EGFR 
binding site. The former option was proposed 117  considering the 
protonated nitrogen of the piperidine ring able to provide an additional 
hydrogen bond with the acidic group of Asp800.118,119 In this way, the 
piperidine group should facilitate the nucleophilic attack at the epoxy 
ring by Cys773116 rather than improving the recognition of 6 at the active 
site. 
6-phenoxy-acetamide derivatives 7-9, designed to undergo a 
nucleophilic attack by Cys773 on their α-methylene activated portion, 
irreversibly and potently inhibit EGFR. Similarly to what had been reported 
for α-chloro-acetamides,84 they could irreversibly alkylate Cys773 with 
subsequent in situ releasing of the phenolic leaving group. Since the 
reactivity of their α-methylene portion mainly depends on the phenol 
leaving group activation, a different decoration of this aromatic ring can 
modulate the reactivity of these classes of inhibitors. 
Following this concept, while the introduction of one electron-
withdrawing fluorine atoms on the phenoxy aromatic ring did not 
significantly change the inhibitory effect of compounds 7 and 8, the 
penta-fluoro substitution (compound 9) greatly increased the α-
methylene portion reactivity versus Cys773 so to provide a significantly 
increase of the EGFR inhibition after 8 h (IC50 0.078 µM, lower than the 
reference compound 2, Figure 2.15 entry H and Table 2.6). These results 
indicate this kind of warhead suitable for further chemical optimization 
focused on modification of the stereoelectronic features of the phenolic 
leaving group. Beyond this, phenoxy-acetamide derivatives could be 
also designed to release pharmacologically active leaving groups inside 
cells subsequently to their binding with EGFR-TK. In this way, phenoxy-
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acetamide warheads could be suitable to provide a multi-target 
approach. 120,121  
Despite both compounds 10 and 11 were designed to establish 
covalent but reversible interactions with nucleophilic cysteine residues, 
carbamate derivative 10 showed a quasi-irreversible inhibition EGFR 
while only a residual effect was observed 8 h after treatment with 
compound 11. These findings could be explained hypothesizing that the 
thiocarbamate adduct resulting from the interaction between Cys773 
and compound 10 would more stable than the thioimidate ester 
produced, in the same way, by compound 11. If this is true, 
carbamoylating agents should be considered more promising than nitrile 
based derivative in terms of suitability for further structural optimizations 
focused to achieve a full irreversible inhibition of EGFR.  
Again, despite sulphenamide armed compounds 12-14 should 
share a common binding reaction mechanism toward Cys773, only the 
1,2,4-thiadiazole 14 was able to provide a potent, yet partial, irreversible 
inhibition of EGFR. Isothiazolinone 12 and benzisothiazolinone 13 armed 
derivatives, indeed, reversibly inhibited EGFR. These compounds should 
covalently react with Cys773 forming a mixed disulfide bond by breaking 
of the sulfenamide bond and subsequent ring opening8,21. Also in this 
case, because of their common covalent inhibition mechanism, a way 
to explain the different reversibility shown by these compounds could be 
to hypothesize a different stability for their covalent disulfide products in 
the testing conditions. 
To evaluate the contribution of 4-anilinoquinazoline driving portion 
to the observed EGFR-TK inhibition effects, compounds 16 and 17 
(Scheme 2.5 and Table 2.6) were synthesized and tested by cell-based 
assays. In these compounds two of the most active cysteine-trap portions 
of the series were linked to a simple naphthalene nucleus as driver 
group. Since naphthalene lacks the structural elements required for 
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interaction with the ATP-binding site of EGFR81, these compounds should 
not be able to recognize the desired molecular target providing, in this 
way, a direct evaluation of warhead reactivity contribution to the 
observed inhibition activity. As expected, compound 16, carrying an 
epoxysuccinic group analogue to compound 4, and compound 17, 
containing the same side chain as compound 7, did not inhibit EGFR 
autophosporylation in A431 human epidermoid cancer cell line, 
demonstrating that target specificity of the series is due to driver-portion 
recognition within the EGFR active site. Moreover, compounds 16 and 17 
exhibited less than 10% inhibition of A431 cell proliferation at 
concentrations up to 10 µM, indicating no relevant aspecific cellular 
toxicity for tested warheads. To assess the intrinsic chemical reactivity of 
warheads characterizing the most promising synthesized candidates 
toward thiol nucleophiles, the formation of conjugates with glutathione 
was evaluated in aqueous buffered solution by LC-UV and LC-ESI-MS 
(see Experimental Section, Chapter 4.1.4). Neither the epoxy-derivatives 
4 and 15, nor the phenoxyacetamides 7 and 17 gave any measurable 
adduct with GSH after 1 h incubation. On the other hand the acrylamide 
2 showed conversion of 36.2 ± 1.9% (mean ± SD; n = 3) of the starting 
compound to its GSH-conjugate ([M+H]+ = 676.11) under the same 
conditions. 
In order to evaluate the ability of synthesized compounds to 
irreversibly inhibit T790M EGFR as well as wtEGFR, the antiproliferative 
activities of compounds that exhibited highest irreversible inhibition 
potency toward A431 cell line (overexpressing wild type EGFR) was 
quantified on gefitinib-resistant H1975 NSCLC cell line (harboring T790M 
EGFR). The antiproliferative activity of tested compounds was reported in 
table 2.7 and it was determined by MTT assay. As already done for the 
set-up of the autophosphorylation assay on A431 cell line, also in this 
case some reversible and irreversible reference compounds, derivatives 
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2-4, 6 and 8-9 respectively, were tested together with the investigated 
compounds, in the same testing conditions. Since H1975 NSCLC cell line 
are known to be resistant to gefitinib (Table 2.7, entry 1, reference 
compound), also this drug was tested as clinically used reference. 
 
Compound H1975 Cell line 
 IC50 (µM) 
1 (Gefitinib) 8.26 ± 1.11 
2 0.61 ± 0.05 
3 19.5 ± 2.46 
4 6.76 ± 0.60 
6 1.72 ± 0.47 
8 7.82 ± 1.19 
9 11.0 ± 1.08 
 
Table 2.7. Viability inhibition potency of NSCLC H1975 gefitinib-resistant cell line was 
reported as concentration to inhibit by 50% their proliferation. The cell proliferation was 
determined by the MTT assay, after 72 h of incubation with compounds (0.1–20 µM). 
Mean values of three independent experiments ± SEM are reported.  
 
As reported in Table 2.7, calculated IC50 values for all investigated 
compounds were greater than IC50 value calculated for the irreversible 
reference compound 2. On the other hand, all tested compounds could 
clinically inhibit H1975 cell proliferation with potencies magnitude equal 
or higher than reversible reference compounds 1 or 3 respectively. 
Notably, the introduction of the basic piperidine group on the reactive 
side chain of compound 4 made compound 6 four times more active 
than 1 on H1975 cells (Figure 2.16 and Table 2.7), with an antiproliferative 
IC50 of 1.72 µM. In this way, compound 6 showed the best potency profile 
among investigated derivatives. 
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Figure 2.16. Effectiveness of irreversible EGFR inhibitor 6 in H1975 NSCLC cell line. 
Antiproliferative effects of compound 6 (▲) in comparison with 1 (●) on H1975 cell line, 
harboring the resistance-associated mutation T790M. Cell proliferation was determined 
by MTT assay, as described in the Experimental Section (Chapter 4.1.3). Results are 
reported as the mean ± SD of three independent experiments. *, P < 0.01 for each dose 
versus 1; n = 3. (B) Comparison of compounds 6, 1, and 2 in their ability to suppress EGFR 
autophosphorylation (p-EGFR), erbB2 autophosphorylation (p-erbB2) and 
phosphorylation of downstream effectors AKT (p-Akt) and MAPK (p-p44/42) in H1975 
cells. Total EGFR, erbB2, AKT and MAPK are shown as loading controls.  
 
The ability of compound 6 to inhibit EGFR signaling in the NSCLC cell 
line H1975 (harboring the T790M mutation) was investigated by Western 
blot analysis. Once again, compounds 1 and 2 were used as reference 
compounds in this test and collected results of Western blot analysis are 
illustrated in Figure 2.17. While 1 showed marginal activity on EGFR and 
erbB2 in H1975 cells up to 10 µM, compound 6 was found to produce a 
dose-dependent inhibition of EGFR and of erbB2 autophosphorylation 
with complete inhibition at 1 µM concentration. Moreover, compound 6 
was also considerably more effective than 1 to inhibit the two major 
EGFR dependent signaling pathways like the PI3K/AKT/mTOR and the 
RAS/RAF/MAPK cascades that were recognized to have a pivotal role in 
controlling cell survival, cell growth and proliferation (Figure 2.17). 
 
EGFR targeting                                                                                    Chapter 2 
83 
 
Figure 2.17. Effectiveness of irreversible EGFR inhibitor 6 in H1975 NSCLC cell line. 
Comparison of compounds 6, 1, and 2 in their ability to suppress EGFR 
autophosphorylation (p-EGFR), erbB2 autophosphorylation (p-erbB2) and 
phosphorylation of downstream effectors AKT (p-Akt) and MAPK (p-p44/42) in H1975 
cells. Total EGFR, erbB2, AKT and MAPK are shown as loading controls.  
 
Moreover, compound 6 was found to be more effective than 
compound 1 to induce apoptosis in living cells (25-30% at 5 µM 
concentration) (Figure 2.18A) and it was associated with caspase-3 
activation (Figure 2.18B).  
 
 
Figure 2.18. Effect of compound 6 on H1975 cell death. (A) H1975 cells were treated 
with the indicated concentration of compound 1 and compound 6 for 72 h and then 
analyzed with propidium iodide/ Hoechst 33342 staining to assess cell death. (*), P < 
0.01 for each dose versus control; n = 3. (B) At the same time the cleavage of 
procaspase-3 was assessed on lysate proteins by Western blotting. The migration 
positions of each full-length procaspase and of its processing products are indicated. 
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Taken together, these results suggest that irreversible inhibitor 6 
could exert both a cytostatic and a cytotoxic effect on the H1975 
cancer cell line. On the other hand, compound 6 proved to have a 
weak cytotoxic profile on a cell line where proliferation is not driven by 
EGFR activity, excluding off-target cytotoxic effects. In fact, compound 6 
at 10 µM inhibited less than 50% of SW620 human colon carcinoma cell 
proliferation, similarly to what observed for 1 and for the epoxysuccinic 
derivative 4. On the opposite, the acrylamide derivative 2 was found 
more toxic, giving an IC50 of 8.23 ± 1.08 µM (Table 2.8). 
 
Compound  SW620 cells proliferation  
 IC50 µMa 
1  >10 
2  8.23±1.08 
4  >10 
6  >10 
Table 2.8. Viability inhibition of SW620 cell line. a Concentration to inhibit by 50% the 
proliferation of SW620 cells. The cell proliferation was determined by the MTT assay, after 
72 h of incubation with compounds. Mean values of at least two independent 
experiments ±SD are reported. 
 
Conclusions 
The results here described extend the chemical diversity of new 
irreversible EGFR inhibitors and represent a good example of the 
application of cysteine reactive compounds to the drug development 
process. In this case, covalent target modification was desired to 
increase the binding affinity of synthesized inhibitors toward T790M EGFR 
in order to develop new EGFR inhibitors able to overcome the drug 
resistance shown by gefitinib-resistant cancer cells. 
Presented inhibitors were designed to react with cysteine through 
different kind of reaction mechanism like nucleophilic addition (epoxides 
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4-6), nucleophilic substitution (phenoxyacetamides 7-9), carbamoylation 
(carbamate 10), Pinner reaction (nitrile 11) and disulphide bond 
formation (isothiazolinone 12, benzisothiazolinone 13, thiadiazole 14). 
Among them, compounds from different chemical classes proved 
efficient in irreversibly inhibiting EGFR autophosphorylation. 122  Epoxy-
derivatives 4-6 showed potencies comparable to the acrylamide 
reference 2. Moreover, the introduction of a terminal basic group 
(compound 6) significantly improves the inhibition potency of epoxyde 
derivatives both in EGFR autophosphorylation and in cell proliferation 
assays. These results indicate that the identified epoxydes could be 
considered good starting points for further structure-based optimization. 
Compound 6 inhibited the EGFR downstream signaling pathways 
showing cytostatic and cytotoxic activities on gefitinib-resistant NSCLC 
cells (H1975). Notably, the independence of observed cytotoxicity of 
compound 6 on H1975 cell line to off-target general cytotoxic effects 
suggests that this compound could induce apoptosis in H1975 cell line 
mainly by EGFR inhibition. Beyond its clinical utility, this finding provide 
one more supporting example of how the aspecific reactivity of 
covalent modifier can be selectively driven toward a desired target by 
proper structural modifications, limiting the occurrence of off-target 
toxicity.  
The potency as well as the irreversibility of inhibition provided by 
compound 9 makes the phenoxyacetamide warhead interesting for 
EGFR irreversible inhibition. Moreover, since each phenoxyacetamide 
carrying compound can release a leaving group subsequently to Cys773 
targeting, these derivatives may be considered for a multi-drug 
approach in cancer treatment. Promising results were also observed with 
the carbamate 10 and the 1,2,4-thiadiazole 14.  
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3.1 Introduction 
N-ArachidonoylEtanolAmmine (AEA, 119, Figure 3.1) and 2-
ArachidonoylGlycerol (2-AG, 122, Figure 3.1) are the most representative 
members of a class of endogenous ligands named endocannabinoids 
that are able to activate cannabinoids receptors (CBs) expressed by 
neurons and cells belonging to the immune system. Once released, AEA 
and 2-AG act as retrograde neuromudulators, inhibiting multiple 
neurotransmission pathways across the brain by presinaptical CB1 
receptor activation. Their removal from peri-synaptic space by reuptake 
mechanisms or by rapid enzymatic deactivation,123 finally terminate their 
signalling. 
Altogether, the cannabinoid receptors, their endogenous ligands, 
and their respective catabolic enzymes constitute the endocannabinoid 
system.125 The endocannabinoid system plays important roles in various 
aspects of neural functions including learning and memory, anxiety, 
depression, addiction, appetite and feeding behaviour, nociception, 
and neuroprotection.124 Despite the therapeutic exploitability of some of 
these responses, it is still difficult to uncouple beneficial effects from 
undesirable ones when an enhanced cannabinoid neurotransmission is 
pharmacologically induced. Moreover, lack of knowledge about the 
physiological role of each single endocannabinoid neuromodulator in 
central nervous system (CNS) and peripheral nervous system (PNS) makes 
the dissection of their contribution to the observed effects difficult. 
Since 2-AG has been considered the true on-demand released 
endocannabinoid ligand for CB1 receptor,124,137 understanding of 
physiological role of 2-AG in CNS is crucial to effectively manipulate the 
endocannabinoid system. Unfortunately, due to its short half-life, it is not 
possible to use 2-AG as therapeutic agent by in vivo direct administration. 
So, a promising way to explore and promote its therapeutic potential 
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could be the selective inhibition of MAGL, the enzyme responsible of 2-
AG degradation. Despite this, few potent and selective MAGL inhibitors 
are available until now. 
The use of covalent modifier to inhibit MAGL could represent a 
good strategy to develop new highly potent and selective 
pharmacological tools for the endocannabinoid system investigation. 
Beyond this, the establishment of a proper covalent interaction with 
MAGL could provide to these inhibitor high basal potency and selectivity 
for the target, constituting a good starting point for their further structural 
optimizations. Combined together, these strategies could lead to the 
development of new effective drugs which are able to selectively 
induce beneficial effects like analgesia, neuroprotection or orexigenic 
responses through an enhanced endocannabinoid neuromodulation. 
 
3.1.1 Structure and physiological role of endocannabinoids 
The endocannabinoids are a family of polyunsaturated fatty acid 
amides or esters (Figure 3.1) derived from arachidonic acid (compound 
120, Scheme 3.1).  
 
 
Figure 3.1. Structure of most representative endocannabinoids.124 
 
Endocannabinoids, mainly represented by anandamide (119, AEA) 
and 2-arachodonoylglycerol (122, 2-AG), aren’t stored in vesicles like 
other neurotransmitters but generated on-demand through stimulus-
dependent cleavage of membrane phospholipidic precursors and 
quickly released into peri-synaptical space by neurons belonging to CNS 
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and PNS.125 Once released, AEA and 2-AG are free to reach the pre-
synaptic terminal by a retro diffusion process to activate Gi/0 protein 
coupled receptors like CB1 and CB2 which are expressed by neighboring 
cells. It was reported that AEA and 2-AG act toward CB1 as partial 
agonist and as full agonist respectively. 126 ,132 After their action, 
endocannabinoids are removed from peri-synaptic space by reuptake 
mechanisms or by rapid enzymatic deactivation (Figure 3.2).123 Because 
of their non-synaptic production and fast elimination, endocannabinoids 
are thought to act in CNS and PNS as short-range modulators of cells 
and synapses activity rather than classical hormones or 
neurotransmitters.127 
 
Presynaptic neuron      Postsynaptic neuron 
 
Figure 3.2. Overview of endocannabinoid signaling.125 Hydrolytic inactivation of AEA 
and 2-AG, mainly due to the activity of FAAH (Fatty Acid Amide Hydrolase) and MAGL 
(MonoAcylGlycerol Lipase) enzymes respectively, is recognized as the main 
bioinactivation mechanism responsible of endocannabinoid signaling termination. 
 
The endocannabinoid neuromodulation plays important roles in 
various aspects of neural functions including learning and memory, 
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anxiety, depression, appetite and feeding behaviour, nociception, 
neuroprotection124 and movement control.128  Among neural functions 
that involve endocannabinoid signalling, nociception, food intake 
modulation and neuroprotection represent the most studied and 
pharmacologically exploitable functions which can be used to develop 
some new analgesic, orexigenic and neuroprotective drugs respectively. 
Considering that CB2 receptors are predominantly present in tissues 
belonging to immune systems (such as spleen, tonsils, lynphonodes, 
macrophages and microglia) and that CB1 receptors are abundantly 
expressed in CNS (cortex, hippocampus, amygdala, basal ganglia 
outflow tracts and cerebellum) and in PNS, 129  it is though that 
endocannabinoids could modulate pain, emesis and food intake 
through CB1 receptor activation.124 Since CB1 receptors are expressed by 
peripheral terminals of primary sensory neurons, by dorsal horn synapses 
and by encephalic neurons involved to pain sensation modulation, it is 
thought that endocannabinoids take part in a natural CB1 receptors 
dependent anti-nociceptive system. It was reported that cannabinoids, 
through CB1 receptor activation, may potentiate the activity of 
supraspinal descending inhibitory pathways as well as activate 
dynorphin containing interneurons located to dorsal horns of the spinal 
cord. In this way, they could induce analgesia modulating the 
neurotransmission between primary afferent fibers and spinothalamic 
neurons. Indeed, CB1 activation in brain stem areas like RVM (rostral 
ventromedial medulla) and PAG (periaqueductal gray) provide 
analgesia by over-activation of descending inhibitory neurotransmission 
(figure 3.3)130 
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Figure 3.3. Possible mechanism for endocannabinoid-mediated control of 
nociception.130 (A) Diagrammatical representation of some of the interactions between 
various brain regions of the descending pain pathway. The PAG have a pivotal role in 
the modulation of this kind of neurotransmission (BLA=Basolateral Amygdala; 
DRN=Dorsal Rafe Nucleous; PAG=Peri-Aqueductal Gray; RVM= rostral ventromedial 
medulla, PN= Peripheral neurons). (B) Two possible outcomes of this net. The final effect 
on the input of ON and OFF cells to the dorsal horn is neutral when no painful stimuli is 
perceived. It is proposed that painful stimuli selectively activate pathway (b) that lead 
the activation of ON cells and the simultaneous inhibition of OFF cell so to allow the full 
nociceptive perception. On the other hand, anti-nociceptive neurotransmission is 
mainly exerted through pathway (a) in which excitatory neurons in the PAG are 
activate by pathways upstream the PAG. These excitatory neurons, in turn, activate the 
firing of OFF cells and, in the same time, inhibit the firing of ON cells through GABAergic 
interneurons.130 
 
It was proposed that the endocannabinoid system could also 
modulate the food-intake behaviour interacting with the orexigenic 
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(e.g., orexins) and anorexigenic (e.g., leptin) mediated neurotransmission 
at mesolimbic level.124 
Moreover, the CB1 activation mediated by endocannabinoids has 
been shown to exert neuroprotection in a variety of in vitro and in vivo 
animal models of neurodegeneration. 124 Despite the neuromodulation 
provided by endocannabinoids is mainly achieved by activation of a 
common receptor (CB1), different neurological responses to AEA or 2-AG 
increased level in CNS have been reported.131 Beyond the differential 
selectivity exerted by these endocannabinoids toward CB1 or CB2, a 
possible explanation of the phenomena could be provided by several 
different hypotheses: 
 
1. State-dependent selectivity of neurons activation: it is reported that 
the physiological action of endocannabinoids in CNS may be 
dependent to the pre-built sensitivity of some neuronal network 
toward cannabinoid ligands. Indeed, it was hypothesized that 
intracellular signalling induced by cannabinoids may vary across 
different neuronal environments dependently to changes in CBs 
receptors expression, changes in endocannabinoid deactivating 
proteins expression (hydrolytic enzymes or reuptake pumps), or to CBs 
receptor/G protein/downstream effectors proteins coupling 
effectiveness differences (Figure 3.4).132 Thus, a given ligand may act, 
for instance, as a partial agonist in well coupled tissues but as an 
antagonist in tissues where receptor coupling and/or G protein-
dependent effectors activation are less well coupled. 
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Peri-synaptical endocannabinoids lifespan
Cross-talking signalling pathways
Differentiation and 
functional state 
dependent factors
Anatomical and functional
dependence of endocannabinoids
effects in CNS
(cell-dependent action selectivity)
 
Figure 3.4. Different levels of CB1 signalling modulation. Due to a fine-control by intra- 
and extracellular factors, the signalling cascades regulated by CB1 cannabinoid 
receptor are cell-specifically pre-organised. In this way, coupling efficiency and 
receptor trafficking control can precisely modulate cellular responses to 
endocannabinoids (cell-based selectivity).132 
 
2. Activation of non-CB1/CB2 receptors: it was reported that the 
activation of some non-CB1/CB2 receptors by endocannabinoids 
could imply a possible cross-talk between the endocannabinoid and 
endovanilloid systems.124. There are some differences between AEA 
and 2-AG in terms of affinity for non-CB1/CB2 receptors like Transient 
Receptor Potential Vanilloid Type 1 (TRPV1) channels or the orphan 
GPR55 receptor. For instance, AEA is physiologically able,133 unlikely 2-
AG, to bind and activate TRPV1 channel in brain, probably 
modulating the nociceptive perception.134 On the other hand, the 
neurophysiological role of endocannabinoid-mediated activation of 
GPR55,124 widely expressed in CNS and PNS areas like frontal cortex, 
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cerebellum, striatum, hypothalamus, brain stem and dorsal root 
ganglia neurons,135 is still unclear.  
 
Although AEA may tonically control pre-synaptic CB1 receptors,136 ,142 
most experimental evidences support the hypothesis that 2-AG could be 
considered the most important retrograde messenger involved to on-
demand induction of short- and long-term synaptic depression through 
CB1 activation. Indeed, the tissue levels and the production rate of 2-AG 
in stimulated nervous tissues and cells are higher than those of AEA so to 
indicate 2-AG as a fast signaling molecule.137 
Moreover, 2-AG has been proposed as the true physiological 
endogenous ligand for CBs receptors124 because, unlikely AEA, it acts as 
a full agonist toward CB1 and CB2 receptors without activating other 
receptor classes like TRPV1.  
 
3.1.2 Endocannabinoids synthesis and metabolism 
AEA and 2-AG are produced following an increased intracellular 
Ca2+ concentrations subsequent to cell depolarization, or caused by 
Gq/11 protein-coupled receptors dependent mobilization of intracellular 
Ca2+ stores.143 AEA is mainly synthesized from pre-existing N-arachidonoyl 
phosphatidylethanolamine (NAPE), whereas 2-AG can be synthesized 
via multiple pathways. Indeed, 2-AG can be produced from arachidonic 
acid-containing diacylglycerol by the action of a diacylglycerol lipase 
(DAGL)(route I), by hydrolysis of lysophosphatidylinositol (lyso-PI) by a 
specific phospholipase C (route II) or by hydrolysis of arachidonic acid-
containing lysophosphatidic acid by the action of a phosphatase (route 
III) (Figure 3.5).138 
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Figure 3.5. Metabolic pathways for 2-AG.The most physiologically important synthetic 
pathway of 2-AG seems to be mediated by diacylglycerol lipase (route “I”).138 
 
AEA and 2-AG signalling can be shut off by a two-step process: 1) 
transport of endocannabinoids from the extracellular to the intracellular 
space; and 2) intracellular hydrolytic degradation or oxidation. Despite 
some experimental evidences suggest the existence of a common 
protein-facilitated mechanism responsible for intracellular accumulation 
of 2-AG and AEA, protein (s) involved in this mechanism are still unknown. 
Whereas FAAH is responsible of hydrolysis of AEA yields arachidonic 
acid and ethanolamine, 139  the major enzyme responsible for 2-AG 
metabolism seems to be the serine hydrolase MAGL.140 The latter enzyme 
is expressed in a variety of human, rat, and mouse tissues 141  and 
mediated hydrolysis of 2-AG giving arachidonic acid 120 and glycerol 
123 as products (Scheme 3.1).144  
 
Scheme 3.1. Hydrolysis of AEA 119 and 2-AG 122 by FAAH and MAGL respectively.143 
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Considering the post-synaptic expression of FAAH and the presence 
of MAGL on pre-synaptic terminals of different neuronal populations, it 
was suggested that FAAH might be involved in the regulation of AEA 
resting levels close to its sites of synthesis whereas MAGL might help to 
inactivate 2-AG close to its sites of action.127,142 
Despite the hydrolysis represents the main deactivation mechanism 
of AEA and 2-AG,127 it is reported that these neuromodulators can also 
undergo oxidative metabolism mediated by enzyme like COX-2 
(cyclooxygenase type 2), 12-LOX (12-Lipooxygenase) and 15-LOX (15-
lipooxygenase. 143  Since it is reported that oxidized product of 
endocannabinoids activate receptors outside the “endocannabinoid 
system”, it is still unclear if oxidative catabolism of AEA and 2-AG 
represents an additive way to terminate endocannabinoid signalling or, 
instead, to start another kind of cells cross talking. 
3.1.3 Structure and expression of MAGL enzyme 
MAGL is a cytosolic serine hydrolase that cleaves 2-
arachidonoylglycerol (2-AG) into fatty acid and glycerol through a 
catalytic mechanism that involves a classical serine-aspartate-histidine 
triad.144 MAGL hydrolyses medium- and long-chain fatty acids, such as 
palmitic acid, oleic acid, and arachidonic acid from the position 2 of 
monoglycerides, with the highest hydrolysis rate for arachidonic acid.145 
The primary structure of MAGL is defined by a 303-long amino acid 
sequence146 that shares a high degree of homology in mouse-, rat-, and 
human. Thus, in term of amino acid homology degree, human and 
mouse MAGL (hMAGL and mMAGL respectively) are 84% identical,144 
whereas mouse and rat MAGL (rMAGL) are 92% identical.140  
Very recently, the crystals of a dimer of human MAGL (hMAGL) in a 
“open” conformation (see the text below) was obtained and solved at 
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2.2 Å of resolution by X-ray diffraction (Figure 3.6).147 MAGL presents the 
hallmarks of the α/β hydrolases superfamily like a central β-sheet core, 
constituted of seven parallel and one antiparallel strands, surrounded by 
six α helices (Figure 3.6). A wider U-shaped cap domain covers the 
structurally conserved β-sheet core and the MAGL active site in which 
the catalytic triad, made up of residues Ser122, Asp239 and His269, is 
located. 
 
 
Figure 3.6. Overall structure of hMAGL monomer in “open” conformation with catalytic 
triad represented as sticks, and cap domain colored magenta (A) Side view, ribbons 
representation. (B) Top view (90° rotation), ribbons representation. (C) Top view, surface 
representation (nucleophilic Serine 122 colored in red). (D) Transverse section 
highlighting the near environment of the nucleophilic serine (lined in red)147 
 
As for other human lipase like human pancreatic lipases (hPL), it has 
been speculated that the cap domain in MAGL serves as a lid domain 
that, once the proteins come into contact with lipid droplets or 2-AG, 
allows the enzymes to unveil their otherwise unreachable hydrophobic 
active site (interfacial activation). This process should allow the enzyme 
to exist in two main conformation, a “closed” and an “open” form. 
Moreover, it has been suggested that the hydrophobic and flexible α4 
helix of MAGL cap domain may help the soluble cytosolic form of MAGL 
A B 
C 
D 
Catalytic 
Triad 
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either to get in close contact with or to anchor in the cytoplasmic 
membrane in order to reach its lipophilic substrates. Despite this could 
explain why MAGL was sometimes considered a cytosolic enzyme and 
sometimes a membrane-associated one,127, 148 ,150b no interfacial 
activations has been described for MAGL, neither there isn’t any 
evidence that alternative biological conformations might exist. 
Beneath the MAGL cap domain, a highly hydrophobic pocket 
connecting the MAGL surface to its catalytic site, deeply buried in the 
protein, has been recognized. This cavity (∼25 Å in length and ∼8 Å in 
width)149 becomes wider as one moves away from the catalytic triad 
environment towards the surface of the protein and seems suitable for 
recognition and accommodation of the long and flexible chain of MAGL 
substrates during their catalyzed hydrolysis process. Another narrow 
cavity (about 5 Å of diameter) was recognized to connects the active 
side to the outside of the protein. The architecture formed by loops 
connecting α4 to α5 and α5 to α6 helices, and the last portion of the α5 
helix, is responsible of the formation of this narrow hole. This small channel 
lies perpendicularly to the trajectory that leads from the hydrophilic 
pocket to the membrane binding site and might act as putative exit 
door for the glycerol moiety, released after 2-AG hydrolysis. 147 
Some site-directed mutagenesis studies were carried out in order to 
understand which aminoacid residues are essential to the catalytic 
activity of MAGL. Not surprisingly, carrying out an alanine scanning 
based mutagenesis the catalytic triad members Ser122, Asp239 and 
His269 (red circled in Figure 3.7), were recognized as essentials for 
catalysis.144 Moreover, using a glycine scanning based mutagenesis, 
three cysteine residues like Cys242, Cys201 (yellow circled in Figure 3.7) 
and Cys208 (green circled in Figure 3.7), were suggested to have a big 
impact on the basal activity of MAGL.179 Involvement of one or more 
cysteine residues on MAGL catalysis regulation was also suggested by 
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previous studies in which the ability of unselective cysteine reactive 
agents like p-chloromercuribenzoic acid (p-CMB) to shut down the 
catalytic activity of MAGL were reported. 150  Recently, an X-ray 
diffraction study has localized these cysteine residues on MAGL (Figure 
3.7). Cys242 was located into the active site of MAGL with its sulphur 
atom very closely positioned to catalytic Ser122 whereas Cys201 and 
Cys208 were found far away from the catalytic serine. Cys201 and 
Cys208 was found solvent-exposed and located at the liphophilic 
tunnel's wide entrance or in the vicinity of the putative glycerol exit hole, 
respectively.149 
 
Figure 3.7. hMAGL top view (crystal structure, surface representation) with lid domain in 
opened conformation. 147 Right: highlighted nucleophilic residue targeted by covalent 
inhibitor of hMAGL(crystal structure, ribbon representation). A Cys201 covalently binded 
molecule of N-ArachidonylMaleimide (NAM), a cysteine trapping MAGL inhibitor, is 
docked inside the active site of MAGL. Left: putative glycerol exit hole (crystal structure, 
surface representation).147 
 
MAGL seems to be expressed in a variety of cells and tissues. In 
human neutrophils, the enzyme activity was detected in granules within 
the cytoplasm and, after stimulation with calcium, close to the plasma 
membrane. In white fat and liver, MAGL is thought to catalyze the final 
step of the lipolytic cascade that releases fatty acids from triacylglycerol 
Glycerol exit hole 
Active site entrance tunnel 
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stores151 but the primary role of MAGL in the brain is to carry out the 
deactivating hydrolysis of 2-AG. MAGL is expressed more predominantly 
in the cortex, hippocampus and cerebellum.127  
3.1.4 Pharmacological potentials of MAGL inhibition 
It is known that exogenous administration of cannabinoids 
(obtained from natural sources like plants or synthetically produced) can 
induce a wide range of neuropharmacological effects mainly related to 
neurotransmission modifications in CNS by CB1 receptor activation.152,153 
For instance, in vivo administration of (-)-∆9-tetrahydrocannabinol (∆9-
THC), a well-known highly potent CB1/CB2 partial agonist present in 
Cannabis genus plants, produce behavioral responses like hypomobility, 
analgesia, catalepsy and hypothermia (collectively defined as “Martin’s 
tetrad”)in mice154 and can induce antiemetic and hyperfagic effects in 
human 155  and in rats 156  respectively. Unfortunately, until now, the 
understanding of the endocannabinoid neurotransmission physiology is 
far to be completed and this doesn’t allow us to entirely know how these 
responses are induced and how to uncouple beneficial and untoward 
properties of exogenous cannabinoid administration. Indeed, 
considering that both AEA an 2-AG act across the CNS mainly activating 
the same CB receptor subtype, it is easy to understand that one of the 
bigger problem that affects the study of endocannabinoid system 
physiology is to dissect the individual role of these endocannabinoids in 
CB1 mediated signaling. Adding complexity to this topic, effects like 
catalepsy were reported after intravenous AEA administration in male 
CB1/CB2 receptor deficient mice (Cnr1−/−/Cnr2−/−) providing an evidence 
that some effect of Martin’s triad could be mediated by activation of 
other kind of receptor than CBs.157 Despite the induction of some CB1 
mediated neurological effects by administration of exogenous CB1 
agonists could be useful for the treatment of chronic pain, emesis and 
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anorexia, the occurrence of a number of undesirable side effects such 
as locomotor or cognitive impairments limits the clinical utility of these 
compounds as therapeutic agents.131 In the same way, the exogenous 
administration of CB1 agonist induce an unselective CB1 activation 
across brain regions so that these agents cannot be used as 
pharmacological tools to unveil the individual physiological role of AEA 
and 2-AG in the endocannabinoid system framework. Since in vivo 
administration of AEA157,158,159,160 and 2-AG as therapeutic agents are 
hampered by their fast hydrolytic bio-inactivation,160 inhibitors of AEA 
and 2-AG degradation offers a potential alternative strategy to stimulate 
in a more physiological way the endocannabinoid system.131 Despite a 
significant number of FAAH inhibitors have been developed, 161 MAGL 
inhibitors have lagged historically. Considering that 2-AG has been 
proposed as the true physiological endogenous ligand for CBs 
receptors,124,137 it is easy to understand how the development of a 
selective inhibitor of MAGL could be useful not only to obtain a more 
effective pharmacological manipulation of endocannabinoid 
neurotransmission but also to dissect the overlapping effects of AEA and 
2-AG signaling.123 Because most of known MAGL inhibitors lack either 
potency and/or selectivity towards FAAH or other hydrolase, new 
selective MAGL inhibitors are required to allow the therapeutic 
exploitation of MAGL enzyme and to specifically investigate the 2-AG 
dependent signaling in the brain.  
Moreover, Nomura K. and coworker (2010) have recently reported 
a MAGL overexpression in many kinds of cancer cells that seems 
correlated with an increased production of FFA (Free Fatty Acids) inside 
them. 162 Since increased levels of FFA are believed to promote cancer 
cells migration, survival and in vivo tumor growth, selective and potent 
MAGL inhibitors could be useful also to develop new anti-cancer drugs 
based on a completely new action mechanism. 
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3.1.5 MAGL inhibition strategies 
As previously reported in Chapter 1.1.1 of this thesis, a covalent 
binding inhibition mechanism often provide high pharmacological 
potency also to ligands not properly structurally optimized for the 
receptor fitting. In this way, a large number of covalent reactive non-
optimized “hit compounds” for a given biological target can be easily 
discovered and quickly submitted to further structural refinement studies. 
Thus, covalent modifiers might be helpful to quickly overcome the 
historical lack of highly potent and selective MAGL inhibitors.  
MAGL covalent inhibitors reported in the literature can be classified 
on the base of their preferred targeted residues. These compounds can 
alternatively bind: 
1. the catalytic triad residues (Ser122-His269-Asp239: red circled in 
figure 3.7) within the MAGL active site, 131,141,145,151,165  
2. the cysteine residues Cys242 and/or Cys201 (yellow circled in 
figure 3.7) located close to Ser122 in the active site or in the vicinity 
of the putative glycerol exit hole, respectively, 145,149 
3. The cysteine residues Cys242 (yellow circled in figure 3.7) and/or 
Cys208 (green circled in figure 3.7) located close to Ser122 or at 
the entrance of the wide liphophilic active site entrance tunnel, 
respectively.33,32, 149,179. 
 
While compounds that target the catalytic triad residues act 
directly disrupting the activity of Ser122, the mechanism through 
remaining cysteine trapping agents inhibit MAGL is not so easy to 
understand. On the base of the mutual position of cysteine residues 
respect to catalytic active Ser112, it was proposed that covalent 
inhibitors that bind Cys242 or Cys201 could disrupt the enzymatic activity 
of MAGL hindering the active site or the putative glycerol exit hole, 
respectively.149 In this way, compounds able to bind Cys242 or 
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Cys201could decrease the MAGL activity hampering the access of 2-AG 
or the fast exiting of cleaved glycerol to the active site.149 On the other 
hand, compound able to selectively bind Cys208 wouldn’t be able to 
directly modify the active site environment. After their covalent binding, 
they could hamper the substrate access to active site hindering the main 
liphophilic tunnel entrance. Otherwise, they could allosterically modulate 
the hydrolytic activity of MAGL,147 perhaps hampering the postulated 
“interfacial activation” of MAGL provided by cap domain conformation 
changes. 
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3.2 Covalent MAGL inhibitors 
Another classification of available covalent MAGL inhibitors can be 
carried out considering the reversibility of established inhibitor-enzyme 
interaction. Generally, covalent and non-covalent interactions concur to 
define both binding affinity and reversibility of a given inhibitor. On the 
other hand, considering that for a covalent modifier the largest part of 
binding energy are from the covalent bond formation, the reversibility of 
MAGL inhibition provided by these compounds mainly depend to the 
chemical and biological stability of established covalent interactions. In 
this way, among described inhibitors, alkylating agents form the most 
stable covalent interaction and can be always considered as irreversible 
inhibitors. Carbamoylating agents bind MAGL forming middle-range 
stable covalent bonds and provide MAGL inhibition that range from 
irreversible (at least from a pharmacological point of view) to partially 
reversible. Finally, despite disulfide bond forming agents and acylating 
agents should form the most easily breakable covalent interactions from 
a chemical and biological point of view, the reversibility of their action 
can easily range from irreversible to completely reversible, dependently 
to the macro or micro environment in which their respective covalent 
interactions take place. The reversibility of covalent interaction of THL 
(55, Orlistat ®, Figure 1.4) toward human pancreatic lipase (hPL) and 
human pancreatic carboxyl-ester lipase (hCEL) could represent a good 
example of how much the environment impacts on the stability of neo-
formed acylated residues. Indeed, it was reported that THL is able to 
acylate the catalytic serine residue in the active sites of both enzymes,163 
but a covalent irreversible inhibition was reported only for hPL,20 because 
of the hydrolytic instability of esterified serine within the hCEL active 
site.163 
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3.2.1 Reversible MAGL inhibitors 
To date, only β-lactone OMDM169 (124, Figure 3.8) has been 
reported as MAGL reversible inhibitor.164 Despite this compound presents 
the same β-lactone warhead of the well-known and structurally similar 
covalent modifier THL (55, Orlistat ®, Figure 4.1),20 the covalent binding 
mode of 124 toward MAGL wasn’t investigated until now. In this way, 124 
could interact with its target by a non-covalent as well as covalent 
reversible mechanism. 
 
 
Figure 3.8. Structure of β-lactone OMDM169, the only putative covalent reversible 
MAGL inhibitor known until now. 
 
It was reported that OMDM169 124 in vitro inhibits MAGL and hPL at 
low µM concentrations without interact with other endocannabinoid 
system members (α-DAGL, FAAH and CB receptors). Intra-peritoneal in 
vivo administration of a dose as little as 2.5 mg/Kg of 124 was able to 
induce cannabinoid receptor-mediated antinociceptive effects in 
vivo.164 
 
3.2.2 Irreversible MAGL inhibitors 
Basing our classification of their inhibition mechanisms, two kinds of 
covalent irreversible MAGL inhibitors can be recognized. The first one is 
represented by compounds able to covalently bind MAGL catalytic 
Ser122, directly disrupting the MAGL hydrolytic activity. Among them, 
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despite these compounds provide the most affective MAGL inhibition, 
only few derivatives have shown high selectivity for the desired target. 
For instance, highly reactive serine-binding fluorophosphonates 125-130 
or fluorosulphonates 131-133 (Table 3.1) are able to block MAGL activity 
with high potency165 but are also able to inhibit other serine-dependent 
enzyme inside and outside the “endocannabinoids system” with 
comparable efficiency. 
 
 107 
Warhead R1 R2 Name # 
MAGL 
IC50 (nM) 
FAAH 
IC50 (nM) 
AchE 
IC50 (nM) 
CB1 
IC50 (nM) 
In vitro 
 
C8H17 Me MOFP 125 3.0±02166 0.79±0.15166 N/A N/A 
C8H17 Et EOFP 126 3.0±07166 0.60±0.05170 120±7170 11000±5000167 
C12H25 Me O-1778 127 N/A 3.0±02168 N/A N/A 
C12H25 i-Pr IDFP 128 0.76±0.33166 2169 N/A 1.8±0.8169 
C20H41 Me O-1624 129 N/A 137±22168 N/A N/A 
C20H33 (arachidonyl) Me MAFP 130 22±0.3a 0.10±0.02170 124±17170 530±130167 
 
C8H17 / OSF 131 140±2166 1.9±0.2166 >500.000170 1300±300 
C12H25 / N/A 132 200±75166 2170 N/A 6.9±3.6169 
C20H33 / N/A 133 N/A N/A N/A 304±23171 
 
Table 3.1. In vitro inhibition of mMAGL, FAAH, AchE (acetylcholinesterase) enzymes and of mouse CB1 receptor by different 
fluorophosphonate and fluorosulphonate agents. All inhibition values are indicated as Mean±SE (n=3-6). a rMAGL in vitro inhibition data 
from Saario S.M. et al.; Biochem. Pharmacol. 2004, 67, 1381–1387. 
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In vivo administration of fluorophosphonate like MAPF 130 induces 
an increasing of 2-AG endogenous levels in rat CNS by inhibition of 
MAGLi but, on the other hand, increases endogenous AEA levels too by 
FAAH inhibition. Moreover, it is reported that some agents like these can 
covalently bind CB1 receptors acting as uncompetitive CB1 inhibitors.168 
This produces an undesirable complex pharmacological response 
from which is difficult to selectively define the 2-AG contribution to the 
observed biological effects. Furthermore, the ability of these 
fluorophosponate derivatives to inhibit multiple serine-dependent 
enzymes ii  is often responsible to high off-target toxicity, sometimes so 
severe to kill the treated subject. For instance, probably by inhibition of 
NeuropathyTargetEsterase (NTE) enzyme in CNS, it is reported that mice 
acutely treated with IDFP die within 48h after treatment.131  
Despite the low target selectivity shown by these labeling 
compounds does not allow their use as drugs and limit their use as 
pharmacological tools, their impressive MAGL inhibitory potency have 
induced many scientists to develop more druggable and specific serine-
trapping agents. 
Recently these efforts are results in a series of carbamoyltetrazoles 
and carbamates and that have shown to covalently inhibit hMAGL with 
high potency and with enhanced selectivity (Table 3.2). 
                                            
 
i) These kinds of compounds are able to inhibit other 2-AG deactivating enzymes such as ABHD6. The 
contribution of this additive inhibition to the 2-AG levels in CNS is very little because 85% of 2-AG is 
metabolized mainly by membrane-associated MAGL (Blankman J. L. et al.; Chem. Biol. 2007, 14, 1347-1356). 
 
ii) They also inhibit the Hormone Sensitive Lipase (HSL), the ether-lipid metabolic enzyme KIAA1363 and the 
Neuropathy Target Esterase (NTE) (Long, J.Z. et al.; Proc Natl Acad Sci 2009,106(48), 20270-20275.). 
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# Name Structure 
hMAGL 
IC50 (nM) 
Irrev. 
inhibition 
Specificity for 
MAGL inhibition 
134 LY2318912176 
 
0.9 NO172 N/A 
135 LY2183240173 
 
5.3 YES NO 
136 
WWL152  
(R1=F)131 
 
WWL162  
(R1=Ome)131 
N
H
O
O
N
H
R1
R1
NO2
 
N/A N/A 
Partial 
(ABHD6 
inhibition) 
137 N/A174 
 
15 N/Aa YES 
138 JZL175131 N
H
O
O
OH
OMe
OMe
NO2
 
N/A YES YES 
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139 JZL184131 
N
H
O
O
OH
O
O
O
O
NO2  
8 YES 
YES 
(very high) 
Table 3.2. In vitro potency of most selective irreversible MAGL serine-trapping inhibitors. 
a Covalent modification of MAGL was only hypothesized for this compound on the 
base of observed covalent binding of MAGL shown by other carbamates with similar 
structure141 
 
Among them, JZL184 (139, Table 3.2) has shown the best 
potency/selectivity profile. It irreversibly inhibits MAGL and FAAH with IC50 
values of 8 nM and 4 µM respectively.141 It was reported that in vivo 
administration of 139 increases 2-AG levels in mice CNS by covalent 
irreversible MAGL inhibition without significantly interact with other 
component of “endocannabinoids systems”.131 When administered in 
mice, 139 evoke a clinically useful strong and prolonged analgesia but 
some side effects like hypomotility and hypothermia were also observed. 
Noteworthy, no catalepsy was detected in mice treated by 139 so to 
prove the ability of these compounds to evoke only a specific subset of 
Martin’s tetrad responses.131,141  
The second kind of covalent irreversible MAGL inhibitor is 
represented by compounds able to indirectly disrupt the MAGL 
hydrolytic activity, covalently binding critical cysteine residues that, even 
if not directly involved in the catalytic hydrolysis mechanism,172 may exert 
a regulatory effect on MAGL catalytic activity. 175  N-substituted 
maleimides represent a good example of irreversible cysteine-trapping 
MAGL inhibitors. These molecules present a lipophilic portion linked to a 
heterocyclic warhead characterized by the presence of a broadly 
conjugate double bond that act as a highly activated Michael 
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acceptor system (Scheme 3.2). The in vitro inhibition potency of these 
compounds against rMAGL increases as lipophilicity increases and N-
arachidonylmaleimide (140, NAM, Scheme 3.2) was found the most 
potent compound with IC50 magnitude in the range of nM.  
 
Scheme 3.2. Michael addition of Cys201 or Cys242 of MAGL to the conjugated carbon-
carbon double bond of NAM 140  
 
Several in vitro studies have shown that 140 covalently inhibits 
hMAGL through an irreversible Michael addition of Cys201 (or Cys242 as 
secondary target),147 without exerting any trapping activity toward the 
catalytic triad at tested concentrations (the latter finding has been 
reported for rMAGL).145 The importance of Cys201 and Cys242 for NAM 
inhibitory binding on hMAGL was confirmed by glycine-scanning175 and 
alanine-scanning147 based mutagenesis independent studies. On the 
other hand, since only alkylated Cys208 (22-26% of alkylation degree) 
and Cys242 (74-78% of alkylation degree) residues were detected inside 
of tryptic fragments of rMAGL (wild type)incubated with NAM, 176 the 
exact identity of cysteine residues targeted by this compound is still 
debated. Even if the MAGL inhibition provided by NAM cannot be 
addressed to direct disruption of Ser-Hys-Asp triad catalytic activity, it 
could be alternatively explained by several other mechanisms. 
Dependently to the kind of bound cysteine residue, NAM could act a) 
obstructing the lipophilic tunnel that allow to 2-AG to reach the active 
site of the enzyme (binding of Cys208), b) obstructing the putative 
glycerol narrow hole that allow to glycerol to exit from the active site 
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once cleaved (binding of Cys201), c) sterically hindering the active site 
so to prevent the contact between catalytic Ser122 and the 
endogenous substrate (binding of Cys242). Despite its in vitro potency, in 
vivo administration of NAM does not produce any observable 
cannabinoid effects belonging to the Martin’s tetrad. On the other 
hand, it was reported that in vivo intra-peritoneal NAM/2-AG mixed 
administration in mice induce a complete expression of Martin’s tetrad 
responses. This “permissive” effect exerted by NAM about exogenous 
administration of 2-AG, normally hampered by short half-life of this 
endocannabinoid, was though due to a reduced 2-AG breakdown by 
covalent and irreversible MAGL inhibition.177 
Among cysteine trapping inhibitors of MAGL, disulfiram (68, Scheme 
1.8 and Figure 3.9) was reported able to in vitro potently inhibit MAGL 
(hMAGL IC50 ≈ 0.363 µM) by covalent binding of a not yet defined 
cysteine residue on the enzyme. The disulfidic nature of this covalent 
interaction was confirmed by the complete and dose-dependent 
reversibility of observed MAGL inhibition after addition of the reducing 
agent DTT. 178  The disulfiram analogue bis(4-
methylpiperidinylthiocarbonyl)disulphide was recently reported able to 
selectively and irreversibly in vitro inhibit hMAGL (hMAGL IC50 ≈ 1.26 µM; 
hFAAH IC50 ≈ 363 µM) by formation of a covalent disulfide bond with 
Cys208 or Cys242.33 Considering that also simple disulfides, 
bis(dialkylamino)disulfides and bis(alkylthiocarbonyl)disulfides were 
reported as in vitro MAGL potent inhibitor,33 disulfide-containing 
molecules could represent a new promising class of irreversible, or at 
least partially reversible, cysteine trapping inhibitor of MAGL (Figure 3.9). 
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Figure 3.9. Overview of disulfide containing inhibitor of MAGL. 
 
The high MAGL inhibitory potency and selectivity shown by some of 
covalent inhibitors described in this chapter make them excellent 
examples of selective labeling agents suitable for pharmacological 
investigation. On the other hand, their long-lasting inhibitory effect on 
MAGL could be detrimental for their clinical use because of eventually 
responsible of the occurrence of behavioral side effects.  
Indeed, it is suggested that side effects like hypothermia and 
hypomotility induced by JZL184 administration would probably due to an 
over-physiological increase of 2-AG levels in the CNS resulting from 
prolonged irreversible block of MAGL.141 In this way, these side effects 
could be pharmacologically uncoupled from beneficial one like 
analgesia by titrating the magnitude of in vivo MAGL inhibition.141 In this 
way, reversible (Chapter 3.2.1) or partially reversible (Chapter 3.2.3) 
MAGL inhibitors like OMDM169 and isothiazol-3(2H)-one related 
compounds respectively could be useful to mildly modulate MAGL 
inhibition across brain regions. This mild approach could be helpful to 
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unveil physiological functions of 2-AG-dependent neurotransmission and 
to validate MAGL as a target for therapeutic drugs. 
3.2.3 Partially reversible MAGL inhibitor 
Only one class of covalent partially reversible MAGL inhibitors has 
been reported until now. This inhibitor class, recently discovered by Prof. 
Mor’s research group, 179  is populated by disulfide-bond forming 
compounds such as isothiazol-3(2H)-one and benzo[d]isothiazol-3(2H)-
one derivatives. These compounds were discovered as “hit compounds” 
during the screening of a short panel of cysteine trapping derivatives 
toward recombinant rMAGL. These reactive molecules (Figure 3.10) were 
chosen to exert their cysteine trapping activity through different kind of 
reaction mechanisms like Michael addition, mixed disulfide formation 
and nucleophilic substitution. 
 
 
Figure 3.10. Red colored portions should be responsible of the cysteine related reactivity 
of depicted warheads. 
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Among them, except N-substituted maleimides 142 and 143 that 
were used by authors as reference standards for MAGL irreversible 
inhibition evaluation, only isothiazol-3(2H)-one and benzo[d]isothiazol-
3(2H)-one derivatives have been shown to potently in vitro inhibit rMAGL 
with IC50 values ranging from low µM to nM concentrations. In order to 
evaluate the reversibility of the MAGL inhibition provided by these 
agents, a rapid dilution assay 180  of rMAGL, pre-incubated with the 
isothiazol-3(2H)-one derivative ochtylinone 145, has been carried out. 
Collected data indicates that MAGL was inhibited by ochtylinone 145 
with a partially reversible mechanism (Figure 3.11) 
 
Figure 3.11. Reversibility of monoacylglycerol lipase (MAGL) inhibition by octhilinone. (A) 
Rapid dilution assays of purified MAGL in the presence of vehicle (dimethylsulphoxide, 
final concentration 2%), octhilinone or methyl arachidonylfluorophosphonate (MAFP). 
Results are expressed in percentage of product generated after a 60 min incubation 
with vehicle (mean ± SEM, n = 3). 
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A glycine scanning based mutagenesis study has suggested that 
their inhibition mechanism involve a covalent interaction between the 
sulfenamidic system and the Cys208 residue of MAGL (Figure 3.12). 
 
Figure 3.12. Concentration-response curves for the inhibition of MAGL activity by 
octhilinone in wild-type MAGL (wtMAGL) and C208G MAGL mutants. Results are 
expressed in percentage of control activity (dimethylsulphoxide, final concentration 
1%) (mean ± SEM, n = 3–5). 
 
It is proposed that this interaction takes place by a nucleophylic 
attach of Cys208 toward the sulfur atom of sulfenamidic system 
producing a subsequent nitrogen displacement181 with formation of a 
mixed disulfide bond (Scheme 3.3).175  
The proposed dependence of MAGL inhibition to the formation of a 
mixed disulfide bond rather than to a Michael addition of Cys208 to the 
isothiazol-3(2H)-one carbon-carbon double bond was in agreement with 
previous published results about reactivity of isothiazol-3(2H)-one 
warhead,8 and it is also supported by two different experimental findings. 
The first one is represented by the observation of a 47-fold decreased 
inhibitory potency of ochtylinone 145 when rMAGL was incubated in 
absence or in presence of a low concentration of DTT. The second one is 
represented by the fact that 2-octyl benzo[d]isothiazol-3(2H)-one 147, 
which cannot undergo Michael addition because of its conjugated 
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double bond is involved in benzene aromaticity, was as potent as 
ochtilinone 145 to inhibit MAGL activity. 
 
 
Scheme 3.3. Hypothesized cysteine trapping dependent inhibition mechanism of MAGL 
provided by isothiazol-3(2H)-one and benzo[d]isothiazol-3(2H)-one derivatives. 
 
Further information about the reactivity these sulfenamidic 
warheads, their cysteine trapping related toxicity and their uses in 
medicinal chemistry are already reported in Chapter 1.2.1 of this PhD 
thesis. 
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3.3 Synthesized MAGL inhibitors 
3.3.1 Aim of the work 
Discovery of isothiazol-3(2H)-one and benzo[d]isothiazol-3(2H)-one 
derivatives as hit compounds for MAGL inhibition has provided the 
fundamentals for the development of new potent and partially reversible 
MAGL inhibitors. Like for other covalent modifier, the targeting of Cys208 
on MAGL provide to these compounds a high binding affinity for the 
target that does not depend so much to a proper receptor fitting. The 
resulting high basal biological activity, represents a good starting point to 
set up a SAR study. Indeed, the establishment of a stable covalent bond 
between the target and tested compounds allows to freely expand the 
diversity of decorating groups around the warhead core with reduced 
risk of binding loss. In this way, the diversity of decorating group around 
the isothiazol-3(2H)-one and benzo[d]isothiazol-3(2H)-one warhead was 
expanded in order to: 
 
1. explore the pharmacophoric space around the targeted Cys208 
to enhance the selectivity of designed inhibitors for MAGL versus 
other hydrolytic enzymes (e.g. FAHH);  
 
2. modulate the reactivity of the considered sulfenamidic warheads 
to optimize their druggability and to achieve a better 
activity/toxicity ratio. 
 
Hypothesizing that the partial reversible character of MAGL inhibition 
shown by ochtilinone (145, Figure 3.10) could be a common feature of 
isothiazol-3(2H)-one and benzo[d]isothiazol-3(2H)-one based 
compounds, the use of these kind of warheads for the development of 
new partially reversible inhibitors of MAGL could provide a new and 
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more physiological way to increase 2-AG levels in CNS without induce 
unwanted side effects like those observed after JZL184 administration. 
In this way, several compounds sharing a common structure motif 
were designed. They were characterized by the presence of (figure 
3.13): 
• a driver group (green colored) lipophilic enough to assure a good 
basal affinity for the enzyme to the synthesized compounds. This 
portion is also designed to modulate the reactivity of sulfenamidic 
warhead through a differential contribution to its electronic 
distribution. 
• an isothiazol-3(2H)-one and benzo[d]isothiazol-3(2H)-one based 
cysteine-reactive warhead (red colored) linked to the lipophilic 
driver group R. 
N
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Figure 3.13. Overviev of synthesized cysteine-reactive compounds. 
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In order to evaluate the impact of a modified receptor fitting on the 
MAGL inhibition potency, the structure of the driver group of compounds 
sharing a common kind of warhead was broadly changed.  
However, the inhibition potency and specificity of these isothiazol-
3(2H)-one and benzo[d]isothiazol-3(2H)-one derivatives may not only 
depend from the receptor fitting but they could be also affected by 
warhead’s reactivity changes. Nevertheless, the sulfenamidic system 
reactivity may probably exert a not negligible impact on warhead’s 
chemical or metabolic stability. 
In order to study these dependencies, a preliminary panel of N-
substituted benzo[d]isothiazol-3(2H)-ones was synthesized (Table 3.3). 
 
 # R # R # R # R 
18 
 
24 
 
28 
 
32 
 
19 
 
25 
 
29 
 
33 
 
20 
 
26 
 
30 
 
34 
 
21 
 
27 
 
31 
 
35 
 
22 
 
13 
 
    
23 
 
      
Table 3.3. Synthesized benzo[d]isothiazol-3(2H)-one based MAGL inhibitors. 
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A brief look-over to the just reported summarizing table (Table 3.3) 
easily shows that this preliminary panel of synthesized compounds is 
characterized by the same structurally conserved benzo[d]isothiazol-
3(2H)-one warhead. Despite this, these compounds should not possess 
the same chemical reactivity because of different steric hindrance and 
of electronic inductive effects exerted by the N-substituent “R” on the 
nitrogen atom of sulfenamidic system. Five different subsets of 
compounds should share similar warhead reactivity: 
• Cluster 1: 2-alkyl and 2-alkylaryl derivatives belong to this cluster. 
Alkyl and alkylaryl substituents should exert the same inductive 
effect on sulfenamidic nitrogen so to confer to these compounds 
a similar warhead reactivity.  
• Cluster 2: only 2-aryl derivatives populate this cluster. The direct 
conjugation of the aryl substituent to the sulfenamidic nitrogen 
lone pair should exert an electron withdrawing effect on the 
sulfenamidic system, probably increasing its reactivity toward 
nucleophils. This “activating” effect has been previously reported 
for N-arylpyrido[5,4-b]isothiazol-3(2H)-ones , where it was proposed 
to be responsible of metabolic instability.182 
• Cluster 3: 2-amino derivatives populate this cluster. In these 
compounds the amino group at 2 position should exert an 
electron withdrawing effect on the sulfenamidic system increasing 
its reactivity toward nucleophils. Notably, the exocyclic nitrogen of 
these compounds could enhance the water solubility of these 
derivatives and it could be protonated under acidic conditions. 
The latter occurrence could enormously increase the electron 
withdrawal effect of exocyclic nitrogen on sulfenamidic system, 
overactivating it. For this reason, these clusters could collect high 
cysteine reactive derivatives. 
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• Cluster 4: only compound 35 populate this cluster (Table 3.3 and 
Figure 3.14). It should possess the strongest warhead reactivity 
among synthesized compound (at least in neutral conditions) 
because of the high electronic shortage of carbamoylated 
exocyclic nitrogen. Despite its structure seems close to those of 
“Cluster 3” members this compound cannot be grouped with 
them mainly because the carbamoyl moiety presence. This 
fragment could act as a serine trapping warhead so to make this 
compound able to bind multiple residues on MAGL. 
 
 
Figure 3.14. Structure of carbamate 35 
 
• Cluster 5: only compound 18 populate this cluster. Compound 18 
should differ from all other synthesized compounds in term of 
reactivity because of the unsubstituted nitrogen atom on the 
benzisothiazol-3(2H)-onic structure. Lack of bulky “R” substituents 
on sulfenamidic nitrogen probably decreases the binding 
specificity of compound 18 toward MAGL but, in the same time, 
allows the existence of a prototropic equilibrium between the 
nitrogen and the oxygen atoms of isothiazol-3-onic warhead 
portion. 183  This hydrogen transfer induces the isothiazol-3-onic 
system aromatization and produces a fully aromatized 3-
hydroxybenzisothiazole 151 (Scheme 3.4). 
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Scheme 3.4. The prototropic equilibrium of isothiazol-3-onic portion of benzisothiazol-
3(2H)-one 18. 
 
In this form, the sulfenamidic system should not present any 
reactivity toward nucleophiles. Indeed, the S-N bond cleavage 
induced by a nucleophilic attack on 3-hydroxybenzisothiazole 
sulfur atom is unfavored in this molecule because it would lead to 
the disruption of heterocyclic system aromaticity. Thus, compound 
17 should be less reactive that other synthesized N-substituted 
compounds, presenting a better chemical and/or metabolic 
stability. 
 
Considering that members of each described cluster share a 
common reactivity, each biological activity variations detected among 
compounds belonging the same cluster should be only dependent to 
receptor fitting changes induced by driver portion structural changes. In 
this way, the contribution of lipophilicity of “R” driver group to the 
observed MAGL inhibition could be roughly evaluated comparing the 
biological activities shown by compounds belonging to the “Cluster 1” 
(table 3.4, all compounds). In the same way, differences in the observed 
inhibitory potency of these derivatives could provide information about 
the tolerability of a steric hindrance in α position to the sulfenamidic 
nitrogen (Table 3.4, compounds  20, 22, 23) or about a different 
positioning of the hindering aromatic systems in these molecules (Table 
3.4, compounds 13, 24-27). 
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# R # R 
19 
 
24 
 
20 
 
25 
 
22 
 
26 
 
23 
 
27 
 
21 
 
13 
 
Table 3.4. Structural comparison of driver groups possessed by members of cluster 1. 
 
Similar considerations can be done for compounds belonging clusters 2 
and 3. In this way, compounds 28-31 could provide information about 
the influence of the presence of different shaped aromatic systems 
(Table 3.5-A, all compounds) or about the tolerability of a steric 
hindrance in α position to the sulfenamidic nitrogen (Table 3.5-B, all 
MAGL targeting                                                                                  Chapter 3 
 126
 
A 
 
# R 
28 
 
29 
 
30 
 
31 
 
 
Table 3.5. Structural comparison of members belonging to A) cluster 1 and  B) cluster 2. 
 
On the other hand, compounds that possess different warhead 
reactivity but that share a similar driving portion structure can be 
grouped performing an orthogonal clustering process. For instance, 
some 2-aryl (compounds 19 and 22-24) and 2-amino derivatives 
(compounds 28 and 32-34) possess similar topological features but 
different warhead reactivity because of the different electron inductive 
effect provided by their driver groups (Table 3.6). A comparison of MAGL 
inhibitory potency values furnished by these compounds could define 
the contribution of the covalent warhead reactivity to the observed 
biological activity of these derivatives. 
B 
 
# R 
32 
 
33 
 
34 
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# R # R 
19  32  
23 
 
28 
 
24 
 
33 
 
22 
 
34 
 
Table 3.6. Structural comparison of MAGL inhibitors possessing topologically similar driver 
group and different warhead reactivity (differential driver group contribution). Listed 
compound are member of clusters 1-3. 
 
With the same strategy in mind, in order to evaluate if the reactivity 
of isothiazol-3(2H)-one and benzo[d]isothiazol-3(2H)-one warhead would 
differently contributes to the observed biological activity, some 
isothiazol-3(2H)-one derivatives (36 and 37) were also designed and 
synthesized. The compared structures are reported in Table 3.7. 
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N R
S
O
 
N R
S
O
 
# R # R 
24 
 
36 
 
30 
 
37 
 
Table 3.7. Structural comparison of MAGL inhibitors possessing topologically similar driver 
group and different warhead reactivity (different warhead type). 
 
Finally, in order to understand if the cysteine-trapping activity could 
be a fundamental requirement for the MAGL inhibition exerted by 
designed benzo[d]isothiazol-3(2H)-one-based compounds, two 3-
alkyloxybenzo[d]isothiazoles (compounds 38 and 39, Table 3.8), 
structurally very close to some previously shown 2-alkyl and 2-alkylaryl 
benzo[d]isothiazol-3(2H)-ones (compounds 19 and 26, Table 3.8), were 
synthesized. The compared structures are reported in Table 3.8. 
N R
S
O
 
N
R
S
O
 
# R # R 
19  38  
26 
 
39 
 
Table 3.8. Structural comparison of MAGL inhibitors possessing topologically similar driver 
group and different warhead reactivity (different warhead type). 
 
For the same reasons considered for the aromatized form 151 of 
compound 18, compounds 38 and 39 should be inactive as cysteine-
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trapping agents because of their stable and fully aromatized 
heterocyclic warhead. 
If this kind of compounds will result active as MAGL inhibitors, the 
cysteine-trapping feature possessed by tested benzo[d]isothiazol-3(2H)-
one derivatives cannot be defined as “essential” for MAGL inhibition 
anymore. In this case, an alternative non-covalent MAGL inhibition 
mechanism will be proposed to explain the collected experimental data 
about this compound class. 
 
3.3.2 Chemistry 
Except for the purchased unsubstituted benzo[d]isothiazol-3(2H)-
one 18 and for EGFR inhibitor 13 (see Chapter 2.3.2), all synthesized 
compounds were prepared following five different synthetic strategies 
that are summarized in Table 3.9. The synthetic route used to synthesize 
compound 13 was already reported in Chapter 2.3.2. 
 
  130
 
Strategy Code Strategies overview 
A 
 
B 
 
C 
 
D 
 
E 
 
Table 3.9. Synthetic strategies overview. 
  131
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Except for strategies A and B,110 all other synthetic strategies were 
based on the activation of carboxylic moiety of the commercially 
available starting materials to produce isolable amides that were 
subsequently oxidatively cyclized to obtain the desired warhead portion. 
Strategies A and B, indeed, did not allow the isolation of any stable 
intermediate and produced desired N-alkylated products from 
commercially available precursors by a one-pot procedure (except for 
compound 21). On the other hand, even the D strategy allowed the 
isolation and the purification of amidic intermediates, using I2/Et3N 
mixture as the oxidative cyclization agent 184  a one-pot and very 
effective modification of this sequence was developed and applied 
during this PhD thesis. When not commercially available, drivers groups 
were synthesized through properly designed synthetic routes. 
Final compounds 19, 20, 21, 24, 38 and 39 ( boxed in scheme 3.5) 
were synthesized following A strategy. 
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Scheme 3.5. Main synthetic scheme for compounds synthesized with method A. (i) CH3I, K2CO3, KI, CH3CN, RT; (ii) K2CO3, 1-chloro-6-
Iodohexane, CH3CN, RT; (iii) K2CO3, KI, piperidine, CH3CN, 60°C; (iv) 1,2-ethylendiamine, NaH, RT 1h then 3-octyn-1-ole 155, 65°C; (v) 
methanesulfonyl chloride, Et3N, CH2Cl2, 0°C to R.T; (vi) K2CO3, CH3CN, reflux, 1h; (vii) methanesulfonyl chloride, Et3N, CH2Cl2, R.T; (viii) K2CO3, 
CH3CN, reflux, 30 min. 
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Thus, they were synthesized by a simple nucleophilic substitution 
reaction between commercially available benzo[d]isothiazol-3(2H)-one 
18 and a proper electrophilic side chain. 185 This reaction was carried out 
activating the benzo[d]isothiazol-3(2H)-one 18 in basic conditions so to in 
situ obtain the activated benzo[d]isothiazol-3(2H)-one nucleophilic 
salted form. Since a basic environment is required to deprotonate the 
nitrogen of benzo[d]isothiazol-3(2H)-one, because of occurrence of 
elimination side reactions, this synthetic strategy was not suitable to 
obtain final compounds in which aliphatic driver groups were joined to 
the heterocyclic warhead by a secondary carbon. While the 
electrophilic activated side chain of compound 153 was commercially 
available, side chains 156 and 158 were activated as reactive 
electrophiles by mesylation of the primary hydroxyl group186 to obtain 
compounds 157 and 159, respectively. p-ethylbenzylalcohol 158 was 
commercially available whereas the precursor 156 was synthesized by a 
contrathermodynamic isomerization of the commercially available 
internal alkynyl alcohol 155 following the methodology developed by 
Brown, C.A. and Yamashita, A.187 Compound 153 was converted to final 
product 21 by a simple displacement of chlorine atom using piperidine 
as nucleophile species.188,189 
Despite strategy A was resulted straightforward to quickly obtain 
several final compounds, the formation of O-alkylated side products, 
often present in 1:1 ratio with the desired product in the reaction mixture, 
was every time observed. Even if this occurrence was exploited in some 
case to obtain useful final compounds (like in the case of compounds 20, 
38, 24, 39), the formation of these side products have lowered the yields 
of reactions carried out to specifically obtain N-alkylated final products 
(like in the case of compound 19 and 153). In order to move around to 
this side reaction occurrence and to achieve a good synthetic 
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methodology for the preparation of N-aryl derivatives, other synthetic 
routes were carried out. 
In this way, further N-alkyl and N-aryl benzo[d]isothiazol-3(2H)-one 
derivatives were synthesized using B strategy110 using a very cheap 
commercially available starting material like dithiosalicylic acid 160. This 
one-pot methodology has furnished desired products 25,42a 26, 27 and 30 
(boxed in scheme 3.6) very quickly but, unlike as reported in literature, 
with low reaction yields. 
S
S
O
O
OH
OH
S
S
O
O
Cl
Cl
S Cl
O
Cl
160 161
162
25
N
S
O
2 X
i ii
iii
27
N
S
O
iv
26
N
S
O
v
30
vi
N
S
O
 
Scheme 3.6. Main synthetic scheme for compounds synthesized with method B. (i) 
SOCl2, reflux, 3h; (ii) Cl2, CCl4, RT; (iii) 2-phenylethylamine, dry Et3N, dry CH2Cl2, RT; (iv) 2-
(napht-1-yl)ethylamine hydrochloride, dry Et3N, dry CH2Cl2, RT; (v) 2-(napht-2-
yl)ethylamine hydrochloride, dry Et3N, dry CH2Cl2, RT; (vi) p-phenylaniline, dry Et3N, dry 
CH2Cl2, RT 
 
Considering the high toxicity of employed reagents, and the intrinsic 
instability of involved intermediates (intermediates 161 and 162), this 
strategy was quickly abandoned in order to find a more safe and 
MAGL targeting                                                                                  Chapter 3 
 136
effective synthetic strategy to obtain the remaining benzo[d]isothiazol-
3(2H)-one derivatives. 
In this way, final compound 28, 29 and 31 (boxed in scheme 3.7) were 
synthesized from commercially available compound 163 following the C 
strategy.190 In this case, the amide coupling step is assisted by a strong 
Lewis acid like AlMe3 affording the desired amides 164-166 with good 
yields. The final oxidative cyclization step was accomplished using an 
hypervalent-iodine species like phenyliodine bis(trifluoroacetate) (PIFA) 
leading to N-aryl final compounds 28, 29 and 31 with good yields. 
 
 
 
Scheme 3.7. Main synthetic scheme for compounds synthesized with method C. 
(i)Aniline, Al(Me)3, dry CH2Cl2, 0°C to RT then compound 163, reflux; (ii) PIFA, TFA, CH2Cl2, 
0 °C; iii) m-phenylaniline, AlMe3, dry CH2Cl2, 0 °C to RT then compound 163, reflux; (iv) 
PIFA, TFA, CH2Cl2, 0 °C; (v)β-naphylamine, Al(Me)3, dry CH2Cl2, 0°C to RT then 
compound 163, reflux; (vi) PIFA, TFA, CH2Cl2, 0 °C. 
 
Despite the observed good yields, this approach wasn’t completely 
satisfactory because of the intrinsic instability of commercial starting 
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material 163 as well as intermediates 164, 165, 166. Indeed, they tend to 
form disulfides when exposed to air so to hamper their purification and 
characterization. Strategy D seems to overcome these troubles, 
providing a fast and effective way to access to the acid sensitive N-
carbamoylmamino final compound 35 and to products like 22 and 23 
(boxed in scheme 3.8). 
 
  
Scheme 3.8. Main synthetic scheme for compounds synthesized with method D. (i)SOCl2, reflux; (ii) dry Et3N, t-butylhydrazinecarboxylate, 
dry THF, 0°C to RT then I2; (iii) TFA/H2O 9/1, RT; (iv) Lithium hexamethyldisilazide (LiHMDS) 1.06M in dry THF, benzylbromide, dry THF, 0°C to RT; 
(v) trichloroacetic acid/H2O 9/1, 0°C then RT; (vi) MeI, imidazole, RT; (vii) dry Et3N, 2-aminononane, dry THF, 0°C  to R.T then I2; (viii) dry Et3N, 
2-aminocyclohexane, dry THF, 0°C to RT then I2. 
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After the chlorinating conversion110 of starting material 160 into the 
highly reactive acylchloride 161, compounds 22, 23 and 35 were 
obtained through an adaption of the procedure described by Kersting, 
B. and coworkers (1999).184  
In this one-pot adaption, the obtained disulfide bis-amides (not 
shown in figure 3.8) were not isolated but directly cyclized in presence of 
Et3N by addition of iodine as oxidizer. Despite the nearly complete 
conversion of bis-amides to desired products, accurate reaction yield 
estimations were done only for solid derivatives like 35 and 23. Indeed, 
the purification of oily products like 22 was difficult and provided multiple 
fractions of desired product with different purity grades.  
A simple N-Boc deprotection of compound 35 afforded the 2-
amino final product 32 (boxed in scheme 3.8) whereas product 33 was 
obtained by benzylation191  and subsequent N-Boc deprotection43a of 
carbamoylated nitrogen of compound 32. Finally, final compound 34 
(boxed in Scheme 3.8) was synthesized by a simple methylation of 
exocyclic nitrogen of product 33 in presence of non-nucleophilic weak 
bases like imidazole. 
Despite the efficacy of strategy D to produce a large array of 
benzo[d]isothiazol-3(2H)-one derivatives, this approach was not 
applicable to the synthesis of isothiazol-3(2H)-one derivatives 38 and 39 
(boxed in scheme 3.9). For this reason, all of them were synthesized 
following strategy E. The 3,3-dithiopropionic acid 168 was converted to 
the highly reactive acylchloride 162 by reflux in SOCl2,110 and coupled 
with the proper amine to give the bis-amide 170. Alternatively, The 3,3-
dithiopropionic acid 168 was directly converted in the bis-amide 172 
using O-(benzotriazol-1-yl)-N,N,N’,N’-tetramethyluronium 
hexafluorophosphate (HBTU) as coupling agent.192  Then obtained bis-
amides 170 and 172 were cyclized to final products 36 and 37 by 
addition of SO2Cl2, a chlorinating agent.108 
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Scheme 3.9. Main synthetic scheme for compounds synthesized with method E. (i) SOCl2, reflux, quantitative; (ii) 2-phenylethylamine, dry 
Et3N, dry ClCH2CH2Cl, RT; (iii) SO2Cl2., dry ClCH2CH2Cl, 0°C; (i)HBTU, ET3N, dry DMF RT then 4-phenylaniline; (ii) SO2Cl2., dry ClCH2CH2Cl, 0°C 
then RT 
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This approach differs from D strategy because the warhead portion 
cyclization109 was not carried out by a simple oxidative process. Indeed, 
the isothiazol-3(2H)-one warhead was obtained from bis-amides like 170 
and 172 by a complex sequence of reactions triggered by the slow 
addition of sulfuryl chloride (SO2Cl2) to the reaction medium. A possible 
reaction mechanism able to explain the formation of isothiazol-3(2H)-one 
warheads is here proposed. (Scheme 3.10) 
 
Scheme 3.10. Proposed reaction mechanism of SO2Cl2 to produce a N-substituted 
isothiazol-3(2H)-one warheads in presence of a general 3,3’-dithiopropionamide. 
 
SO2Cl2 directly chlorinate sulfur atoms of bis-amide I inducing the 
breakage of disulfide bond and affording highly reactive sulfenyl 
chlorides II. These species undergo an intramolecular cyclization 
producing isothiazolidin-3(2H)-one III that are quickly further chlorinated 
on sulfur atom to form sulfonium-salt IV. At this time, the Pummerer 
rearrangement takes place transferring the chlorine atom to the 
neighboring α-carbon16 with production of HCl. Finally, an elimination 
reaction provides the formation of an endocyclic carbon-carbon double 
bond leading to the isothiazol-3(2H)-one warhead VI. 
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It is reported that obtained isothiazol-3(2H)-one can be further 
chlorinated producing side product like 5-Chloroisothiazol-3(2H)-one 
when the reaction was carried out using an excess of SO2Cl2.109 This 
reaction conditions can locally occurs when SO2Cl2 is added too quickly 
to the reaction mixture or when the solubility of starting material in the 
reaction medium is low. During the synthesis of isothiazol-3(2H)-ones 38 
and 39, despite a very slow addition of SO2Cl2 to the reaction mixture 
using high dilution conditions, 5-Chloroisothiazol-3(2H)-one by-products 
were always produced, lowering, in this way, the reaction yields. 
 
3.3.3 Results and discussion 
At the moment, only a first group of synthesized benzo[d]isothiazol-
3(2H)-one-based compounds were tested toward purified rMAGL. The 
MAGL inhibition assay was carried out as described in the Experimental 
Section (Chapter 4.2.3) of this PhD thesis. Collected MAGL inhibition data 
provided by tested benzo[d]isothiazol-3(2H)-one-based inhibitors are 
reported in Table 3.10. 
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Compound R IC50 (nM) 
19 
 
59±5.7 
21 
 
195±12 
25 
 
19±1.8 
27 
 
22±5.2 
26 
 
54±16 
13 
 
21±0.9 
30 
 
15±0.6 
Table 3.10. Synthesized MAGL inhibitor already evaluated as MAGL inhibitor on rMAGL 
purified enzyme. 
 
All tested compounds show potent inhibition of MAGL but no 
significant variation of IC50 value were observed within the series, despite 
the structural variability of the R substituents. In this way, IC50 changes 
observed for tested inhibitors could be addressed mainly to lipophilicity 
changes. This hypothesis is supported by comparison between IC50 value 
of already published compounds 147179 and IC50 values calculated for 
compounds 21. Indeed, the increased polarity of compound 21 side 
chain, provided by the presence of the piperidinyl moiety, significantly 
increased its IC50 value with respect to those obtained for its structural 
homologues 147 
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T 
Compound R IC50 (nM) 
147  59±7 
21 
 
195±12 
Table 3.11. Comparison of IC50 values measured for compound 147 and 21. Despite the 
different source of these data, IC50 values can be compared because obtained using 
the same experimental methodology. 
 
These results were in agreement with a previously published SAR 
study focused on a short panel of isothiazol-3(2H)-one based inhibitors 
(table 3.12).179  
 
# Warhead R IC50 (nM) 
144 
N
S
O
R
 
Methyl 239±68 
145 n-Octyl 88±12 
146 Oleoyl 43±8 
Table 3.12. Comparison of IC50 value published for compound 144-145. 
 
Also in this case, indeed, a pivotal relationship between MAGL 
inhibition potency and lipophilicity of tested compounds has been 
observed. This study has been shown that an increased lipophilicity of the 
carbon side chain of isothiazol-3(2H)-one derivatives enhances their 
inhibitory potency toward MAGL. Indeed, substitution of their n-octyl 
group driver group (compounds 145) with a more lipophilic oleoyl chain 
(compound 146) increased their potency, while substitution with a 
methyl group (compound 144) decreased it. 
The constant magnitude of IC50 values shown by compounds 
synthesized during this PhD project could have two the different 
explanations: 
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1. an over-reactivity of the cysteine-trapping warhead could have 
overcome the structural diversity provided by the R substitution 
 
2. there is a very large pharmacophoric space to explore around the 
target cysteine. In this case, the diversity of designed driver groups 
could not be broad enough to properly exploit the 
pharmacophoric space features located around the binding site. 
 
The latter hypothesis is supported by the MAGL crystal structure 
(recently available) in which targeted Cys208 was accurately localized 
at the entrance of the lipophilic tunnel that allow to 2-AG to reach the 
enzyme active site.149 It was reported that this fully solvent exposed 
cysteine residue does not point toward the main liphophilic tunnel 
entrance and this suggests the presence of a huge pharmacophoric 
space to explore around it. 
 
3.3.4 Conclusions 
Too few biological data were collected until now to allow the 
proposal of any meaningful conclusive considerations. The dependence 
of observed IC50 values from liphophilicity of tested products and their 
proposed covalent binding with Cys208 residue on MAGL surface only 
suggests some considerations about the binding mode of tested 
compounds. In a first time, these compounds could be recognized by a 
Cys208 neighboring liphophilic cleft so to establish non-covalent and 
non-polar interaction with it. Afterwards, they could react with Cys208 
producing a covalent mixed disulfide bond, strengthening the 
compound-target binding. In this framework, the lipophilicity of 
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synthesized compound could enhance the non-covalent target binding 
so to favor the establishment of the covalent interaction with Cys208. 
The position and the spatial orientation of Cys208 on MAGL surface 
suggests that synthesized benzo[d]isothiazol-3(2H)-one and isothiazol-
3(2H)-one derivatives could act through an allosteric inhibition 
mechanism,149 perhaps hampering the postulated “interfacial 
activation” of MAGL by induction of cap domain conformation 
changes. Despite this, an inhibition mechanism based on a non-
competitive obstruction of the active site entrance cannot be ruled out. 
The intrinsic reactivity evaluation of synthesized compounds and the 
biological activity data about compounds not yet tested will be 
probably helpful to verify these hypotheses and to set-up a properly 
refined SAR study focused on this new class of cysteine-trapping MAGL 
inhibitors. However, the high basal inhibition potency provided by tested 
cysteine trapping benzo[d]isothiazol-3(2H)-one derivatives can be 
considered a good starting point for further structural optimizations 
directed to achieve new MAGL partially irreversible inhibitors with 
improved selectivity and bioavailability. 
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4.1 EGFR inhibitors 
4.1.1 Chemistry 
Reagents were obtained from commercial suppliers and used 
without further purification. Solvents were purified and stored according 
to standard procedures. Anhydrous reactions were conducted under a 
positive pressure of dry N2. Reactions were monitored by TLC, on 
Kieselgel 60 F 254 (DC-Alufolien, Merck). Final compounds and 
intermediates were purified by flash chromatography (SiO2 60, 40-63 µm). 
Microwave reactions were conducted using a CEM Discover synthesis 
unit (CEM Corp., Matthews, NC). Melting points were not corrected and 
were determined with Gallenkamp melting point apparatus. The 1H NMR 
spectra were recorded on a Bruker 300 MHz spectrometer and on a 
Bruker 300 MHz Avance spectrometer. Chemical shifts (δ scale) are 
reported in parts per million (ppm) relative to the central peak of the 
solvent. 1HNMR spectra are reported in the following order: multiplicity, 
approximate coupling constant (J value) in hertz (Hz), and number of 
protons; signals were characterized as s (singlet), d (doublet), dd 
(doublet of doublets), t (triplet), dt (doublet of triplets), q (quartet), m 
(multiplet), br s (broad signal). Mass spectra were recorded using an API 
150 EX instrument (Applied Biosystems/MDS SCIEX, Foster City, CA). Liquid 
chromatography/mass spectrometry analysis was performed on an 
Agilent 1100 LC gradient system coupled with an Applied Biosystem 150-
EX single quadrupole mass spectrometer equipped with a TurboIon-
Spray ion source working in positive ion mode. Final compounds 1,193 2,98 
and 399 were synthesized according to literature methods. The final 
compounds were analyzed on ThermoQuest (Italia) FlashEA1112 
Elemental Analyzer for C,H, and N (analyses were within 0.4% of 
theoretical values). All tested compounds were >95% pure by elemental 
analysis. 
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4.1.2 Synthesis  
A) Intermediate compounds: 
 
Potassium (2R,3S)-3-(piperidin-1-ylmethyl)oxirane-2-carboxylate 
(94). To an ice cold stirring solution of (2R,3S)-ethyl 3-(piperidin-1-
ylmethyl)oxirane-2-carboxylate 109 (170 mg, 0.80 mmol) in abs. EtOH (1 
mL), a solution of KOH (45 mg, 0.8 mmol) in abs. EtOH (1.5 mL) was 
added dropwise. The resulting mixture was stirred for 2 h at 0 °C. The 
solvent was removed under reduced pressure and the residue was 
washed with petroleum ether. The product 19 was obtained as a pale 
brown solid (83%): mp > 230 °C; MS (APCI) m/z 184.2; 1H NMR (300 MHz, 
CDCl3) δ 1.49 (m, 2H), 1.63 (m, 4H), 2.32 (dd, J = 13.4, 6.7 Hz, 1H), 2.54 (m, 
4H), 2.74 (dd, J = 13.4, 3.7 Hz, 1H), 3.02 (d, J = 2.16 Hz, 1H), 3.12 (m, 1H). 
2-(3-Oxoisothiazolin-2-yl)acetic acid (100). A suspension of ethyl 2-
(3-oxoisothiazolin-2-yl)acetate 112109 (200 mg, 1.07 mmol) in 1 M 
trifluoroacetic acid (TFA) (25 mL, 25 mmol) was refluxed for 12 h and then 
evaporated. The residue was dried at 50-55 °C in vacuo to yield 100 
(98%) as a white solid: mp 171-172 °C; 1H NMR (300 MHz, DMSO-d6) δ 4.41 
(s, 2H), 6.19 (d, J = 6.2 Hz, 1H), 8.51 (d, J = 6.2 Hz, 1H). 
(2R,3S)-Ethyl 3-(hydroxymethyl)oxirane-2-carboxylate (108).106 To a 
stirred 0°C cooled solution of (2R,3R)-diethyl oxirane-2,3-dicarboxylate 
107104 (1.2 g, 6.377 mmol) in abs. EtOH (10 ml), a solution of NaBH4 (305 
mg, 7.943 mmol) in abs. EtOH (13 ml) was dropwise added over 5 min 
under nitrogen atmosphere. The mixture was stirred for 2 h and then the 
reaction was quenched by addition of a pH=7.0 Phosphate buffer (40 
ml). The crude was extracted with CH2Cl2 (4 X 10ml) and the combined 
organic layers were dried over anhydrous Na2SO4, filtered and 
evaporated under reduced pressure giving 742 mg of yellow oil. It was 
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purified by FC (SiO2, EtOAc/Hexane 50/50) giving 572 mg of desired 
(2R(2R,3S)-ethyl 3-(hydroxymethyl)oxirane-2-carboxylate 108 as white 
crystals (62%). mp = 44-45°C (Lit. 43-44°C)106; H1-NMR (300 MHz, CDCl3): δ 
= 1.30 (t, J= 7.09 Hz, 3H), 3.39 (m, 1H), 3.53 (d, J = 2.00 Hz,1H), 3.76 (dd, J1= 
3.31 Hz, J2= 13.05 Hz, 1H), 4.02 (dd, J1= 2.16 Hz, J2= 13.15 Hz, 1H), 4.24 (m, 
2H) 
(2R,3S)-Ethyl 3-(piperidin-1-ylmethyl)oxirane-2-carboxylate (109). A 
0°C cooled solution of (2R,3S)-ethyl 3-(hydroxymethyl)oxirane-2-
carboxylate 108 (405 mg, 2.77 mmol) and Et3N (582 µL, 4.16 mmol) in 
anhydrous CH2Cl2 (12 mL) was stirred for 30 min before the dropwise 
addition of methanesulfonyl chloride (MsCl) (407 µL, 4.16 mmol). The 
mixture was then stirred for 10 min at 0 °C and for 2 h at RT, then the 
solvent was evaporated. The resulting yellow paste was dissolved in 
anhydrous DMF (12 mL) and KI (23 mg, 0.14 mmol) was added. The 
yellow solution was cooled to 0 °C and stirred for 5 min before the 
dropwise addition of anhydrous piperidine (830 µL, 8.31 mmol). The 
resulting suspension was slowly warmed to RT and stirred for 7 days, 
diluted with saturated aqueous NaHCO3 (85 mL) and extracted with 
Et2O. The combined organic layers were dried and evaporated to give a 
brown oil that was purified by FC (CH2Cl2:MeOH, 100:0 to 96:4) furnishing 
109 as yellow oil (30%); 1H NMR (300 MHz, CDCl3) δ 1.25 (t, J = 7.1 Hz, 3H), 
1.39 (m, 2H), 1.55 (m, 4H), 2.31 (dd, J = 13.6, 6.4 Hz, 1H), 2.36-2.55 (m, 4H), 
2.71 (dd, J = 13.6, 3.4 Hz, 1H), 3.19 (d, J = 2.0 Hz, 1H), 3.29 (m, 1H), 4.18 (m, 
2H). 
N-(4-(3-bromoanilino)quinazolin-6-yl)-3-chloropropanamide (118). 
A stirring suspension of 6-amino-4-(3-bromoanilino)quinazoline (3) (300 
mg, 0.95 mmol) and 3-chloropropionyl chloride (3 mL, 31.28 mmol) was 
refluxed for 16 h, cooled to RT and filtered. The filtered solid was washed 
with Et2O, dried under reduced pressure and purified by FC (SiO2, eluent= 
CH2Cl2/CH3OH from 98:2 to 95:5) furnishing the pure compound (36%) as 
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a pale yellow solid: mp >230; MS (APCI): m/z 407.4; 1H NMR (CDCl3, 300 
MHz): δ 2.96 (t, J = 6.2 Hz, 2H), 3.95 (t, J = 6.2 Hz, 2H), 7.31-7.33 (m, 2H), 
7.78 (m, 3H), 8.14 (s, 1H), 8.55 (s, 1H), 8.72 (s, 1H). 
 
B) Final compounds: 
 
N-(4-(3-Bromophenylamino)quinazolin-6-yl)acrylamide (2). 
Anal.calc. for C17H13BrN4O (MW= 369,22) C, 55.30; H, 3.55; N, 15.17. 
Found: C, 54.96; H, 3.83; N, 14.98. 
6-Amino-4-(3-bromoanilino)quinazoline (3). Anal.calc. for 
C14H11BrN4 1,5H2O (MW= 342,19) C, 49.92; H, 3.65; N, 16.63. Found: C, 
49.73; H, 3.92; N, 16.23. 
 (2R,3R) Ethyl 3-(4-(3-bromoanilino)quinazolin-6-
ylcarbamoyl)oxirane-2-carboxylate (4). Method A. Dichloromethylene 
dimethyliminium chloride (356 mg, 2.19 mmol) was added to a stirred 
solution of (2R,3R)-2,3-epoxysuccinic acid monoethyl ester 92105  (350 mg, 
2.19 mmol) in anhydrous CH2Cl2 (10 mL). After the reactants were stirred 
for 1 h with ice-cooling, 6-amino-4-(3-bromoanilino)quinazoline 3 (458 
mg, 1.46 mmol) and NaHCO3 (613 mg, 7.3 mmol) were added, and the 
suspension was stirred for 1 h at 0 °C. The mixture was washed with water, 
dried, and concentrated to obtain the crude compound. Crystallization 
from MeOH gave the pure product 4 as white crystals (60%): mp (MeOH) 
> 230 °C dec.; MS (APCI) m/z 458.3, 459.2; 1H NMR (300 MHz, DMSO-d6) δ 
1.26 (t, J = 7.1 Hz, 3H), 3.82 (d, J = 1.7 Hz, 1H), 3.93 (d, J = 1.7 Hz, 1H), 4.23 
(q, J = 7.1 Hz, 2H), 7.29 (d, J = 8.1 Hz, 1H), 7.35 (t, J = 7.9 Hz, 1H), 7.82-7.92 
(m, 3H), 8.16 (br s, 1H), 8.60 (s, 1H), 8.72 (d, J = 1.3 Hz, 1H), 9.93 (br s, 1H), 
10.80 (br s, 1H). Anal.calc. for C20H17BrN4O4 (MW=457,28) C, 52,53; H, 3.75; 
N, 12.25. Found: C, 52.19; H, 3.76; N, 11.91. 
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(2S,3S) Ethyl 3-(4-(3-bromoanilino)quinazolin-6-
ylcarbamoyl)oxirane-2-carboxylate (5). 6-Amino-4-(3-
bromoanilino)quinazoline 3 was reacted with (2S,3S)-2,3-epoxysuccinic 
acid monoethyl ester 93107 according to the procedure described in 
method A. The crude product was purified by silica gel chromatography 
(CH2Cl2:MeOH, 99:1 to 97:3) to give 5 (66%) as white solid: mp (MeOH) > 
230 °C; MS (APCI) m/z 457.9, 459.3; 1H NMR (300 MHz, DMSO-d6) δ 1.26 (t, 
J = 7.2 Hz, 3H), 3.81 (d, J = 1.7 Hz, 1H), 3.92 (d, J = 1.7 Hz, 1H), 4.23 (q, J = 
7.1 Hz, 2H), 7.29 (d, J = 8.1 Hz, 1H), 7.35 (t, J = 7.8 Hz, 1H), 7.80-7.87 (m, 2H), 
7.89 (dd, J = 9.0, 2.2 Hz, 1H), 8.16 (s, 1H), 8.60 (s, 1H), 8.72 (s, 1H), 9.94 (br s, 
1H), 10.80 (br s, 1H). Anal.calc. for C20H17BrN4O4 (MW=457,28) C, 52.53; H, 
3.75; N, 12.25. Found: C, 52.62; H, 3.81; N, 11.89. 
 (2R,3S) N-(4-(3-Bromoanilino)quinazolin-6-yl)-3-(piperidin-1-
ylmethyl)oxirane-2-carboxamide (6). Method B. To a suspension of 
potassium (2R,3S)-3-(piperidin-1-ylmethyl)oxirane-2-carboxylate 94 (58 
mg, 0.26 mmol) in anhydrous DMF (2 mL), HBTU  (205 mg, 0.54 mmol) was 
added at RT. The mixture was stirred for 40 min before the dropwise 
addition of 6-amino-4-(3-bromoanilino)quinazoline 3 (80 mg, 0.26 mmol) 
in DMF (2 mL). The reaction mixture was stirred for 16 h, the solvent was 
removed and the residue was dissolved in CH2Cl2 and washed with 
saturated aqueous Na2CO3. The organic phase was evaporated and the 
crude product purified by silica gel chromatography (CH2Cl2:MeOH, 99:1 
to 97:3) to give 6 as a pale yellow solid (30%): mp > 230 °C; MS (APCI) m/z 
482.2, 484.2; 1H NMR (300 MHz, CD3OD): δ 1.41-1.43 (m, 2H), 1.53-1.64 (m, 
4H), 2.36 (dd, J = 13.6, 6.7 Hz, 1H), 2.48-2.56 (m, 4H), 2.80 (dd, J = 13.7, 3.4 
Hz, 1H), 3.30-3.34 (m, 1H), 3.39 (d, J = 1.89 Hz, 1H), 7.21-7.22 (m, 2H), 7.64-
7.69 (m, 2H), 7.77 (dd, J = 9.0, 2.2 Hz, 1H), 8.03 (s, 1H), 8.45 (s, 1H), 8.56 (d, 
J = 2.1 Hz, 1H). Anal.calc. for C23H24BrN5O2 (MW=482,37) C, 57.72; H, 5.01; 
N, 14.52. Found: C, 57.35; H, 5.20; N, 14.22. 
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N-(4-(3-Bromoanilino)quinazolin-6-yl)-2-phenoxyacetamide (7). 
Method C. Phenoxyacetic acid 95 (361 mg, 2.37 mmol) was added to a 
stirred suspension of PCl5 (490 mg, 2.37 mmol) in CH2Cl2 (15 mL) at RT. The 
reactants were refluxed for 30 min, then cooled to RT, and 6-amino-4-(3-
bromoanilino)quinazoline 3 (500 mg, 1.59 mmol) was added in 10 min. 
After refluxing for 2 h, the mixture was cooled in an ice/water bath, 2.5 
mL of water were added, the mixture stirred for 30 min and then Na2CO3 
was added. The solid was filtered and purified by silica gel 
chromatography (CH2Cl2:MeOH, 99:1 to 97:3) to afford 7 as a white solid 
(77%): mp (EtOH/water) 212 °C; MS (APCI) m/z 449.0, 451.0; 1H NMR (300 
MHz, DMSO-d6) δ 4.79 (s, 2H), 6.99 (t, J = 7.4 Hz, 1H), 7.05 (d, J = 7.8 Hz, 
2H), 7.27-7.36 (m, 4H), 7.80 (d, J = 8.9 Hz, 1H), 7.85 (d, J = 7.9 Hz, 1H), 7.95 
(dd, J = 9.0, 2.1 Hz, 1H), 8.16 (s, 1H), 8.58 (s, 1H), 8.74 (d, J = 1.7 Hz, 1H), 
9.93 (s, 1H), 10.44 (s, 1H). Anal.calc. for C22H17BrN4O2 (MW=449,30) C, 
58.81; H, 3.81; N, 12.47. Found: C, 58.89; H, 4.03; N, 12.09. 
N-(4-(3-Bromoanilino)quinazolin-6-yl)-2-(4-
fluorophenoxy)acetamide (8). 6-Amino-4-(3-bromoanilino)quinazoline 3 
was reacted with 2-(4-fluorophenoxy)acetic acid 96 according to the 
procedure described in method C. The crude product was purified by 
silica gel chromatography (CH2Cl2:MeOH, 99:1 to 97:3) to give 8 (67%) as 
white solid: mp (EtOH/water) 224 °C; MS (APCI) m/z 467.3, 469.1; 1H NMR 
(300 MHz, DMSO-d6) δ 4.78 (s, 2H), 7.07 (dd, J = 9.2, 4.3 Hz, 2H), 7.15-7.21 
(m, 2H), 7.27-7.37 (m, 2H), 7.85 (m, 2H), 7.95 (dd, J = 8.2, 1.4 Hz, 1H), 8.16 
(br s, 1H), 8.59 (s, 1H), 8.74 (br s, 1H), 9.93 (br s, 1H), 10.44 (br s, 1H). 
Anal.calc. for C22H16BrN4O2 (MW=448,29) C, 56.55; H, 3.45; N, 11.99. 
Found: C, 56.30; H, 3.51; N, 11.59. 
N-(4-(3-Bromoanilino)quinazolin-6-yl)-2-
(perfluorophenoxy)acetamide (9). 6-Amino-4-(3-
bromoanilino)quinazoline 3 was reacted with 2-
(perfluorophenoxy)acetic acid 97 according to the procedure 
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described in method C. The crude product was purified by silica gel 
chromatography (CH2Cl2:MeOH, 99:1 to 97:3) to give 9 (50%) as white 
solid: mp 220-221 °C; MS (APCI): m/z 539.1, 541.1. 1H NMR (300 MHz, 
DMSO-d6) δ 4.99 (s, 2H), 7.24-7.34 (m, 2H), 7.75-7.87 (m, 3H), 8.11 (s, 1H), 
8.55 (s, 1H), 8.66 (s, 1H), 9.91 (br s, 1H), 10.50 (br s, 1H). Anal.calc. for 
C22H12BrF5N4O2 (MW=539,25) C, 49.00; H, 2.24; N, 10.39. Found: C, 49.29; H, 
2.76; N, 9.92. 
N-[2-[(4-(3-Bromoanilino)quinazolin-6-yl)amino]-2-oxoethyl] 
phenylcarbamate (10). Method D. 2-(Phenoxycarbonylamino)acetic 
acid 98 (375 mg, 1.92 mmol) and N,N’-dicyclohexylcarbodiimide (DCC) 
(416 mg, 1.04 mmol) were added to a solution of 3 (400 mg, 1.28 mmol) 
in anhydrous DMF (6 mL) at 0 °C. The mixture was stirred 16 h at RT, the 
solid was removed by filtration and the filtrate evaporated in vacuo to 
obtain the crude product, which was purified by silica gel 
chromatography (EtOAc). The pure product 10 (55%) appeared as a 
white solid: mp (EtOH/water) >250 °C dec.; MS (APCI) m/z 492.1; 1H NMR 
(300 MHz, DMSO-d6) δ 4.20 (s, 2H), 6.73-6.78 (m, 3H), 7.15 (t, J = 8.6 Hz, 
2H), 7.32 (dt, J = 8.1, 1.6 Hz, 1H), 7.37 (t, J = 7.9 Hz, 1H), 7.82-7.93 (m, 3H), 
8.21 (s, 1H), 8.50 (s, 1H), 8.57 (d, J = 1.7 Hz, 1H), 8.70 (s, 1H), 9.32 (s, 1H), 
9.98 (br s, 1H). Anal.calc. for C25H20BrN3O30.5H20 (MW=499,36) C, 53.75; 
H, 3.56; N, 13.63. Found: C, 53.65; H, 3.95; N, 13.29. 
N-(4-(3-Bromoanilino)quinazolin-6-yl)-2-cyanoacetamide (11). 6-
Amino-4-(3-bromoanilino)quinazoline 3 was reacted with 2-cyanoacetic 
acid 99 according to the procedure described in method C. The crude 
product was purified by silica gel chromatography (EtOAc) to give 11 
(55%) as white solid: mp (EtOH/water) 263 °C; MS (APCI) m/z 382.0, 384.1; 
1H NMR (300 MHz, DMSO-d6) δ 4.00 (s, 2H), 7.30-7.35 (m, 2H), 7.81-7.86 (m, 
3H), 8.15 (t, J = 1.7 Hz, 1H), 8.59 (s, 1H), 8.70 (s, 1H), 9.95 (s, 1H), 10.64 (s, 
1H). Anal.calc. for C17H12BrN5O1.5H2O (MW=409,24) C, 49.90; H, 2.96; N, 
17.11. Found: C, 50.28; H, 2.99; N, 16.71. 
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N-(4-(3-Bromoanilino)quinazolin-6-yl)-2-(3-oxoisothiazolin-2-
yl)acetamide (12). 6-Amino-4-(3-bromoanilino)quinazoline 3 was reacted 
with 2-(3-oxoisothiazolin-2-yl)acetic acid 100 according to the procedure 
described in method D. The crude product was purified by silica gel 
chromatography (EtOAc:MeOH, 99:1 to 90:10) to give 12 (40%) as a 
white solid: mp (EtOH/water) > 230 °C; MS (APCI) m/z 456.1, 458.3; 1H 
NMR (300 MHz, DMSO-d6) δ 4.65 (s, 2H), 6.24 (d, J = 6.2 Hz, 1H), 7.28 (d, J = 
8.0 Hz, 1H), 7.33 (t, J = 7.9 Hz, 1H), 7.79-7.85 (m, 3H), 8.10 (s, 1H), 8.55 (d, J 
= 6.2 Hz, 1H), 8.55 (s, 1H), 8.71 (s, 1H), 9.94 (br s, 1H), 10.69 (br s, 1H). 
Anal.calc. for C19H14BrN5O2S1.5H2O (MW=483,34) C, 47.21; H, 3.52; N, 
14.48. Found: C, 47.70; H, 3.39; N, 13.98. 
N-(4-(3-Bromoanilino)quinazolin-6-yl)-2-(3-oxobenzo[d]isothiazolin-
2-yl)acetamide (13). 6-Amino-4-(3-bromoanilino)quinazoline 3 was 
reacted with 2-(3-oxobenzo[d]isothiazolin-2-yl)acetic acid 101 according 
to the procedure described in method D. The crude product was 
purified by silica gel chromatography (EtOAc:n-hexane, 99:1) to afford 
13 (50%) as a white solid; mp (MeOH) 238 °C; MS (APCI) m/z 506.1, 508.1; 
1H NMR (300 MHz, DMSO-d6) δ 4.75 (s, 2H), 7.25-7.31 (m, 2H), 7.43 (t, J = 
7.5 Hz, 1H), 7.69 (t, J = 7.8 Hz, 1H), 7.76-7.83 (m, 3H), 7.88 (d, J = 7.9 Hz, 1H), 
7.98 (d, J = 8.5 Hz, 1H), 8.09 (s, 1H), 8.54 (s, 1H), 8.72 (s, 1H), 9.89 (br s, 1H), 
10.66 (br s, 1H). Anal.calc. for C23H16BrN5O2S0.5H2O (MW=515,38) C, 
52.32; H, 3.42; N, 13.25. Found: C, 52.30; H, 3.28; N, 12.91. 
N-(4-(3-Bromoanilino)quinazolin-6-yl)-3-isopropyl-1,2,4-thiadiazole-
5-carboxamide (14). Method E. Potassium tert-butoxide (84 mg, 0.75 
mmol) was added to a premixed mixture of ethyl 3-isopropyl-1,2,4-
thiadiazole-5-carboxylate 102111 (150 mg, 0.75 mmol) and 6-amino-4-(3-
bromoanilino)quinazoline 3 (235 mg, 0.75 mmol) in anhydrous DMF (1 
mL). The reaction mixture was microwaved (150 W) to 100 °C for 8 min. 
The solution was diluted with water and extracted with EtOAc. The 
organic phase was evaporated to obtain the crude compound, that 
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was purified by silica gel chromatography (CH2Cl2:MeOH, 99:1 to 97:3) to 
give 14 (50%) as a pale yellow crystals: mp (CH2Cl2) 224 °C; MS (APCI) 
m/z 469.0, 471.0; 1H NMR (300 MHz, DMSO-d6) δ 1.47 (d, J = 6.9 Hz, 6H), 
3.43 (m, 1H), 7.34 (dt, J = 8.2, 1.5 Hz, 1H), 7.40 (t, J = 8.0 Hz, 1H), 7.90 (d, J = 
8.9 Hz, 1H), 7.93 (d, J = 7.9 Hz, 1H), 8.20-8.23 (m, 2H), 8.68 (s, 1H), 8.93 (d, J 
= 1.8 Hz, 1H), 10.01 (s, 1H), 11.33 (br s, 1H). Anal.calc. for 
C20H17BrN6OS0.5H2O (MW=478,37) C, 50.22; H, 3.79; N, 17.57. Found: C, 
50.17; H, 3.72; N, 17.29. 
N-(4-(3-Bromoanilino)quinazolin-6-yl)-3-
(dimethylamino)propanamide (15). A 33% v/v solution of dimethylamine 
in abs EtOH (0.8 mL, 4.46 mmol) was added over 15 min to a stirring 
suspension of 3-chloropropionamide 118 (145 mg, 0.357 mmol) and NaI 
(37.50 mg, 0.25 mmol) in EtOH abs (10 ml). The resulting mixture was 
refluxed for 8h. After cooling to 0 °C, the mixture was basified with KOH 
(741 mg, 13.21 mmol) and stirred for 1 h at 0 °C. The solvent was 
evaporated under reduced pressure and the obtained solid residue was 
dissolved with EtOAc and diluted with brine. The organic layer was 
separated, dried over anhydrous Na2SO4, filtered, concentrated under 
reduced pressure, purified by FC (SiO2, eluent CH2Cl2/CH3OH from 100:0 
to 70:30), and crystallized from EtOAc/Hexane. The pure product was 
isolated as a yellow solid (86%): mp 170-172°C; MS (APCI): m/z 414.4; 1H 
NMR (DMSO-d6, 300 MHz) δ 2.35, (s, 6H), 2.65 (t, J = 6.5 Hz, 2H), 2.78 (t, J = 
6.5 Hz, 2H), 7.29-7.31 (m, 2H), 7.74 (m, 3 H), 8.12 (b s, 1H), 8.53 (s, 1H), 8.66 
(b s, 1H). Anal.calc. for C19H20BrN5O (MW=414.30) C, 55.08; H, 4.87; N, 
16.90. Found: C, 54.64; H, 4.89; N, 16.63. 
 (2R,3R) Ethyl 3-(naphthalen-2-ylcarbamoyl)oxirane-2-carboxylate 
(16). Compound 16 was synthesized by coupling the carboxylic acid 92 
and 2-naphthylamine 106 following the procedure described in method 
A. Purification by silica gel chromatography (n-hexane:EtOAc, 90:10 to 
70:30) gave the pure compound (70%) as a white solid: mp (EtOH/water) 
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118-119 °C; MS (APCI) m/z 283.3; 1H NMR (300 MHz, CDCl3) δ 1.32 (t, J = 
7.1 Hz, 3H), 3.66 (d, J = 1.9 Hz, 1H), 3.85 (d, J = 2.0 Hz, 1H), 4.29 (m, 2H), 
7.39-7.49 (m, 3H), 7.77-7.83 (m, 4H), 8.18 (d, J = 2.0 Hz, 1H). Anal.calc. for 
C16H15NO4 (MW=285,29) C, 67.36; H, 5.30; N, 4.91. Found: C, 67.25; H, 5.41; 
N, 4.75. 
N-(Naphthalen-2-yl)-2-phenoxyacetamide (17). Compound 17 was 
synthesized by coupling the carboxylic acid 95 and 2-naphtylamine 106 
using the procedure described in method C. Purification by silica gel 
chromatography (n-hexane:EtOAc, 70:30) gave the pure compound 
(80%) as a pale yellow solid: mp (EtOH/water) 142-144 °C; MS (APCI) m/z 
184.3; 1H NMR (300 MHz, CDCl3) δ 4.65 (s, 2H), 7.00-7.09 (m, 3H), 7.33-7.55 
(m, 5H), 7.77-7.82 (m, 3H), 8,25 (d, J = 1.7 Hz, 1H), 8.43 (br s, 1H). Anal.calc. 
for C16H15NO4 (MW=277,32) C, 77.96; H, 5.45; N, 5.05. Found: C, 77.56; H, 
5.49; N, 4.92. 
4.1.3 Biology  
Collected biological data were from experimentations carried out 
by Prof. P.G. Petronini’s research group of (Dipartimento di Medicina 
Sperimentale – Università degli studi di Parma, Parma, Italy). 
 
Kinase assay. Evaluation of the effects of compounds on the kinase 
activity of human EGFR was performed by measuring the 
phosphorylation of the substrate Ulight-CAGAGAIETDKEYYTVKD (JAK1) 
using a human recombinant enzyme expressed in insect cells194 and the 
LANCE detection method,195 employing the Cerep EGFR kinase assay.196 
Briefly, the test compound, reference compound or water (control), was 
mixed with the enzyme (0.0452 ng) in a buffer containing 40 mM 
Hepes/Tris (pH 7.4), 0.8 mM EGTA/Tris, 8 mM MgCl2, 1.6 mM DTT, 0.008% 
Tween 20 and 100 nM poly-D-lysine. Thereafter, the reaction was initiated 
by the addition of 100 nM of the substrate and 10 µM ATP, and the 
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mixture was incubated for 15 min at room temperature. For control basal 
measurements, the enzyme was omitted from the reaction medium. 
Following incubation, the reaction was stopped by the addition of 13 
mM EDTA. After 5 min, the anti-phopho-PT66 antibody labeled with 
europium chelate was added. After 60 min, the fluorescence transfer 
was measured at excitation wavelength 337 nm and emission 
wavelength 620 nm using a microplate reader (Envision, Perkin Elmer). 
The concentration of compound that inhibited receptor phosphorylation 
by 50% (IC50) was calculated from inhibition curves. 
Cell culture. The human A431 epidermoid cancer cell line was 
cultured in D-MEM 4.5 g/L glucose. NSCLC cell line H1975 and SW620 cell 
line were cultured in RPMI. All media were supplemented with 2 mmol/L 
glutamine, 10% FCS. A431 was from ATCC, H1975 was kindly provided by 
Dr E. Giovannetti (Department of Medical Oncology, VU University 
Medical Center, Amsterdam, The Netherlands) and were maintained 
under standard cell culture conditions at 37 °C in a water-saturated 
atmosphere of 5% CO2 in air. 
Antibodies and reagents. Media were from Euroclone, FBS was 
purchased from Gibco-BRL (Grand Island, NY, USA). Monoclonal anti-
EGFR, polyclonal anti-phospho-EGFR (Tyr1068), monoclonal anti erbB2, 
monoclonal anti-phospho-erbB2 (Tyr 1221/1222), polyclonal Akt, 
polyclonal anti-phospho-Akt (Ser473), monoclonal anti-p44/42 MAPK, 
monoclonal anti-phospho-p44/42 MAPK (Thr202/Tyr204), polyclonal anti-
caspase-3 antibodies were from Cell Signaling Technology (Beverly, MA, 
USA). Horseradish peroxidase-conjugated (HRP) secondary antibodies 
were from Pierce. The enhanced chemiluminescence system (ECL) was 
from Millipore (Millipore, MA, USA). Reagents for electrophoresis and 
blotting analysis were obtained from, respectively, BIO-RAD Laboratories 
and Millipore. 
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Western blot analysis. Procedures for protein extraction, 
solubilization, and protein analysis by 1-D PAGE are described 
elsewhere.197 50-100 µg proteins from lysates were resolved by 5-15% SDS-
PAGE and transferred to PVDF membranes (Millipore). The membranes 
were then incubated with primary antibody, washed and then 
incubated with HRP-anti-mouse or HRP-anti-rabbit antibodies. 
Immunoreactive bands were visualized using an enhanced 
chemiluminescence system. 
Autophosphorylation assay. Inhibition of EGFR autophosphorylation 
was determined as previously described using specific anti-
phosphotyrosine and anti-total EGFR antibodies by Western blot 
analysis.88  
Cell growth inhibition. Cell viability was assessed after 3 days of 
treatment by tetrazolium dye [3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT), Sigma, Dorset, UK] assay as previously 
described.197 Representative results of at least three independent 
experiments were used for evaluation of dose-response curves, 
calculated from experimental points using Graph Pad Prism5 software. 
The concentration that inhibits 50% (IC50) (e.g., the point at which viability 
is 50%) was extrapolated from the dose-response curves. The compounds 
were renewed every 24 h. 
Cell death. Cell death was assessed by morphology on stained 
(Hoechst 33342, propidium iodide) or unstained cells using light, phase 
contrast, and fluorescence microscopy.121 Activation of caspase-3 was 
evaluated by Western blotting procedure as previously described.121  
 
4.1.4 Stability  
Reactivity with reduced glutathione. The reactivity of compounds 4, 
16 and 7, 17 with reduced glutathione (GSH) was evaluated in an 
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aqueous buffered solution (Phosphate Buffered Saline, PBS, pH 7.4), at 37 
°C and compared to that of the acrylamide 2. Briefly, 10 µL of the 
compound standard solution in DMSO (1 mM) was diluted with 890 µL of 
PBS pH 7.4. Then 100 µL of a freshly prepared GSH solution in PBS (20 mM) 
were added. Conversion of the compounds and formation of 
conjugates at 37 °C and at different time points were measured by LC-
UV and LC-ESI-MS. The LC column used was a Phenomenex Synergi 
Fusion (2.0 × 100 mm, 4 µm) and the mobile phase was a gradient of 50-
10% aqueous trifluoroacetic acid (0.05%) in methanol in 10 min at the 
flow rate of 250 µL/min.  
 
Experimental section.                                                                         Chapter 4 
 161 
4.2 MAGL inhibitors 
4.2.1 Chemistry  
Reagents were obtained from commercial suppliers and used 
without further purification. Solvents were purified and stored according 
to standard procedures. Anhydrous reactions were conducted under a 
positive pressure of dry N2. Reactions were monitored by TLC, on 
Kieselgel 60 F 254 (DC-Alufolien, Merck). Final compounds and 
intermediates were purified by flash chromatography (SiO2 60, 40-63 µm). 
Microwave reactions were conducted using a CEM Discover synthesis 
unit (CEM Corp., Matthews, NC). Melting points were not corrected and 
were determined with a Büchi instrument (Tottoli) and with a Gallenkamp 
melting point apparatus. The 1H NMR spectra were recorded on a Bruker 
300 MHz spectrometer and on a Bruker 300 MHz Avance spectrometer. 
Chemical shifts (δ scale) are reported in parts per million (ppm) relative 
to the central peak of the solvent. 1HNMR spectra are reported in the 
following order: multiplicity, approximate coupling constant (J value) in 
hertz (Hz), and number of protons; signals were characterized as s 
(singlet), d (doublet), dd (doublet of doublets), t (triplet), dt (doublet of 
triplets), q (quartet), m (multiplet), br s (broad signal). Mass spectra were 
recorded using an API 150 EX instrument (Applied Biosystems/MDS SCIEX, 
Foster City, CA). Liquid chromatography/mass spectrometry analysis was 
performed on an Agilent 1100 LC gradient system coupled with an 
Applied Biosystem 150-EX single quadrupole mass spectrometer 
equipped with a TurboIon-Spray ion source working in positive ion mode. 
Final compound 18 was purchased from Sigma-Aldrich whereas 
compound 28 was synthesized according to literature methods.190 Final 
compounds were analysed on ThermoQuest (Italia) FlashEA1112 
Elemental Analyzer for C, H, and N (analyses were within 0.4% of 
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theoretical values). All tested compounds were >95% pure by elemental 
analysis. 
4.2.2 Synthesis 
A) Intermediate compounds: 
2-(6-Chlorohexyl)benzo[d]isothiazol-3(2H)-one (153). To a RT stirring 
solution of benzo[d]isothiazol-3(2H)-one 18 (100 mg 0.66 mmol) in CH3CN 
(2 ml) K2CO3 (91.41 mg, 0.66 mmol) was added and the resulting 
suspension was stirred for 10 min under nitrogen atmosphere. 1-chloro-6-
iodohexane (1,0 ml, 6.6 mmol) was dropwise added over 5 min and the 
resulting mixture was stirred for 18 h and then refluxed for 1h. The solvent 
was removed by distillation under reduced pressure and the crude was 
purified by FC (SiO2, EtOAc/Hx 50/50) to give 66 mg of the expected 
product 153 as colorless oil (37%). 1H NMR (300 Mz, CDCl3): δ 1.51 (m, 4H), 
1.78 (m, 4H), 3.52 (t, J=6.63 Hz, 2H), 3.90 (t, J=7.1 Hz, 2H), 7.40 (td,J1=7.95 
Hz, J2=1.32 Hz, 1H), 7.55 (d, J = 6.9 Hz, 1H), 7.60 (td, J1=8.04 Hz, J2=1.17 Hz, 
1H), 8.03 (d, J= 7.86 Hz, 1H). 
7-Octyn-ole (156).198 To a stirring 0°C cooled 1,2-ethylendiamine (90 
ml, 1346 mmol) under nitrogen atmosphere, NaH (4,8 g, 200,19 mmol) 
was added in one portion. The cooling bath was removed and the 
resulting yellow suspension was allowed to slowly warm up to R:T. During 
the worm up, the color of the suspension turn to a deep blue-violet and 
bubbling was observed. The reaction mixture was stirred for 1h at RT, 1h 
at 60°C and then was cooled to 45°C. 3-Octyn-1-ole 155 (7,4 ml, 50,047 
mmol) was dropwise added and the resulting mixture was stirred at 60-
65°C for 1h. The resulting blue-black solution was cooled to 0°C and H2O 
(90 ml) and HCl 1.0M (90 ml) were slowly added. The solution was diluted 
with further HCl 1.0M (180 ml) and extracted with Et2O (2 times). The 
combined organic layers were dried over anhydrous Na2SO4, filtered and 
evaporated under reduced pressure to give 4,7 g of yellow oil that was 
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purified by FC (SiO2, EtOAc/Hexane 30/70) furnishing 3.350 g of pure 
product 156 as pale yellow oil (53%); H1-NMR (300 MHz, CDCl3): δ = 1.17-
1.45 (m, 8H), 1.79 (t, J=2.64 Hz, 1H), 2.03 (td, J1=6.51 Hz, J2=2.61 Hz, 2H), 
2.18 (s, 1H), 3,46 (t, J=6.6 Hz, 2H). 
Oct-7-ynyl methanesulfonate (157). 199  Methanesulfonyl chloride 
MsCl (795,59 µl, 8,146 mmol) was dropwise added over 5 min to a 0°C 
cooled stirring solution of 7-Octyn-ole 156 (514 mg, 4,073 mmol) and Et3N 
(1,142 ml, 8,146 mmol) in dry CH2Cl2 (5ml) under nitrogen atmosphere. 
The resulting mixture was slowly warmed up to R.T, stirred for 16h and 
then washed with H2O. The organic phase was dried over anhydrous 
Na2SO4, filtered and evaporated under reduced pressure to give 1.106 g 
of red oil that was purified by FC (SiO2, CH2Cl2 100%) furnishing 703 mg of 
pure product 157 as pale yellow oil (quantitative); H1-NMR (300 MHz, 
CDCl3): δ = 1.46-1.55 (m, 8H), 1.92 (t, J=2.91 Hz, 1H), 2.16 (td, J1=6.85 Hz, 
J2=2.60 Hz, 2H), 2.97 (s, 3H), 4,19 (t, J=6.53 Hz, 2H). 
4-Ethylbenzyl methanesulfonate (159). Methansulfonyl chloride MsCl 
(732 µl, 7.473 mmol) was dropwise added over 5 min to a 0°C cooled 
stirring solution of 4-Ethylbenzylalcool 158 (500 µl, 3.736 mmol) and Et3N 
(1,053 ml, 7.473 mmol) in dry CH2Cl2 (5ml) under nitrogen atmosphere. 
The resulting mixture was slowly warmed up to R.T, stirred for 16h and 
then washed with H2O. The organic phase was dried over anhydrous 
Na2SO4, filtered and evaporated under reduced pressure furnishing 864 
mg of dark-red oil that was purified by FC (SiO2, petroleum ether 100%) 
furnishing 325 mg of pure product 159 as pale yellow oil (40%). 
2,2'-Disulfanediyldibenzoyl chloride (161).,200 A RT stirring suspension 
of 2,2’-Dithiosalicylic acid 160 (600 mg 1.959 mmol) in SOCl2 (19.6 ml, 
268.4 mmol) was refluxed until it became a solution and then for further 
3h. The solution was cooled to RT and exceeding SOCl2 was distilled 
away under reduced pressure. The obtained dark-red residue was 
stripped with anhydrous toluol (twice) and used, without any further 
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purification, to synthesize compound 22, 23, 35 and 162. 1H NMR (300 
MHz, CDCl3): δ 7.40 (bt, J=8.13 Hz, 2H), 7.57 (td, J1=7.35 Hz, J2=1.41 Hz, 2H), 
7.78 (dd, J1=8.16 Hz, J2=0.84 Hz, 2H), 8.40 (dd, J1=7.95 Hz, J2=1.29 Hz, 2H) 
2-(Chlorocarbonyl)phenyl hypochlorothioite (162). The crude 2,2'-
disulfanediyldibenzoyl chloride was suspended in dry CCl4 at RT and an 
anhydrous3  flux of Cl2 was bubbled through the suspension until the 
suspended solid residue was completely dissolved. The reaction vessel 
was tightly closed and the bubbling was stopped so to leave the 
reaction mixture under a Cl2 saturated atmosphere for an additional 1 h. 
The reaction mixture was rapidly filtered and the solvent was distilled 
away under reduced pressure giving a yellow oil which was used, 
without any further purification, to synthesize compounds 25-27 and 30.  
2-Mercapto-N-phenylbenzamide (164). 190 To a 0°C stirring solution 
of aniline (232µl, 2.377mmol) in dry CH2Cl2 (3 ml), a 2.0 solution of Al(Me)3 
in dry toluol (1.19 ml, 2.377mmol) was dropwise added under nitrogen 
atmosphere. When the addition was complete, the reaction mixture was 
allowed to warm to RT and the stirring was continued until the gas 
evolution ceased (30 min). Then, a 1.44M solution of methyl thiosalycilate 
163 in dry CH2Cl2 (1.651 ml, 2.377 mmol) was dropwise added and the 
resulting mixture was refluxed overnight. The mixture was cooled to RT 
and carefully added of 5 % aq HCl (5 mL) HCl 5% v/v aqueous solution 
(tree times) and the solvent was distilled away under reduced pressure. 
The resulting crude residue (874 mg) was purified by FC (SiO2, EtOAc/Hx 
20/80 to 40/60) giving 315 mg of desired product 164 (23%). mp = 116-
118°C [Lit. 117-118°C (Et2O)];190 H1-NMR (300 MHz, CDCl3): δ = 4.55 (s, 1H), 
7.14-7.22 (m, 2H), 7.27-7.39 (m, 4H), 7.56-7.62 (m, 3H), 7.82 (br s, 1H). 
                                            
 
3 Dried by bubbling in concentrated H2SO4  
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2-Mercapto-N-(naphtalen-2-yl)benzamide (165). 190 To a 0°C stirring 
solution of β-naphtylamine (286 mg, 2.0 mmol) in dry CH2Cl2 (5 ml), a 
2.0M solution of Al(Me)3 in dry toluol (1.00 ml, 2.0 mmol) was dropwise 
added under argon atmosphere. The resulting reaction mixture was 
allowed to warm up to RT and the stirring was continued until the gas 
evolution ceased (30 min). A 1.44M solution of methyl thiosalycilate 163 in 
dry CH2Cl2 (1.39 ml, 2.0 mmol) was dropwise added and the resulting 
mixture was refluxed overnight. The mixture was cooled to RT and 
carefully added of 5 % aq HCl (5 mL)with HCl 5% v/v aqueous solution 
(tree times) and the solvent was distilled away under reduced pressure. 
The resulting crude residue was purified by FC (SiO2, EtOAc/Hx 50/50) 
giving 520 mg of desired product 165 as white solid (yield = 93%). mp 
(Et2O)= 168-169°C [Lit. 167-168°C (Nitrobenzene)]; MS (APCI): m/z 278.2; 
H1-NMR (300 MHz, CDCl3): δ = 4.57 (s, 1H), 7.23 (m, 1H), 7.33 (td, J1=5.92 
Hz, J2=1.26 Hz,1H), 7.38-756 (m, 4H), 7.64 (dd, J1=7.60 Hz, J2=1.29 Hz, 1H), 
7.77-7.85 (m, 3H), 7.94 (br s, 1H), 8.33 (d, J=0.96 Hz, 1H). 
N-(Biphenyl-3-yl)-2-mercaptobenzamide (166). A solution of AlMe3 
(1.43 mL of 2.0 M sol. in toluene, 2.86 mmol) was added dropwise to a 
cooled (O °C) suspension of 3-biphenylamine (487 mg, 2.86 mmol) in 
anhydrous CH2Cl2. When the addition was complete, the reaction 
mixture was allowed to warm to RT and stirring was continued until the 
gas evolution ceased (30 min). Then, a solution of methyl thiosalicylate 
163 (241 mg, 1.43 mmol) was added and the mixture was refluxed 
overnight. The mixture was cooled to RT and carefully added of 5 % aq 
HCl (5 mL). The organic layer was separated and the aqueous layer was 
extracted with CH2Cl2 (3x). The combined organic extracts were further 
washed with 1N HCl (2x), saturated NaHCO3 and brine. Then, the organic 
layer was dried over anhydrous Na2SO4, filtered and the solvent was 
evaporated under reduced pressure. The residue was crystallized from 
CH2Cl2/petroleum ether furnishing 309 mg of desired product 166 as pale 
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yellow solid (71 %). mp (CH2Cl2/petroleum ether) 131-132 °C. MS (APCI): 
m/z 304.2. 1H NMR (CDCl3, 300 MHz): δ 4.60 (s, 1H), 7.26 (t, J = 7.4 Hz, 1H), 
7.33-7.49 (m, 7H), 7.63-7.65 (m, 4H), 7.82 (bs, 1H), 7.89 (br s, 1H). 
tert-Butyl benzyl(3-oxobenzo[d]isothiazol-2(3H)-yl)carbamate (167). 
Lithium hexamethyldisilazide (LiHMDS) 1.06M in dry THF (3.542 ml, 
3.755 mmol) was dropwise added to a 0°C stirring solution of 2-
(butoxycarbonylamino)-benzo[d]isothiazol-3(2H)-one 35 (1,0 g 3.755 
mmol) in dry THF (5 ml). After 30 min, benzylbromide (547 µl, 4.506 mmol) 
was dropwise added and the resulting solution was stirred at RT for 20h. 
The reaction mixture was cooled back to 0°C and further LiHMDS 1.06M 
in dry THF (708 µl, 0.751 mmol) and benzylbromide (92 µl, 0.751 mmol) 
wad dropwise added. The resulting solution was allowed to reach RT. 
After 2h, the solvent was removed under reduced pressure and the 
obtained orange residue was taken up with Et2O. The organic phase was 
washed with pH=7.0 phosphate buffer (2 times) and brine giving 2.3 g of 
pale yellow oil. The crude was purified by FC (SiO2, EtOAc/Hx, 10/90 then 
20/80) furnishing 467 mg of the desired compound as white solid (59%). 
mp 110-111°C; MS (ACPI): m/z 357.2; 1H NMR (300 MHz, CDCl3): δ 1.43 (br 
s, 9H), 1.63 (d, J=3.99 Hz, 2H), 4.47 (d, J=14.8 Hz, 1H), 5.28 (d, J=14.5 Hz, 
1H), 7.32-7.37 (m, 7H), 7.58 (t, J=7.26 Hz,1H), 8.03 (s, J=8.11 Hz,1H). 
3,3'-Dithiopropionyl chloride (169). A stirring suspension of 3,3’-
Dithiopropionic acid 168 (1200 mg 5.7 mmol) in SOCl2 (6 ml) was refluxed 
until complete dissolution of the solid starting material (30 min). The 
solvent was evaporated under reduced pressure giving a brown oil that 
was used for the synthesis of compound 170 without any further 
purifications (Quantitative) 1H NMR (300 MHz, CDCl3): δ 3.33 (t, J=6.9 Hz 
4H), 2.96 (t, J=6.9 , 4H). 
3,3'-Disulfanediylbis(N-phenethylpropanamide) (170).109 To a 0°C 
stirring solution of 2-phenylethanamine (1370 µl, 10.88 mmol) and Et3N 
(987 µl, 7.04 mmol) in dry 1,2-dichloroethane (17 ml) a 1.18 M solution (2.7 
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ml, 3.2 mmol) of 2,2'-dithiopropionyl chloride 169 in dry CH2Cl2 was 
dropwise added over 2 min maintaining the temperature of reaction 
mixture below 15°C. The resulting suspension was allowed to reach RT 
and was stirred for 2 h. The crude was diluted with CH2Cl2 (30 ml), 
washed with pH=4.75 acetate buffer (10 ml, 2 times) and water (10 ml, 1 
time). The organic layer was dried over anhydrous Na2SO4, filtered and 
the solvent was evaporated under reduced pressure giving 2.020 g of 
pale yellow solid. The obtained solid was washed with Et2O giving 1.389 g 
of desired product 170 as a white solid (85%). mp 134-135°C [Lit. 131-
134];109 MS (APCI): 417.4; 1H NMR (300 MHz, CDCl3): δ 2.53 (t, J=6.99 Hz, 
4H), 2.84 (t, J=7.02 Hz, 4H), 3,55 (q, J=6.87 Hz, 4H), 5.93 (br s, 2H), 7.20-7.35 
(m, 10H) 
3,3'-Disulfanediylbis(N-(biphenyl-4-yl)propanamide) (172). To a 0°C 
cooled stirring solution of 3,3’-dithiopropionic acid 168 (200 mg, 0.95 
mmol) in dry DMF (6.8 ml), Et3N (202 µl, 2.079 mmol) and HBTU (765 mg, 
1.98 mmol) were added. The resulting solution was allowed to reach RT 
and it was stirred under N2 for 45 min. 4-phenylaniline (321 mg, 1.9 mmol) 
was added in one portion and suddenly the crude solution became a 
white suspension. After DMF removal by vacuum distillation, the crude 
was diluted with CH2Cl2 and filtered giving 392 mg of desired product 
172 as white solid. mp >230°C; MS(APCI): 256.3; 1H NMR (300 MHz, CDCl3): 
δ 2.77 (t, J=6.84 Hz, 4H), 3.04 (t, J=7.05 Hz, 4H), 7.31 (t, J=6.72 Hz, 2H), 7.42 
(t, J=7.77 Hz, 4H), 7.58-7.68 (m, 12H), 10.15 (br s, 2H). 
 
B) Final compounds: 
2-Methylbenzo[d]isothiazol-3(2H)-one (19).190, 201  To a RT stirring 
solution of benzo[d]isothiazol-3(2H)-one 18 (61 mg, 0.393 mmol) in CH3CN 
(2 ml) anhydrous K2CO3 (54 mg, 0.393 mmol) and KI (88 mg, 166.00) was 
added. The resulting white suspension was refluxed for 30 min and then 
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cooled back to RT. Iodomethane (25 µl, 0.393 mmol) was added and the 
reaction mixture was stirred at RT for 20h under nitrogen atmosphere. The 
solvent was evaporated under reduced pressure and the crude was 
purified by FC(SiO2, CH2Cl2 100% then CH2Cl2/Et2O 95/5) furnishing 287 
mg of pure 2-methylbenzo[d]isothiazol-3(2H)-one 19 as white waxy solid 
(65%); mp = 54°C (Lit. 54°C);201 MS (APCI): m/z 165.8; 1H NMR (300 MHz, 
CDCl3): δ 3.46 (s, 3H) , 7.41 (td, J1= 7.98 Hz, J2= 1.23 Hz, 1H), 7,55 (d, J=7.86 
Hz, 1H), 7.62 (d, J1= 8.1 Hz, J2= 7.05 Hz, 1H), 8.05 (d, J= 7.98 Hz, 1H). 
Anal.calc. for C8H7NOS (MW=165.21) C, 58.15; H, 4.27; N, 8.48. Found: C, 
58.43; H, 4.35; N, 8.19. 
2-(Oct-7-ynyl)benzo[d]isothiazol-3(2H)-one (20).,A stirring suspension 
of benzo[d]isothiazol-3(2H)-one 18 (486 mg, 3.213 mmol), K2CO3 (555 mg, 
4,06 mmol) and KI (89 mg, 0,536 mmol) CH3CN (24 ml) was refluxed for 30 
min under nitrogen atmosphere and cooled back to RT. Then, a solution 
13.38M of oct-7-ynyl methanesulfonate 157 (200 µl, 2,68 mmol) in dry 
CH2Cl2 was dropwise added and the resulting mixture was refluxed for 
1h. The solvent was evaporated under reduced pressure, EtOAc was 
added and the obtained suspension was washed (twice) with H2O. The 
organic phase was dried over anhydrous Na2SO4, filtered and 
evaporated under reduced pressure furnishing 536 mg of yellow oil that 
was purified by FC (SiO2, CH2Cl2/Et2O 95/5) furnishing 156 mg of pure 
product 20 as pale yellow powder (23%); mp = 46-48°C; MS (APCI) m/z 
259.8; H1-NMR (300 MHz, CDCl3): δ = 1.32-1.50 (m, 6H), 1.73 (quint, J=7.38 
Hz, 2H), 1.89 (t, J=2.61 Hz, 1H), 2.13 (td, J1=6.75 Hz, J2=2.55 Hz, 2H), 3.85 (t, 
J=7.08 Hz, 2H), 7.34 (t, J=6.76 Hz, 1H), 7.57-7.4881 (m, 2H), 7.97 (br d, 
J=7.92 Hz, 1H) Anal.calc. for C15H17NOS (MW=259,37) C, 69.46; H, 6.61; N, 
5.40. Found: C, 69.55; H, 6.65; N, 5.31. 
2-(6-(Piperidin-1-yl)hexyl)benzo[d]isothiazol-3(2H)-one (21). 
Piperidine (29 µl, 0.29 mmol) was dropwise added to a RT stirring solution 
of K2CO3 (169.03 mg, 1.223 mmol), KI (8.13 mg, 0.049 mmol) and 2-(6-
Experimental section.                                                                         Chapter 4 
 169 
chlorohexyl)benzo[d]isothiazol-3(2H)-one 153 (66 mg, 0.245 mmol) in dry 
DMF (1 ml). The resulting suspension was heated to 60°C and stirred 
under nitrogen atmosphere. After 18 h the reaction wasn’t complete so 
further piperidine (29 µl, 0.29 mmol) and DMF (1 ml) was added and the 
reaction was carried out by microwave irradiation (Power=200 W, 
Temperature=110°C, Pressure=100 psi, Time=5 min). DMF was removed by 
distillation under reduced pressure and EtOAc was added. After filtration, 
the crude was purified by FC (SiO2, CH2Cl2/MeOH 95/5 then 
CH2Cl2/MeOH(NH3) from 99/1 to 97/3) giving 33 mg of expected product 
21 as colorless oil (Yield=41%); MS (APCI): m/z 319.5; 1H NMR (300 MHz, 
CDCl3): δ 1.32-1.61 (m, 12H) , 1.75 (q, J= 7.08 Hz, 2H), 2.27 (t, J=7.77 Hz, 
2H), 2.35 (br s, 4H), 3.87 (t, J=7.29 Hz, 2H), 7.38(t, J=6.72 Hz, 1H), 7.53 (d, 
J=7.41 Hz, 1H), 7.58 (t, J=5.88 Hz, 1H), 8.00 (d, J=7.89 Hz, 1H); Anal.calc. for 
C18H26N2OS x ½ H2O (MW=327.48) C, 66.01; H, 8.31; N, 8.55. Found: C, 
66.33; H, 8.15; N, 8.42. 
Nonan-2-ylbenzo[d]isothiazol-3(2H)-one (22). To a 0°C stirring 
solution of Et3N (2207 µl, 15.732 mmol) and 2-aminononane (1007 µl, 5.496 
mmol) in dry THF (13.77 ml), a 0.21 M solution of 2,2'-disulfanediyldibenzoyl 
chloride 161 in dry THF (12.30 ml, 2.583 mmol) was dropwise added over 
15 min under nitrogen atmosphere. The obtained white suspension was 
gradually warmed to RT and stirred for 16h. A 0.08M solution of I2 in dry 
THF (52 ml, 4.16 mmol) was dropwise added and the resulting pale brown 
suspension was stirred overnight. The solvent was distilled away under 
reduced pressure. Then, a pH=7.00 phosphate buffer was added and 
the resulting mixture was extracted with CH2Cl2 (3 times). The combined 
organic layers were dried over anhydrous Na2SO4, filtered and 
concentrated under reduced pressure to give 591 mg of yellow residue 
that was purified by FC (SiO2, EtOAc/Hx 10/90 then 55/45) and distilled 
(rectified using a distillation apparatus equipped with Vigreux column) 
furnishing 170 mg of pure product 22 as colourless oil (44%) and 103 mg 
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of slightly dirty desired product as pale yellow oil. MS (APCI): m/z 277.8; 
H1-NMR (300 MHz, CDCl3): δ = 0.87 (t, J=6.45 Hz, 3H), 1.31-1.25 (m, 10H), 
1.39 (d, J=6.66 Hz, 3H), 1.71 (m, 2H), 4.93-4.82 (m, 1H), 7.41 (ddd, J1=7.95 
Hz, J2=6.33 Hz, J3=1.86 Hz, 1H), 7.64-7.57 (m, 2H), 8.06 (d, J=7.86 Hz, 1H). 
Anal.calc. for C16H23NOS (MW=277,42) C, 69.27; H, 8.36; N, 5.05. Found: C, 
69.57; H, 8.32; N, 5.05 
Cyclohexylbenzo[d]isothiazol-3(2H)-one (23).42a To a 0°C stirring 
solution of Et3N (2.200 ml, 15.72 mmol) and aminocyclohexane (635 µl, 5.5 
mmol) in dry THF (10.7 ml), a 0.22 M solution of 2,2'-disulfanediyldibenzoyl 
chloride 161 in dry THF (11.90 ml , 2.62 mmol) was dropwise added over 
15 min under nitrogen atmosphere. The obtained white suspension was 
gradually warmed to RT and stirred for 16h. A 1.6 M solution of I2 in dry THF 
(3.62 ml, 5.8 mmol) was dropwise added and the resulting pale brown 
suspension was stirred overnight. The solvent was distilled away under 
reduced pressure. Then, a pH=4.55 acetate buffer was added and the 
resulting mixture was extracted with CH2Cl2 (3 times). The combined 
organic layers were washed with brine, dried over anhydrous Na2SO4, 
filtered and purified by FC (SiO2, Hx/Et2O 64/46) and vacuum distillation 
furnishing 312 mg of white solid (30%). mp = 84-85°C [Lit. 85-87];42a MS 
(APCI): m/z 234.0; H1-NMR (300 MHz, CDCl3): δ = 1.20-1.30 (m, 1H), 1.42-
1.60 (m, 4H), 1.74 (br d, J=13.08 Hz, 1H), 1.89 (d, J=11.97 Hz, 2H), 2.06 (d, 
J=10.32 Hz, 2H), 4.58-4.65 (m, 1H), 7.39 (ddd, J1=7.95 Hz, J2=6.15 Hz, 
J3=1.95 Hz, 1H), 7.62-7.55 (m, 2H), 8.04 (d, J=7.89 Hz, 1H). Anal.calc. for 
C15H17NOS (MW=233,33) C, 66.92; H, 6.48; N, 6.00. Found: C, 66.68; H, 6.58; 
N, 5.82. 
2-(4-Ethylbenzyl)benzo[d]isothiazol-3(2H)-one (24). A stirring 
suspension of benzo[d]isothiazol-3(2H)-one 18 (238 mg, 1.568 mmol), 
K2CO3 (271 mg, 1.96 mmol) and KI (44 mg, 0,26 mmol) CH3CN (12 ml) was 
refluxed for 30 min under nitrogen atmosphere and cooled back to RT 
Then, a solution 6.53M of 4-Ethylbenzyl methanesulfonate 159 (200 µl, 
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1.307 mmol) in dry CH2Cl2 was dropwise added and the resulting mixture 
was refluxed for 30 min. The reaction mixture was filtered and the solvent 
was evaporated under reduced pressure. The resulting residue (395 mg) 
was purified by FC (SiO2, CH2Cl2 100% then CH2Cl2/MeOH 98/2) giving 195 
mg of desired product 24.(55%); mp (Hexane) = 84-86°C ; MS (APCI): m/z 
270.4; H1-NMR (300 MHz, CDCl3): δ = 1.22 (t, J=7.5 Hz, 3H), 2.63 (quart, 
J=7.8 Hz, 2H), 5.02 (s, 1H), 7.19 (d, J=8.1 Hz, 2H), 7.27 (d, J=8.1 Hz, 2H), 7.40 
(ddd,J1=7.8 Hz, J2=7.2 Hz, J3=1.2 Hz, 1H), 7.40 (dt, J1=8.1 Hz, J2=0.9 Hz, 1H), 
7.59 (ddd, J1=8.1 Hz, J2=7.2 Hz, J3=1.5 Hz, 1H) 8.06 (br d, J=7.8 Hz, 1H). 
Anal.calc. for C15H17NOS * 1/3 H2O (MW=275,31) C, 69.80; H, 5.73; N, 5.09. 
Found: C, 70.00; H, 5.65; N, 5.11. 
2-(Phenylethyl)benzo[d]isothiazol-3(2H)-one (25).42a To a 0°C stirring 
suspension of 2-phenylethanamine (74 µl, 0.587 mmol) and Et3N (400 µl, 
2.853 mmol) in dry CH2Cl2 (1 ml) a 0.392M solution (1.0 ml, 0.39 mmol) of 
2-(chlorocarbonyl)phenyl hypochlorothioite 162 in dry CH2Cl2 was 
dropwise added over 2 min. The reaction mixture was stirred at RT under 
N2 overnight (18 h). The solvent was distilled away under reduced 
pressure from the reaction mixture obtaining a dark-yellow residue. It was 
taken up with EtOAc and the resulting mixture was washed with Na2CO3 
saturated aqueous solution (10 ml), 0.1M HCl aqueous solution (3*10 ml) 
and brine. The organic layer was concentrated under reduced pressure 
and purified by FC (SiO2, EtOAc/Hx 30/70) giving 16 mg of expected 
product 25 as pale yellow powder (11%). mp (Hexane) 90-92°C [Lit. 93-
95] 42a MS (APCI): m/z = 256.2;1H NMR (300 MHz, CDCl3): δ 3.09 (d, J=7.68 
Hz, 2H) , 4.15 (d, J= 7.35 Hz, 2H), 7.24-7.35 (m, 5H), 7.40 (td, J1=7.95 Hz, 
J2=1.02 Hz, 1H), 7.52 (br d, J=8.1 Hz, 1H), 7.60 (td, J1=8.16 Hz, J2=1.2 Hz, 1H), 
7.53 (d, J=7.41 Hz, 1H), 7.58 (t, J=5.88 Hz, 1H), 8.04 (dd, J1=7.86 Hz, J2=0.66 
Hz, 1H). Anal.calc. for C15H13NOS (MW=255,33) C, 70.56; H, 5.13; N, 5.49. 
Found: C, 70.58; H, 5.10; N, 5.39. 
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2-(2-(Naphthalen-2-yl)ethyl)benzo[d]isothiazol-3(2H)-one (26). To a 
0°C stirring suspension of 2-(naphthalen-2-yl)ethanamine hydrochloride 
(129.2 mg, 0.5909 mmol) and Et3N (500 µl, 3.587 mmol) in dry CH2Cl 2 (1 
ml) a 0.392M solution (2.60ml, 1.0187 mmol) of 2-(chlorocarbonyl)phenyl 
hypochlorothioite (162) in dry CH2Cl2 was dropwise added over 2 min. 
The reaction mixture was stirred at RT under N2 overnight (18 h). The 
solvent was distilled away under reduced pressure from the reaction 
mixture obtaining a dark-yellow residue. It was taken up with EtOAc and 
the resulting mixture was washed with Na2CO3 saturated aqueous 
solution (10 ml), 0.1M HCl aqueous solution (3*10 ml) and brine. The 
organic layer was concentrated under reduced pressure and purified by 
FC (SiO2, CH2Cl2 100%) giving 28 mg of expected product 26 as pale 
yellow powder (15%). mp (Hexane) 114-115°C; MS (APCI): m/z = 306.3; 1H 
NMR (300 MHz, CDCl3): δ 3.24 (t, J= 7.5Hz Hz, 2H) , 4.23 (t, J= 7.2 Hz, 2H), 
7.36-7.50 (m, 5H), 7.581 (td, J1= 8.16 Hz, J2= 1.17 Hz, 1H), 7.71 (s, 1H), 7.76-
7.83 (m, 3H), 8.04 (d, J=7.8 Hz, 1H). Anal.calc. for C19H15NOS * 1/10 H2O 
(MW=307.17) C, 74.28; H, 4.99; N, 4.56. Found: C, 74.21; H, 4.97; N, 4.58. 
2-(2-(Naphthalen-1-yl)ethyl)benzo[d]isothiazol-3(2H)-one (27). To a 
0°C stirring suspension of 2-(naphthalen-1-yl)ethanamine hydrochloride 
(129.2 mg, 0.5909 mmol) and Et3N (500 µl, 3.587 mmol) in dry CH2Cl2 (1 ml) 
a 0.392M solution (2.60ml, 1.0187 mmol) of 2-(chlorocarbonyl)phenyl 
hypochlorothioite (162) in dry CH2Cl2 was dropwise added over 2 min. 
The reaction mixture was stirred at RT under N2 overnight (18 h). The 
solvent was distilled away under reduced pressure from the reaction 
mixture obtaining a dark-yellow residue. It was taken up with EtOAc and 
the resulting mixture was washed with Na2CO3 saturated aqueous 
solution (10 ml), 0.1M HCl aqueous solution (3*10 ml) and brine. The 
organic layer was concentrated under reduced pressure and purified by 
FC (SiO2, CH2Cl2 100%) giving 25 mg of expected product 27 as pale 
yellow powder (14%). mp (Hexane) 101-102°C; MS (APCI): m/z = 306.2; 1H 
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NMR (300 MHz, CDCl3): δ 3.54 (t, J=7.8 Hz, 2H) , 4.218 (t, J=7.8 Hz, 2H), 7.63-
7.388 (m, 7H), 7.777 (t, J = 4,5 Hz, 1H), 7.881 (d, J=7.8 Hz, 1H), 8.078 (d, 
J=7.8 Hz, 1H), 8.25 (d, J=8.4 Hz, 1H). Anal.calc. for C19H15NOS (MW=305,39) 
C, 74.72; H, 4.95; N, 4.59. Found: C, 74.66; H, 4.98; N, 4.61. 
2-Phenylbenzo[d]isothiazol-3(2H)-one (28).190 To a 0°C stirring 
solution of 2-mercapto-N-phenylbenzamide 164 (315 mg, 1.373 mmol) 
and TFA (312.45 µl, 4.08 mmol) in dry CH2Cl2 (16.6 ml), a solution of PIFA 
([bis(trifluoroacetoxy)iodo]benzene) (877.3 mg, 2.04 mmol) in dry CH2Cl2 
(27.4 ml) was dropwise added under nitrogen atmosphere and the 
resulting mixture was stirred for 1h. The solvent was removed under 
reduced pressure and the crude was purified by FC (SiO2, EtOAc/Hx 
30/70) giving 311 mg of pure product 28 as brown solid (99%); mp 
(Hexane) = 135-137°C [Lit. 139-140 (EtOH)] 190; H1-NMR (300 MHz, CDCl3): δ 
= 7.34 (tt, J1=7.5 Hz, J2=1.0 Hz, 1H), 7.488 (dt, J1=8.13 Hz, J2= 7.35 Hz, 3H), 
7.61 (br d, J=8.01 Hz, 1H), 7.67-7.75 (m, 3H), 8.13 (br d, J=7.92 Hz, 1H). MS 
(APCI): m/z 228.0. Anal.calc. for C13H9NOS (MW=227,28) C, 68.70; H, 3.99; 
N, 6.16. Found: C, 68.88; H, 4.13; N, 6.01. 
2-Naphtyllbenzo[d]isothiazol-3(2H)-one (29). 190 To a 0°C stirring 
solution of 2-mercapto-N-(naphtalen-2-yl)benzamide 2 (140 mg, 0.5 
mmol) and TFA (114 µl, 4.08 mmol) in dry CH2Cl2 (16.6 ml), a solution of 
PIFA ([bis(trifluoroacetoxy)iodo]benzene) (877.3 mg, 1.49 mmol) in dry 
CH2Cl2 (8 ml) was dropwise added under nitrogen atmosphere and the 
resulting mixture was stirred for 1h. The solvent was removed under 
reduced pressure and the crude was purified by FC (SiO2, CH2Cl2/Hx 
80/20) giving 85 mg of desired product 29 as brown solid (61%). mp 
(petroleum ether)= 164-166°C [Lit. 165 (EtOH)];202 MS (APCI): m/z 278.1; 
H1-NMR (300 MHz, CDCl3): δ = 7.48 (d, J=7.2 Hz, 1H), 7.52-7.58 (m, 2H), 7.63 
(d, J=7.95 Hz, 1H), 7.72 (t, J=7.15 Hz), 7.89-7.98 (m, 4H), 8.16 (m, 2H). 
Anal.calc. for C17H11NOS (MW=277,34) C, 73.62; H, 4.00; N, 5.03. Found: C, 
73.39; H, 4.04; N, 5.00. 
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2-(Biphenyl-4-yl)benzo[d]isothiazol-3(2H)-one (30). To a 0°C stirring 
suspension of p-phenylaniline (100 mg, 0.5909 mmol) and Et3N (500 µl, 
3.587 mmol) in dry CH2Cl2 (1 ml) a 0.392M solution (2.30ml, 0.90 mmol) of 
2-(chlorocarbonyl)phenyl hypochlorothioite (162) in dry CH2Cl2 was 
dropwise added over 2 min. The reaction mixture was stirred at RT under 
N2 overnight (18 h). The solvent was distilled away under reduced 
pressure from the reaction mixture obtaining a dark-yellow residue. It was 
taken up with EtOAc and the resulting mixture was washed with Na2CO3 
saturated aqueous solution (10 ml), 0.1M HCl aqueous solution (3*10 ml) 
and brine. The solvent was distilled away from organic layer under 
reduced pressure giving a crude that was purified by FC (SiO2, CH2Cl2 
100%) giving 21 mg of expected product 30 as pale yellow powder 
(12%); mp (Hexane) 175-176°C; MS (APCI): m/z = 304.5; 1H NMR (300 MHz, 
CDCl3): δ 7.37 (t, J=7.2 Hz, 1H) , 7.46 (t, J= 7.5 Hz, 3H), 7.59-7.705 (m, 6H), 
7.79 (d, J=8.4 Hz, 4H), 8.13 (d, J=7.8 Hz, 1H). Anal.calc. for C19H13NOS * 1/2 
H2O (MW=312,39) C, 73.05; H, 4.52; N, 4.48. Found: C, 72.75; H, 4.31; N, 
4.36. 
2-(Biphenyl-3-yl)benzo[d]isothiazol-3(2H)-one (31) A solution of PIFA 
([bis(trifluoroacetoxy)iodo]benzene), 598 mg, 1.39 mmol) in 20 mL of 
anhydrous CH2Cl2 was added at 0 °C to a solution of 166 (284 mg, 0.930 
mmol) and TFA (0.216 mL, 2.79 mmol) in 15 mL of anhydrous CH2Cl2, and 
the solution was stirred for 1 h. Then, the solvent was removed under 
reduced pressure and the resulting residue was purified by FC (SiO2, n-
hexane/EtOAc, 5:1) furnishing 200 mg of desired product 31 as white 
solid (71 %). mp (EtOH/ H2O) 104-105 °C; MS (APCI): m/z 304.4. 1H NMR 
(CDCl3, 300 MHz) δ 7.38 (t, J = 7.0 Hz, 1H), 7.44-7.49 (m, 3H), 7.54-7.55 (m, 
2H), 7.59-7.71 (m, 5H), 7.95 (t, J = 1.0 Hz), 8.12 (d, J = 8.5 Hz, 1H). Anal.calc. 
for C19H13NOS (MW=303.38) C, 75.22; H, 4.32; N, 4.62. Found: C, 75.32; H, 
4.11; N, 4.57. 
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2-Amino-benzo[d]isothiazol-3(2H)-one (32)43a A mixture of 
trifluoroacetic acid (8.9 ml, 116 mmol), water (1 ml) and 2-
(butoxycarbonylamino)-benzo[d]isothiazol-3(2H)-one 35 (510 mg, 1.91 
mmol) was stirred for 150 min at RT. Then, NaHCO3 10% aqueous solution 
(123.2 ml) was added and the resulting solution was extracted with 
CH2Cl2 (three times). The combined organic layers were dried over 
anhydrous Na2SO4, filtered, concentrated under reduced pressure and 
purified by FC (SiO2, EtOAc/Hx 60/40) giving 180 mg desired product 32 
as pale yellow solid (yield = 57%). mp (H2O)= 128-129°C[Lit. 138-141 
(H2O)];43a MS (APCI): m/z 167.2; H1-NMR (300 MHz, CDCl3): δ = 4.65 (br s, 
2H), 7.39 (br t, J=7.72 Hz, 1H), 7.50 (d, J=8.2 Hz, 1H), 7.62 (ddd, J1=8.23 Hz, 
J2= 5.42 Hz, J3=1.125 Hz, 1H), 8.02 (br d, J=7.86 Hz, 1H). Anal.calc. for 
C7H6N2OS * 1/10 H2O (MW=168,00) C, 50.04; H, 3.72; N, 16.67. Found: C, 
50.39; H, 3.59; N, 16.28 
2-(Benzylamino)benzo[d]isothiazol-3(2H)-one (33). A 0°C cooled 
suspension of tert-butyl benzyl(3-oxobenzo[d]isothiazol-2(3H)-
yl)carbamate (167) (400 mg, 1.1216 mmol) in Cl3CCOOH/H2O 9:1 w/w 
mixture (4.447 mg) was stirred for 2h and then for further 2h at RT. To the 
resulting solution, a NaHCO3 saturated aqueous solution was dropwise 
added until the gas evolution ceased. The crude was saturated with 
Na2CO3 and extracted with EtOAc (4 times). Mixed organic layers was 
evaporated to dryness and purified by FC (SiO2, CH2Cl2 100% then 
CH2Cl2/Et2O 90/10) giving 282 mg of desired final product 33 as a pale 
yellow residue (98%). mp (Hexane) 121.1-121.5°C; MS (ACPI): m/z  257.2; 
1H NMR (300 MHz, CDCl3): δ 3.66 (bs, 1H), 4.34 (s, 2H), 7.47-7.33 (m, 8H), 
7.62 (td, J1=7.08 Hz, J2=0.99 Hz, 1H), 8.0 (d, J=7.86 Hz ,1H). Anal.calc. for 
C14H12N2OS (MW=256,32) C, 65.60; H, 4.72; N, 10.93. Found: C, 65.60; H, 
4.72; N, 10.93. 
2-(Benzyl(methyl)amino)benzo[d]isothiazol-3(2H)-one (34). To a RT 
stirring solution of 2-(benzylamino)benzo[d]isothiazol-3(2H)-one 33  (58 
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mg, 0.226 mmol) in MeI (700 µl, 11.18 mmol) imidazole (16 mg, 0.235 
mmol) was added in one portion. The stirring was maintained for 16 h 
under nitrogen atmosphere. The solvent was evaporated under reduced 
pressure. The crude was purified by FC (SiO2, CH2Cl2/MeOH 99/1) and by 
vacuum distillation giving 39 mg of desired product 34 as a pale yellow 
waxy solid (64%). mp 136-139°C (darkening) then 142-143°C (melting); MS 
(APCI): 271.3; 1H NMR (300 MHz, CDCl3): δ 2.95 (s, 3H), 4.24 (s, 2H), 7,25-
7.35 (m, 4H), 7.44 (d, J= 8.01 Hz,1H), 7.58 (td, J1= 7.98 Hz, J2= 1.23 Hz,1H), 
8.00 (d, J=7.86 Hz,1H). Anal.calc. for C15H14N2OS (MW=270,35) C, 66.64; H, 
5.22; N, 10.36. Found: C, 66.87; H, 5.46; N, 9.84. 
2-(Butoxycarbonylamino)-benzo[d]isothiazol-3(2H)-one (35).43a To a 
0°C stirring solution of Et3N (1.520 ml, 10.84 mmol) and tert-butyl 
hydrazinecarboxylate (501 mg, 3.78 mmol) in dry THF (7.4 ml), a 0.209 M 
solution of 2,2'-disulfanediyldibenzoyl chloride 161 (620 mg, 1.8 mmol) in 
dry THF (8.6 ml) was dropwise added over 15 min under nitrogen 
atmosphere. The obtained white suspension was gradually warmed to RT 
and stirred for 16h. A 0.263M solution of I2 (15 ml) in dry THF was dropwise 
added and the resulting pale brown suspension was stirred for 4h. The 
solvent was distilled away under reduced pressure, a pH=7.00 phosphate 
buffer was added and the resulting mixture was extracted with CH2Cl2 (3 
times). The combined organic layers were dried over anhydrous Na2SO4, 
filtered and concentrated under reduced pressure furnishing 1.6 g of 
brown residue that was purified by FC (SiO2, EtOAc/Hx 40/60) giving 865 
mg of desired product 35 as a pale yellow wax (90%). m.p. (CH2Cl2/Et2O) 
= 170-171°C [Lit. 170-171 (EtOAc)] 43a MS (APCI): m/z 267.2; H1-NMR (300 
MHz, CDCl3): δ = 1.51 (s, 9H), 7.06 (bs, 1H), 7.41 (t, J=7.26 Hz, 1H), 7.51 (d, 
J=8.07 Hz, 1H), 7.67 (t, J=8.22 Hz, 1H), 8.07 (d, J=7.89 Hz, 1H). Anal.calc. for 
C12H14N2O3S (MW=266,32) C, 54.12; H, 5.30; N, 10.52. Found: C, 54.08; H, 
5.14; N, 10.52. 
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2-Phenethylisothiazol-3(2H)-one (36). 109 A 0.75M solution of SO2Cl2 in 
dry 1,2-dichloroethane (4,8 ml, 3.6 mmol) was dropwise added to a 0°C 
stirring suspension of 3,3'-disulfanediylbis(N-phenethylpropanamide) 170 
(500 mg, 1.2 mmol) in dry 1,2-dichloroethane (7 ml) over 2h. The solvent 
was evaporated under reduced pressure and the yellow oily residue was 
taken up with CH2Cl2. The resulting mixture was washed with H2O (10 ml, 
2 times), dried over anhydrous Na2SO4, filtered and concentrated under 
reduced pressure giving 697 mg of yellow oil. The crude was purified by 
FC (SiO2, CH2Cl2/Et2O 98/2 then 90/10) giving 194 mg of desired product 
36 as a pale yellow powder (39%). mp (Hexane) 78-79°C [Lit. 76-78 
(benzene/hezane)]; 109 MS (APCI):  206.2; 1H NMR (300 MHz, CDCl3): δ 3.04 
(t, J=7.44 Hz, 2H), 4.051 (t, J=7.14 Hz, 2H), 6.27 (q, J=6.24 Hz, 1H), 7.22-7.35 
(bs, 5H), 8.00 (d, J=6.24 Hz, 1H). 
2-(Biphenyl-4-yl)isothiazol-3(2H)-one (37) A 0.75M solution of SO2Cl2 
in dry 1,2-dichloroethane (2,37 ml, 1.78 mmol) was dropwise added to a 
0°C stirring suspension of 3,3'-disulfanediylbis(N-(biphenyl-4-
yl)propanamide) 172 (300 mg, 0.58 mmol) in dry 1,2-dichloroethane (3 
ml) over 2h. The resulting white suspension was allowed to reach RT and 
stirred for 1h. The solvent was evaporated under reduced pressure and 
the solid residue was taken up with CH2Cl2. The obtained suspension was 
filtered, concentrated to reduced pressure and purified by FC( (SiO2, 
EtOAc/Hx 30/70 then 50/50) giving 80 mg of pale yellow solid. Two 
consecutive crystallization from toluene gave 40 mg of desired product 
39 as white crystals (54%). mp (toluol) 196-197°C; MS (APCI): 254.1; 1H 
NMR (300 MHz, CDCl3): δ 6.38 (d, J=6.33 Hz, 1H), 7.39 (t, J=7.29 Hz, 1H), 
7.48 (t, J=7.17 Hz, 2H), 7.61 (d, J=7.44 Hz, 2H), 7.69 (s, 4H), 8.20 (d, J=6.36 
Hz, 1H). 
3-(Oct-7-ynyloxy)benzo[d]isothiazole (38). It was co-synthesized 
with compounds 20. The crude product (300 mg of yellow oil) was 
purified by FC (SiO2, EtOAc/Hx 4/96) furnishing 218 mg of pure product as 
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a pale yellow oil (31%); MS (APCI): m/z 260.2; H1-NMR (300 MHz, CDCl3): δ 
= 1.61 (m, 6H), 1.90 (m, 3H), 2.23 (td, J1=6.57 Hz, J2=2.52 Hz, 2H), 4.56 (t, 
J=6.57 Hz, 2H), 7.39 (t, J=7.83 Hz, 1H), 7.53 (t, J=8.01 Hz, 1H), 7.78 (d, J=8.1 
Hz, 1H), 7.93 (d, J=7.98 Hz, 1H). Anal.calc. for C15H17NOS (MW=259,37) C, 
69.46; H, 6.61; N, 5.40. Found: C, 69.62; H, 6.60; N, 5.37. 
3-(4-Ethylbenzyl)benzo[d]isothiazol-3(2H)-one (39). It was co-
synthesized with compounds 24. The crude residue (395 mg) was purified 
by FC (SiO2, EtOAc/Hx 4/96) giving 169 mg of desired product 39 as a 
pale yellow oil (48%); MS (APCI): m/z 270.4; H1-NMR (300 MHz, CDCl3): δ = 
1.259 (t, J=7.8 Hz, 3H), 2.68 (q, J=7.8 Hz, 2H), 5.56 (s, 2H), 7.24 (d, J=7.8 Hz, 
2H), 7.37 (t, J=7.8 Hz, 1H), 7.45 (d, J=8.1 Hz, 2H), 7.51 (t, J=6.9 Hz, 2H), 7.77 
(d, J=7.5 Hz, 1H), 7.93 (d, J=7.8 Hz, 1H). Anal.calc. for C15H17NOS 
(MW=269,36) C, 71.34; H, 5.61; N, 5.20. Found: C, 71.46; H, 5.61; N, 5.30. 
 
4.2.3 Biology 
Collected biological data were from experimentations carried out 
by Prof. D. Piomelli’s research group (Department of Pharmacology, 
University of California Irvine, Irvine, CA, USA). 
 
MAGL inhibition assay. Monoacylglycerol lipase activity was 
measured as previously described (King et al., 2007). Briefly, either 10 ng 
of purified MAGL or 2.5–50 µg of protein from MAGL-transfected HeLa 
cell lysates were pre-incubated with inhibitors for 10 min at 37°C in assay 
buffer (50 mM Tris-HCL, pH 8.0, 0.5 mg/ml bovine serum albumin, fatty 
acid-free). Following pre-incubation, 2-oleoylglycerol (2-OG) substrate 
(10 µM final) was added, and samples were incubated for an additional 
10 min at 37°C. Reactions were stopped with chloroform/methanol (2:1, 
v/v), containing heptadecanoic acid (5 nmol) as an internal standard. In 
some experiments with cell lysates, 1-heptadecanoylglycerol (1-HG) and 
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heptadecenoic acid were used as substrate and internal standard 
respectively. Samples were subjected to centrifugation at 2000 x g at 
4°C for 10 min, and the organic layers were collected and dried under a 
stream of N2. The residues were suspended in chloroform/methanol (1:3, 
v/v) and analyzed by liquid chromatography/mass spectrometry 
(LC/MS). 
LC/MS analysis. A reversed-phase Eclipse C18 column (30 x 2.1 mm 
i.d., 1.8 µM, Agilent Technologies, Wilmington, DE, USA) was used. It was 
eluted with 95% of solvent A and 5% solvent B for 0.6 min at a flow rate of 
0.6 mL/min-1 with column temperature set at 50°C. Solvent A consisted of 
methanol containing 0.25% acetic acid and 5 mM ammonium acetate. 
Solvent B consisted of water containing 0.25% acetic acid and 5 mM 
ammonium acetate. Under these conditions, analytes eluted from the 
column at the following retention times: oleic acid, 0.34 min; 
heptadecanoic acid, 0.37 min; heptadecenoic acid, 0.29 min. 
Electrospray ionization was in the negative mode, capillary voltage was 
set at 4 Kv, and fragmentor voltage was 100 V. N2 was used as drying gas 
at a flow rate of 13 L/min-1 and a temperature of 350°C. Nebulizer 
pressure was set at 60 psi. For quantification purposes, we monitored the 
[M-H]- ions of m/z = 281.3 for oleic acid, m/z = 269 for heptadecanoic 
acid, and m/z = 267 for heptadecenoic acid. 
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